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OVERVIEW: DIETARY AND PHYSICAL ACTIVITY BEHAVIORS, 
KNOWLEDGE, AND BELIEFS ASSOCIATED WITH POLYCYSTIC OVARY 
SYNDROME 
Annie Lin, PhD, MS, RD 
Cornell University 2017 
Polycystic ovary syndrome (PCOS) occurs in approximately 7 to 18% of 
reproductive-aged women worldwide and is characterized by oligo/amenorrhea, 
hyperandrogenism, and/or polycystic ovaries. Women with PCOS are at higher risk of 
poor physical and mental health outcomes. Up to 80% of women with PCOS have 
reported BMI ≥25 kg/m2, leading researchers to hypothesize that obesity contributes to 
the development of PCOS. Although poor diet and physical inactivity are known 
contributors of obesity, it remains uncertain whether these activities can predict the 
development of PCOS features.  
Weight loss interventions are the first recommendation in treating reproductive 
and metabolic symptoms of PCOS, yet adherence with these interventions varies greatly 
across PCOS studies. To encourage behavior change, it is essential to understand: 1) the 
associations between diet and physical activity (PA) behaviors with PCOS and 2) the 
health-related knowledge and beliefs associated with PCOS. This dissertation addresses 
these research gaps by investigating the cross-sectional associations between PCOS and 
dietary and physical activity behaviors, as well as knowledge, and beliefs. Our published 
narrative review (Chapter 1) summarizes the current evidence of the health-related 
behaviors – PCOS link and identifies gaps in the literature to inform the studies 
conducted in Parts 1 and 2 of this dissertation.  
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Two approaches were used in Part 1 to investigate the link between health-
related behaviors with combined and/or isolated features of PCOS. Chapter 2 presents 
a secondary data analysis using data from the longitudinal cohort, Coronary Artery Risk 
Development in Young Adults (CARDIA) Women’s Study. We show that diet quality 
was associated with PCOS, and that this association varied by race. When macro- or 
micronutrient intake were considered individually, there were no differences between 
women with and without PCOS. Similarly, there were no differences in PA by PCOS 
status. Results from our prospective case-comparison study (Assessment of Dietary 
Intake and Physical Activity in Women with and without PCOS) in Chapter 3 
confirmed that diet, but not PA, was linked to PCOS status. These findings suggest that 
some aspects of diet could serve as targets for tailored PCOS interventions.  
Part 2 explored associations between health-related knowledge and beliefs with 
PCOS status. We developed and validated two instruments that were distributed to 
reproductive-aged women in the United States. Findings from Chapter 4 (Instrument 
for PCOS: Knowledge, Health-Related Beliefs, and Self-Efficacy) demonstrate that 
women with PCOS had less favorable health-related beliefs than the comparison group, 
but reported similar self-efficacy in performing salubrious diet behaviors. In Chapter 5 
(Instrument for PCOS: Medical Experiences), we report that specific domains of trust 
and social support directed toward healthcare professionals differed between women 
with and without PCOS, thereby identifying factors that could improve the physician 
and PCOS patient relationship. Collectively, this dissertation integrates physiological, 
sociological and epidemiological concepts with nutrition in order to contribute to the 
development of effective behavioral interventions for PCOS patients.  
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PART ONE PREFACE 
 
In a published narrative review, we summarized the current evidence on the comparison 
of health-related lifestyle behaviors between women with and without PCOS (Chapter 
1). We recommended three courses of action that build on the previous literature: 1) 
explore the associations between health-related lifestyle behaviors and features of 
PCOS; 2) consider the role of race on reproductive status; and 3) use accelerometry to 
measure and provide objective measures of PA. To address these research gaps, this 
dissertation used data from a longitudinal cohort study (Chapter 2) and a case-
comparison study (Chapter 3) for the following specific aims:  
 
AIM 1: To investigate the associations between lifestyle behaviors and PCOS. 
Chapter 2 was restricted to analyzing the classic PCOS phenotype (1990 NIH 
criteria defined as oligo/amenorrhea and hyperandrogenism) and its isolated 
features due to the available data. To explore whether results may differ based on 
more current PCOS diagnostic criteria, the Rotterdam consensus criteria (2003) 
was used in Chapter 3.  
SUBAIM 1.1. To identify lifestyle predictors of isolated features of PCOS.  
This aim was achieved in Chapter 2.  
 
AIM 2: To investigate whether associations between lifestyle behaviors and PCOS 
vary by race, while also considering isolated features of PCOS.  
This aim was achieved in Chapter 2.  
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Accelerometers were used in Chapter 3 to quantify the PA behaviors of reproductive-
aged women. We compared PA estimates from three recently developed algorithms to 
understand how variations in algorithm development can impact results and to select an 
approach to analyze our PA data (Appendix A). The above projects led to one narrative 
review and three primary research manuscripts.  
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CHAPTER 1: REVIEW ON THE COMPARISON OF DIETARY INTAKE 
AND PHYSICAL ACTIVITY BETWEEN WOMEN WITH AND WITHOUT 
POLYCYSTIC OVARY SYNDROME* 
Submitted and Accepted: June 2, 2014 by Advances in Nutrition 
* Lin AW, Lujan ME. Comparison of dietary intake and physical activity between women with and 
without polycystic ovary syndrome: a review. Adv Nutr 2014;5:486–96. 
ABSTRACT 
Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder affecting women 
of reproductive age worldwide. In addition to imparting deleterious effects on fertility, 
women with PCOS are at increased risk for obesity, diabetes, cardiovascular disease, 
depression and certain cancers. Hormonal and metabolic aberrations in PCOS have the 
potential to influence dietary intake and physical activity levels. There are emerging 
global data that women with PCOS have different dietary energy intake compared to 
women without PCOS. These alterations in diet may exacerbate clinical symptoms and 
compound risk for chronic disease for PCOS patients. Few studies have compared 
physical activity levels among women with and without PCOS. Although comparisons 
among studies are confounded by several factors, the data point to no differences in 
activity levels among PCOS and non-PCOS groups. This review provides an assessment 
of the current literature on dietary intake and physical activity levels in women with 
PCOS. Future recommendations to strengthen research in this area are provided, given 
their implications to aid in the development of effective nutrition-focused for PCOS.  
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INTRODUCTION 
As a leading cause of anovulatory infertility and a risk factor for endometrial 
dysfunction and uterine cancer, polycystic ovary syndrome (PCOS) represents a serious 
health concern for women across the life span (1,2). PCOS is characterized by a 
heterogeneous collection of symptoms: infrequent or absent menstrual cycles, 
biochemical or clinical evidence of androgen excess, and polycystic ovarian 
morphology (3,4). PCOS occurs in a striking proportion of women of reproductive age, 
ranging from 6% to 15% worldwide, depending on the diagnostic criteria used (3,5,6). 
PCOS should be regarded as a broad-spectrum disorder because its consequences for 
patients extend beyond impairments of the reproductive system to include serious 
metabolic (i.e., metabolic syndrome, type 2 diabetes, and cardiovascular disease) and 
psychological sequelae (i.e., depression, anxiety, poor self-esteem, and reduced quality 
of life) (3,7,8). 
Researchers have established that up to 80% of the PCOS population is 
overweight or obese with obesity prevalence rates, dependent on the ethnicity and 
geographical location (3,9). Although PCOS can manifest in both normal weight and 
overweight women, some evidence supports that increased central adiposity is present 
across all BMI categories (10–12). It is debatable as to whether women with PCOS have 
a unique predisposition to obesity or whether obesity contributes to the development of 
PCOS (13). Data supporting lower basal metabolic rate (14) and postprandial 
thermogenesis (15) in individuals with PCOS compared with age- and weight-matched 
controls may account for a higher prevalence of obesity among the PCOS population. 
However, reports on differences in basal metabolic rate among women with or without 
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PCOS are inconsistent (16). There is also the potential for appetite circuits to be affected 
by the abnormal hormone profile in PCOS. Testosterone replacement was shown to 
increase meal frequency in male rodents (17), whereas anti-androgenic pharmaceutical 
therapy was found to reduce meal-related hunger in women with bulimia (18). The anti-
androgenic finding may be particularly relevant because women with PCOS exhibit 
appetite indications similar to those in women with bulimia (19). Women with PCOS 
also demonstrated smaller reductions in postprandial ghrelin (i.e., an orexigenic 
hormone) and lower postprandial cholecystokinin concentrations (i.e., an anorexigenic 
hormone) compared with age- and/or weight-matched controls (20,21). Collectively, 
these findings are consistent with the hypothesis that women with PCOS have lower 
perceived 
satiety and greater appetite compared with women without PCOS. These findings are 
tempered by other studies that showed no differences or a blunted response in ghrelin 
concentrations among women with or without PCOS (22,23). Last, experimental and 
clinical evidence supports that testosterone promotes abdominal fat deposition in 
women (11,24,25). Increased abdominal adiposity has been linked to elevated leptin 
secretion and leptin resistance, which may result in impaired satiety and increased 
energy intake (26). Irrespective of whether PCOS causes obesity or a reverse causation 
exists, it is recognized that obesity, particularly abdominal obesity, worsens clinical and 
metabolic features of PCOS (3). 
Diet and PA interventions are recommended as a first-line treatment in 
overweight and obese women with PCOS (27). Uncontrolled trials involving 
hypocaloric diets with physical activity (1200 kcal/d) and low-carbohydrate, ketogenic 
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diets (<20 g carbohydrate/d, unlimited consumption of high-biologic-value protein and 
dairy) support improvements in hyperandrogenism, frequency of menses, ovulation, 
pregnancy rates, insulin resistance, and lipid profile when accompanied by modest 
weight reductions for women with PCOS (28,29). Randomized controlled trials with 
reduced-energy diets also support improvements in hyperandrogenism and insulin 
resistance in women with PCOS. Yet, data on ovulation and other reproductive 
outcomes are less clear (30–32). There are limited data on the feasibility or effectiveness 
of long-term weight-loss interventions for this population. Moreover, only a few studies 
examined diet alterations to improve cardiometabolic risk factors in normal weight 
women with PCOS (33,34). Understanding the dietary intake and physical activity 
levels of the PCOS population is essential to aid in the development of effective weight 
loss interventions in free-living settings. The primary aim of this review was to examine 
the current literature on dietary intake and physical activity behaviors in women with 
PCOS. Furthermore, this review provides recommendations for future studies in this 
area of research. 
Studies were identified by searching the electronic databases PubMed, 
CINAHL, and PsycINFO for studies published after 1990 and before January 2014. A 
search was performed by using a combination of the following keywords: ‘diet’, 
‘polycystic ovary syndrome’, food frequency questionnaire’, ‘food records’, and ‘diet 
recall.’ Ten studies from various countries were included in the review based on a 
Population, Intervention, Comparison, Outcome framework established a priori by the 
authors. In short, studies included for review were limited to original research articles 
in which 1) the primary objective was to assess diet and physical activity levels between 
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adult women with and without PCOS, 2) enrollment exceeded 10 participants in each 
study arm, and 3) diet and physical activity were assessed in a free-living sample. A 
description and the main findings of each study included for review are summarized in 
Table 1.1. 
Comparison of dietary intake between women with and without PCOS. Two studies 
compared dietary intake between women with and without PCOS by using case-control 
study designs in the United States (35,36). Wright et al. (36) assessed dietary intake by 
using FFQs in mostly middle-aged women undergoing the perimenopausal transition. 
This was evidenced by the number of women in both control and PCOS groups who 
reported the absence of menses for 12 mo. By contrast, Douglas et al. (35) assessed the 
food records of reproductive-aged women who were ~20 y younger than the sample 
used by Wright et al. Both dietary assessment methods used by these studies have been 
commonly used to assess dietary intake (37,38), yet each has distinct strengths and 
weaknesses. Whereas diet records over several days are expected to reflect usual  intake 
and have less reliance on participant memory, this approach may have limited accuracy 
because participants are aware that their dietary intake would be scrutinized on specific 
days. This may result in atypical dietary intake and provide misleading dietary 
information (38,39). The FFQ is an appropriate measure to assess usual dietary 
composition over a longer period of time; however, the accuracy of the data can be 
limited by the respondents’ abilities to recall their diet habits (38). It is also impossible 
to discern whether a PCOS diagnosis may have been a catalyst to altered dietary intake 
due to the study design.  
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Table 1.1. Cross-sectional study characteristics assessing diet and physical activity in women with and without polycystic ovary syndrome1  
Author(s) Sample, Assessments Used Outcomes2 Limitations 
Wright et al. 
2004 (33) 
Groups 
N=84, PCOS 
N=79, controls 
Age (years) 
46.7 ± 5.8, PCOS 
48.2 ± 5.7, controls 
BMI (kg/m2)3  
32.1 ± 9.3, PCOS  
29.0 ± 6.0, controls 
Location 
Pittsburgh, US 
Race  
Caucasian: 83% PCOS, 90% controls 
Non-Caucasian: 13% PCOS, 10% 
controls 
PCOS definition 
Oligoamenorrhea plus either 
hirsutism, hyperandrogenism and/or 
elevated LH:FSH 
No specific exclusion criteria were 
applied 
Assessments 
FFQ 
Physical activity questionnaire 
 
No differences in daily food and nutrient intake or  
physical activity between PCOS and control    
     groups 
Lower nutrient intake in lean PCOS (N=21) vs. lean  
control (N=33) groups*:  
Total energy/d, CHO (g/d), protein (g/d), fat (g/d), 
SFA (g/d), MUFA (g/d), PUFA (g/d), cholesterol 
(mg/d) 
Lower bread, cereal, rice, pasta, meat, fish, poultry,  
egg intake in lean PCOS vs. lean control groups 
(servings)* 
Lower milk product intake in overweight PCOS  
     (N=15) vs. overweight control (N=19) groups  
     (servings)* 
Lower meat, fish, poultry, egg intake in obese PCOS  
(N=48) vs. obese control (N=27) groups 
(servings)* 
Higher carbohydrate and lower fat intakes in PCOS  
group vs. Reaven study recommendations (49) 
 
Diagnostic criteria used yielded a  
heterogeneous PCOS cohort 
Population studied used medications  
known to influence endocrine 
profile (e.g. oral contraceptive, anti-
androgens)  
No reported exclusion criteria on  
medications that may influence 
weight, appetite  
Older, potentially perimenopausal, 
populations studied, heterogeneous 
control group used with 41% 
reporting oligo-amenorrhea. Low 
generalizability to younger women 
with PCOS.  
Power analysis not provided for post- 
     hoc comparisons among BMI- 
     matched groups 
Did not report energy expenditure or  
energy balance 
Did not compare with US DRI 
 
 
Douglas et 
al. 2006 
(34) 
Groups 
N=30, PCOS 
N=27, controls 
Age (years) 
28.9 ± 6.3, PCOS 
28.9 ± 6.5, controls 
BMI (kg/m2)  
29.1 ± 4.8, PCOS  
No differences in nutrient intake between PCOS and  
control groups 
Greater white bread intake in PCOS vs. control  
     groups (servings)*  
 
Population studied used drugs known  
     to influence endocrine profile  
No reported exclusion criteria on other  
medications that may influence 
weight, appetite  
Comprehensive dietary intake not  
collected on all days of week 
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Table 1.1. Cross-sectional study characteristics assessing diet and physical activity in women with and without polycystic ovary syndrome1  
Author(s) Sample, Assessments Used Outcomes2 Limitations 
29.7 ± 4.8, controls 
Location 
Birmingham, US 
Race  
Caucasian: 83% PCOS, 85% controls 
Black: 13% PCOS, 11% controls 
Other: 4% PCOS, 4% controls 
PCOS definition 
Oligoamenorrhea plus hirsutism 
and/or hyperandrogenism  
Exclusion criteria 
Diabetes, use of insulin sensitizers or 
glucose-lowering drugs and 
adherence to a modified diet 
Assessments 
4-day food records 
(Wed/Thu/Sat/Sun) 
 
Overall study cohorts not matched for 
BMI 
Power analysis not provided 
Data on physical activity not collected 
Did not compare with US DRI 
Alvarez-
Blasco et al. 
2011 
(38) 
Groups 
N=22, PCOS 
N=59, controls 
Age (years)3 
26.3 ± 7.6, PCOS 
32.2 ± 7.5, controls 
BMI (kg/m2)  
35.2 ± 6.7, PCOS  
32.2 ± 6.1, controls 
Location 
Madrid, Spain 
Race not reported 
PCOS definition 
Oligoamenorrhea plus hirsutism 
and/or hyperandrogenism  
Exclusion criteria 
No differences in nutrient intake and physical activity  
between PCOS and control groups 
PCOS group intake vs. United States dietary 
recommended intake*: 
Above: total fat (g/d), SFA (% energy/d), MUFA 
(% energy/d), dietary cholesterol (mg/d), 
sodium (mg/d), vitamin C (mg/d), vitamin D 
(µg/d), calcium (mg/d), magnesium (mg/d) 
Below: fiber (g/d), potassium (mg/d), vitamin E 
(mg/d) 
Study cohorts not matched for age 
Power analysis not provided 
Details on physical activity assessment  
tool not reported 
Did not report energy expenditure or  
energy balance 
Did not compare intake with EFSA  
recommended intake which is 
established for European countries 
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Table 1.1. Cross-sectional study characteristics assessing diet and physical activity in women with and without polycystic ovary syndrome1  
Author(s) Sample, Assessments Used Outcomes2 Limitations 
Use of hormonal contraception and 
medications that interfere with 
metabolism, hypocaloric dieting, 
implausible energy intake, 
supplement use 
Assessments 
FFQ 
Exercise habits assessed using 
interview 
 
Barr et 
al.2011 
(39) 
Groups 
N=198, PCOS 
Age (years) 
32.6 ± 6.3 
BMI (kg/m2)  
27.4 ± 7.3 
Location 
London, UK 
Race  
Caucasian: 97% PCOS 
Unknown: 3% PCOS 
PCOS definition not provided 
Exclusion criteria 
Pregnancy, breastfeeding, eating 
disorders and use of weight loss 
medications 
Assessments 
7-day food and activity record  
 
Greater daily nutrient intake in PCOS vs. controls 
(national survey reference)*:  
Total energy/d, CHO (g/d), protein (g/d), fat (g/d), 
fat (% energy/d), SFA (g/d), MUFA (g/d), PUFA 
(g/d), total sugar (g/d), fiber (g/d) 
Lower daily nutrient intake in PCOS vs. controls 
(national survey reference)*:  
CHO (% energy/d) 
Lower daily glycemic index in lean (N=80) vs. 
overweight PCOS (N=100) groups* 
PCOS group intake vs. UK recommended intake*: 
Above: total energy/d, protein (g/d), fat (g/d), SFA 
(g/d), MUFA (g/d), PUFA (g/d) 
Below: CHO (g/d), fiber (g/d) 
Greater activity in moderate intensity physical 
activity (min/day) in lean (N=80) vs. overweight 
(N=100) PCOS groups* 
 
Diagnostic criteria for PCOS not  
provided, heterogeneous PCOS 
cohort studied  
Recruitment based on self-reported  
diagnosis of PCOS 
Reference population may contain 
women with PCOS 
No reported exclusion criteria on  
medications that may influence 
endocrine profile 
Older, potentially perimenopausal,  
women included 
Did not report energy expenditure or  
energy balance 
 
Toscani et al. 
2011 
(37) 
Groups 
N=43, PCOS 
N=37, controls 
Age (years)3 
22.7 ± 5.6, PCOS 
No differences in nutrient intake between PCOS and  
control groups 
PCOS group intake vs. US recommended intake*: 
Below:  fiber (g/d), MUFA (% energy/d), PUFA 
(% energy/d) 
Study cohorts not matched for age 
No reported exclusion criteria on  
medications that may influence 
weight and appetite  
High reporting bias as participants may  
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Table 1.1. Cross-sectional study characteristics assessing diet and physical activity in women with and without polycystic ovary syndrome1  
Author(s) Sample, Assessments Used Outcomes2 Limitations 
29.7 ± 4.9, controls 
BMI (kg/m2) 
30.9 ± 5.5 PCOS  
29.7 ± 5.2 controls 
Location 
Porto Alegre, Brazil 
Race  
Caucasian: 90% PCOS; 74% controls 
African-European: 10% PCOS; 26% 
controls 
PCOS definition 
Oligoamenorrhea plus either 
hirsutism and/or hyperandrogenism 
Exclusion criteria 
Medications known to interfere with 
hormone levels, BMI>40kg/m2 and 
diabetes 
Assessments 
24-hour dietary recall 
 
No associations among androgen status and nutrients 
 
alter diet before scheduled visit 
Data on physical activity not collected 
Comparisons with US recommended 
intake may not be appropriate for 
Brazilian populations 
 
 
 
Tsai et 
al.2012 
(43)  
Groups 
N=45, PCOS 
N=161, controls 
Age (years) 
32.7 ± 4.2, PCOS 
34.7 ± 3.6, controls 
BMI (kg/m2)3  
23.0 ± 4.4, PCOS 
21.3 ± 2.9, controls 
Location 
Taipei, Taiwan 
Race not reported 
PCOS definition  
Greater daily nutrient intake in PCOS vs. control 
groups*: Fat (% energy/d) 
Lower daily nutrient intake in PCOS vs. control 
groups*:  
Total energy/d, CHO (g/d), CHO (% energy/d)  
Positive associations among hormones and nutrients 
in PCOS*:  
FSH and CHO (g/d), FSH and CHO (% energy/d) 
No differences in daily nutrient intake between  
hyperandrogenic (N=21) and non-androgenic 
(N=24) PCOS groups  
 
Diagnostic criteria used yielded  
heterogeneous PCOS cohort 
Control group comprised infertile  
women with various etiologies  
including unexplained infertility 
Study cohorts not matched for BMI 
No reported exclusion criteria on  
medications that may influence 
weight and appetite  
Power analysis not provided for post- 
     hoc comparisons among PCOS  
     phenotypes 
Data on physical activity not collected 
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Table 1.1. Cross-sectional study characteristics assessing diet and physical activity in women with and without polycystic ovary syndrome1  
Author(s) Sample, Assessments Used Outcomes2 Limitations 
Two of three symptoms: 1) 
oligoamenorrhea, 2) hirsutism and/or 
hyperandrogenemia, 3) polycystic 
ovaries 
Exclusion criteria 
Hormonal therapy 
Assessments 
3-day food record (2 weekdays, 1 
weekend day) 
 
Altieri et al. 
2013 
(49)  
Groups 
N=100, PCOS 
N=100, controls 
Age (years) 
27.7 ± 5.2, PCOS 
28.4 ± 5.8, controls 
BMI (kg/m2) 
34.7 ± 5.5, PCOS 
34.8 ± 5.4, controls 
Location 
Bologna, Italy 
Race not reported 
PCOS definition 
Two of three symptoms: 1) 
oligoamenorrhea, 2) hirsutism and/or 
hyperandrogenemia, 3) polycystic 
ovaries 
Exclusion criteria 
Endocrine or metabolic disorders, 
medications that influence appetite, 
reproduction, glucose or lipid levels, 
psychoactive drugs, eating disorders, 
intensive lifestyle interventions 
Assessments 
Greater daily nutrient intake in PCOS vs. control 
groups*:  
Fiber (g/d) 
Lower daily nutrient intake in PCOS vs. control 
groups*:  
Lipids (% energy/d) 
Greater starchy sweets (g/d), cheese (g/d), oil (g/d) 
in PCOS vs. control groups* 
Lower cooking fats (g/d) in PCOS vs. control groups* 
Positive associations among hormones and nutrients 
in PCOS*: 
A4 and total energy, A4 and protein (g/d), A4 and 
cholesterol (mg/d)) 
Negative associations among hormones and nutrients 
in PCOS*: 
SHBG and total energy/d, SHBG and CHO (g/d), 
SHBG and CHO (% energy/d), SHBG and 
oligosaccharides (g/d)  
Diagnostic criteria used yielded a  
heterogeneous PCOS cohort 
Data on physical activity not collected 
Did not compare intake with EFSA  
recommended intake which is 
established for European countries 
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Table 1.1. Cross-sectional study characteristics assessing diet and physical activity in women with and without polycystic ovary syndrome1  
Author(s) Sample, Assessments Used Outcomes2 Limitations 
7-day food records 
 
Moran et al. 
2013 
(40) 
Groups 
N=409, PCOS 
N=7057, controls 
Age (years)3 
33.5 ± 1.4, PCOS 
33.7 ± 1.5, controls 
BMI (kg/m2)3 
29.3 ± 7.5, PCOS  
25.6 ± 5.8, controls 
Location 
Australia (national survey) 
Race not reported 
PCOS definition not provided 
No specific exclusion criteria were 
applied 
Assessments 
FFQ 
Physical activity 1-week recall 
 
Greater daily nutrient intake in PCOS vs. control 
groups*: 
Total energy/d, fiber (g/d), folate (µg/d), iron 
(mg/d), magnesium (mg/d), phosphorus (mg/d), 
vitamin E (mg/d), sodium (mg/d)3, zinc (mg/d)3, 
calcium (mg/d)3, potassium (mg/d)3, niacin 
(mg/d)3 
Lower daily nutrient intake in PCOS vs. control 
groups*: 
SFA (% energy/d), glycemic index, retinol (µg/d) 
PCOS group reported higher diet quality than control  
group* 
PCOS group intake vs. US DRI *: 
Above: SFA (% energy) 
No differences in self-reported physical activity  
      between PCOS and control groups 
PCOS group reported greater amount of sitting time  
compared to controls* 
Recruitment based on self-reported  
diagnosis of PCOS 
Control group may contain  
      undiagnosed women with PCOS  
No reported exclusion criteria on  
medications that may influence 
weight, appetite or reproduction  
Cohorts included women who are  
pregnant women and using   
hormones 
Study cohorts not matched for age or  
BMI 
Did not compare intake with 
Australian nutrient reference values  
 
 
Graff et al. 
2013 
(42) 
Groups 
N=61, PCOS 
N=44, controls 
Age (years) 
22.7 ± 6.2, PCOS 
25.0 ± 6.3, controls 
BMI (kg/m2) 
28.9 ± 5.6, PCOS 
27.1 ± 5.7, controls 
Location 
Porto Alegre, Brazil 
Race  
Greater daily nutrient intake in PCOS vs. control 
groups*: 
Total energy/d, glycemic index3, glycemic load3, 
sodium (mg/d) 3 
Higher energy intake/d and glycemic index diet 
between Classic PCOS (N=39) and control (N=44) 
groups*  
Higher glycemic index diet between Classic PCOS  
(N=39) and Ovulatory PCOS (N=22) groups*  
No differences in total energy intake and glycemic  
      index diet between Ovulatory PCOS (N=22) and  
      control (N=44) groups  
Diagnostic criteria used yielded a  
heterogeneous PCOS cohort 
Included both adolescents and adults  
with PCOS 
No reported exclusion criteria on  
medications that may influence 
weight and appetite  
Power analysis not provided for post- 
     hoc comparisons among PCOS    
     phenotypes 
Pedometer may not comprehensively  
capture physical activity data 
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Table 1.1. Cross-sectional study characteristics assessing diet and physical activity in women with and without polycystic ovary syndrome1  
Author(s) Sample, Assessments Used Outcomes2 Limitations 
Caucasian: 88% of sample 
African-European: 12% of sample 
PCOS definition 
1) Classic PCOS: oligoamenorrhea, 
hirsutism and/or hyperandrogenemia 
with or without  polycystic ovaries; 
2) Ovulatory PCOS: hirsutism and 
polycystic ovaries in the presence of 
regular menstrual cycles and normal 
androgens 
Exclusion criteria 
Diabetes, medications that alter 
hormone levels, pregnancy, BMI ≥ 40 
Assessments 
FFQ 
6-day pedometer use 
 
No differences in physical activity between PCOS  
      and control groups 
 
Did not report energy expenditure or  
energy balance 
 
 
Ahmadi et al. 
2013 (41) 
Groups 
N=65, PCOS 
N=65, controls 
Age (years) 
25.1 ± 6.1, PCOS 
26.1 ± 6.5, controls 
BMI (kg/m2) 
23.4 ± 3.6, PCOS 
23.1 ± 3.8, controls 
Location 
Shiraz, Iran 
Race not reported 
PCOS definition 
Two of three symptoms: 1) 
oligoamenorrhea, 2) hirsutism and/or 
hyperandrogenemia, 3) polycystic 
ovaries 
Greater daily nutrient intake in PCOS vs. control 
groups*: 
Total kcal/d, fat (% energy/d), SFA (g/d), PUFA 
(g/d) 
No significant self-reported physical activity  
      differences between PCOS and control groups  
No differences in daily nutrient intake between lean  
(N=49) and overweight (N=16) PCOS groups 
 
Diagnostic criteria used yielded a  
heterogeneous PCOS cohort 
Power analysis not provided for post- 
     hoc comparisons among PCOS  
     groups 
Details on physical activity assessment  
tool not reported 
Did not report energy expenditure or  
energy balance 
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Table 1.1. Cross-sectional study characteristics assessing diet and physical activity in women with and without polycystic ovary syndrome1  
Author(s) Sample, Assessments Used Outcomes2 Limitations 
Exclusion criteria 
Liver, kidney and heart disease, 
hormone use, medications that 
influence metabolism or body 
composition, incomplete FFQ, 
implausible energy intake and 
intensive lifestyle interventions 
Assessments 
Three 24-hour recalls (2 weekdays, 1 
weekend day) 
Exercise habits assessed using 
demographic questionnaire 
1A4, androstenedione; CHO, carbohydrates; DGI, Dietary Guideline Index for Australian adults. Possible range 0 to 130 (highest compliance with 
guidelines); DRI, Dietary Reference Intake; EFSA, European Food Safety Authority; FSH, follicle stimulating hormone; FFQ, Food Frequency 
Questionnaire; MUFA, monounsaturated fatty acids; PCOS, polycystic ovary syndrome; PUFA, polyunsaturated fatty acids; SFA, saturated fatty acid; 
SHBG, sex hormone binding globulin; UK, United Kingdom; US, United States.  
2Only data pertaining to diet and/or physical activity reported 
3Not significant after adjustment for energy intake or age and BMI 
*P < 0.05 
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When the data were pooled without regard to body composition, both Wright et 
al. (36) and Douglas et al. (35) reported no significant differences in micro- and/or 
macronutrient intake among women with PCOS and controls. The data were consistent 
with studies conducted in Italy (40,41) and Spain (42), in which researchers either 
reported no differences in energy and/or nutrient intake among women with and without 
PCOS as evidenced by 24-h dietary recall, 7-d food records, and FFQ (35,36). However, 
Douglas et al. (35) noted that the PCOS group consumed more servings of white bread 
compared with the control group. When dietary intake was assessed with respect to BMI 
categories, Wright et al. (36) reported that normal weight women with PCOS (BMI <25 
kg/m2) consumed significantly lower total energy diets compared with BMI-matched 
women without PCOS (~400 fewer kcal). This may be attributed to the lower reported 
intakes of carbohydrates (~43 g), protein (~15 g), total fat (~19 g), saturated fat (~5 g), 
monounsaturated fat (~7 g), polyunsaturated fat (~6 g), and cholesterol (~60 mg) by the 
normal weight PCOS group compared with controls. An examination of food servings 
also revealed that normal weight women with PCOS consumed less bread, cereal, rice, 
pasta, and meat products compared with BMI-matched controls. This may be considered 
clinically significant as it provided an energy difference of ≥250 kcal/d between the 2 
groups. These findings led Wright et al. to hypothesize that women with PCOS within 
a normal weight range restricted their daily energy intake to a clinically significant 
margin to offset weight gain. In the higher BMI categories, Wright et al. noted no 
differences in overall macronutrient and energy intake among overweight and obese 
women with PCOS compared with their respective BMI-matched controls. Overweight 
women with PCOS reported lower intakes of milk products compared with overweight 
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controls, whereas obese women with PCOS reported consuming more servings of meat, 
fish, poultry, and eggs than the obese controls. Most of these differences were less than 
1 serving apart. This may or may not be considered clinically significant, depending on 
the type of protein consumed. 
By using the 7-d food records from a large cohort of women (n = 198) with a 
self-reported PCOS diagnosis, Barr et al. (43) reported that women with PCOS in the 
United Kingdom had higher total energy intakes (~350 kcal) compared with a reference 
population. They noted that women with PCOS consumed higher amounts of total 
carbohydrates (229.0 vs. 198.0 g), protein (78.0 vs. 66.3 g), dietary fat (85.0 vs. 61.1 g), 
saturated fat (26.5 vs. 22.2 g), monounsaturated fat (29.7 vs. 21.7 g), polyunsaturated 
fat (16.2 vs. 12.6 g), sugar (102.0 vs. 87.4 g), and dietary fiber (16.5 vs. 13.0 grams) 
compared with a reference population (43). On the basis of these results, it can be 
recommended that sugar intake should be monitored when conducting dietary 
assessments in patients with PCOS in the United Kingdom. Barr et al. also reported that 
overweight women with PCOS consumed higher glycemic index diets compared with 
normal weight women with PCOS. These findings were consistent with reports from 
Australia involving a cohort of women (n = 409) with a self-reported diagnosis of PCOS 
(44). Moran et al. (44) noted a small, but statistically significant difference in total daily 
energy intake (~50 kcal) between women with PCOS and controls on the basis of a 
validated FFQ. The PCOS group consumed higher amounts of iron (12.3 vs. 11.6 mg), 
magnesium (272 vs. 258 mg), phosphorus (1471 vs. 1401 mg), and vitamin E (5.9 vs. 
5.6 mg) when adjusted for total daily energy intake and lower amounts of saturated fat 
(15.1% vs. 15.4% of energy) and retinol (295 vs. 311 mg). Although the studies by Barr 
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et al. (43) and Moran et al. (44) represent the largest studies that assessed dietary intake 
in PCOS to date, both were limited by their reliance on a self-reported diagnosis of 
PCOS. It is possible that the control populations contained women with PCOS and/or 
other endocrine issues because Barr et al. (43) did not exclude PCOS features from their 
control population survey. Moran et al. used a diagnostic question within a survey that 
restricted PCOS diagnosis and treatment to within 3 y. This may have classified women 
with PCOS who were diagnosed earlier in their lives or not seeking treatment as 
controls. Collectively, there is the potential for differences in dietary intake between 
groups to be underestimated by these studies.  
Higher energy diets were also reported in Iranian (45) and Brazilian (46) women 
with PCOS. Ahmadi et al. (45) compared the 3-d, 24-h dietary recalls of Iranian women 
with and without PCOS and noted that overall daily energy intake was higher (~300 
kcal) in women with PCOS. Iranian women with PCOS also reported higher total fat 
(~2% kcal), polyunsaturated fat (0.6 g), and saturated fat (0.8 g) intakes compared with 
controls. This was contradicted by Altieri et al. (40), who reported that the Italian PCOS 
group consumed a lower fat diet (~1% kcal) compared with healthy controls. The 24-h 
dietary recall used by Ahmadi et al. has similar disadvantages to a FFQ because it relies 
on participant memory. However, it is a convenient method that can provide accurate 
dietary information when collected by a trained interviewer using standardized 
approaches. Similar to Ahmadi et al., Graff et al. (46) reported that Brazilian women 
with PCOS had higher total daily energy intakes (~250 kcal) compared with controls 
with the use of an FFQ. Brazilian women with PCOS reported consuming a higher 
glycemic index (2 units), glycemic load (~33 units), and sodium (~430 mg) diet. 
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However, these differences disappeared after adjusting for age and BMI. Graff et al. 
(46) recognized the heterogeneous composition of their PCOS population and 
performed an assessment of dietary intake on the basis of PCOS phenotypes. They found 
that women with a classical form of PCOS (i.e., chronic anovulation and 
hyperandrogenism), but not those with ovulatory PCOS (i.e., hyperandrogenism, 
polycystic ovaries but regular menstrual cycles), had significantly higher total daily 
energy intake compared with controls. These differences became negligible after 
adjusting for age and BMI. Last, Tsai et al. (47) investigated dietary intake in Taiwanese 
women with PCOS by using 3-d food records. Taiwanese women with PCOS reported 
lower total daily energy intakes (110 kcal) compared with infertile women without 
PCOS. The PCOS group consumed more total dietary fat (~3% of energy) but lower 
amounts of total daily carbohydrates (~4% of energy; 30 g), which likely accounted for 
the energy difference between groups. Comparing the results of this study with others 
is challenging because groups were not matched for BMI and their control population 
comprised infertile women (including those with unexplained infertility). 
Comparison with national dietary guidelines. Six of the 10 studies compared nutrient 
intake in women with PCOS with established dietary guidelines (35,36,41–43,48). 
Wright et al. (36) noted that women with PCOS in the United States had slightly higher 
carbohydrate and lower fat intakes compared with the dietary recommendations for 
insulin resistant individuals established by Reaven (49) (i.e., diet consisting of 45% 
carbohydrates, 15% protein, 10% polyunsaturated fat, 20% monounsaturated fat, and 
<10% saturated fat). The Reaven recommendations may not be an optimal comparator 
for this population because certain PCOS phenotypes may not be prone to insulin 
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resistance (50) and the low carbohydrate recommendation may be difficult to achieve 
in a free-living setting. When compared with the 2010 Dietary Guidelines for Americans 
(51), women with PCOS in the United States consumed excessive saturated fat (12% of 
total daily energy intake vs. <10% of total daily energy intake). The PCOS group 
consumed amounts within the Acceptable Macronutrient Distribution Ranges for 
carbohydrate and protein (51), which was similar to the results of the U.S. study 
conducted by Douglas et al. (35). Douglas et al. (35) determined that the PCOS group 
consumed more than the recommended amount of saturated fat as established by the 
National Cholesterol Education Program (<7% kcal/d). The PCOS group also exceeded 
American Heart Association recommendations for sodium (≤2400 mg/d) and did not 
meet dietary fiber recommendations (25–30 g/d). When compared with the 2010 
Dietary Guidelines, their reported values are consistent with the conclusion that 
American women with PCOS consume excessive sodium and insufficient fiber in their 
diets (35,51). When the PCOS group was stratified by BMI, normal weight and obese 
women with PCOS exceeded dietary fat Acceptable Macronutrient Distribution Range 
recommendations by 2% and 5%, respectively, whereas overweight women with PCOS 
consumed within the normal range (36). This emphasizes the importance of accounting 
for BMI when assessing nutrient intake within the PCOS population. 
Barr et al. (43) used the UK’s Reference Nutrient Intake (RNI) guidelines to 
determine whether their PCOS group met dietary guidelines. On the basis of the results, 
women with PCOS exceeded the reference intakes for fat (i.e., total fat, saturated fat, 
polyunsaturated fat) and mean dietary glycemic index but did not meet fiber 
recommendations. The reported values also indicated that women with PCOS in the 
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United Kingdom consumed more protein and but did not meet carbohydrate 
recommendations. The RNI established in the United Kingdom may not be an 
appropriate measure to determine nutrient adequacy (52). There is significant potential 
to overestimate the percentage of women with PCOS who are not meeting dietary 
guidelines because the RNI values are defined as nutrient intakes required to meet the 
recommendations for 97.5% of a national population. 
Álvarez-Blasco et al. (42), Toscani et al. (41), and Moran et al. (44) used DRIs 
established in the United States to assess nutrient intake in Spanish, Brazilian, and 
Australian populations, respectively (Table 1.1). The dietary recommendations 
designed to meet the needs of the American population may not be a useful reference 
for countries that have different dietary patterns, food environment, and cultural beliefs 
and the potential for genetic variations in metabolism. The European Food Safety 
Association has established dietary reference values for the intake of carbohydrates, 
fats, and water that are likely more appropriate for European countries, including Spain 
(53). Similarly, the Australian National Health and Medical Research Council and the 
New Zealand Ministry of Health have established nutrient reference values specifically 
for the Australian and New Zealand populations (54). To the best of our knowledge, 
there are no established South American nutrient value recommendations. 
When comparing the dietary intake results with the corresponding national 
dietary guidelines, we concluded that Spanish, British, and Australian women with 
PCOS exceeded the recommended intakes for total, saturated, and/or monounsaturated 
fats when compared with women without PCOS (42–44). Álvarez-Blasco et al. (42) 
reported that women with PCOS in Spain exceeded the U.S. recommended dietary 
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cholesterol intake, while not meeting the fiber, potassium, and vitamin E 
recommendations. Both Spanish (42) and Italian (40) women with PCOS consumed 
excessive total fat but inadequate fiber when compared with European Food Safety 
Association recommendations. Similarly, Australian women with PCOS had inadequate 
fiber and vitamin E intakes compared with the Australian nutrient reference values (44). 
The global data indicate that women with PCOS exceed total fat and saturated fat 
recommendations, while not meeting recommended amounts of dietary fiber in their 
diet. Women without PCOS included in these studies appear to have similar results 
when comparing nutrient intake to national nutrient reference values across countries. 
Meeting nutrient recommendations may be a key public health issue for clinicians and 
researchers to resolve across both PCOS and non-PCOS populations. 
Biomarkers and diet. Two of the studies included in this review determined associations 
between biochemical markers and nutrients (Table 1.1). Tsai et al. (47) reported a 
positive association between carbohydrate intake (g and % of energy) and follicle-
stimulating hormone. Follicle-stimulating hormone is a hormone that promotes 
follicular growth in the ovaries and is typically lower compared with its companion 
gonadotropin (luteinizing hormone) in a subset of women with PCOS (55,56). Altieri et 
al. (40) observed positive associations of total energy, protein (g), and cholesterol 
intakes with androstenedione (a precursor of testosterone). Although androstenedione 
is not a diagnostic marker of PCOS, a subgroup of women with PCOS exhibit elevated 
concentrations of this androgen (57). Collectively, these data are consistent with the 
hypothesis that PCOS symptoms may be related to dietary intake. Further research is 
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needed to corroborate these findings and to determine the physiologic mechanisms 
behind these associations. 
Physical activity. Six of the 10 studies performed an evaluation of physical activity 
levels in women with PCOS (36,42–46). By using a validated physical activity 
questionnaire, Wright et al. (36) did not detect any differences in self-reported physical 
activity levels between American women with PCOS and healthy controls. Both the 
PCOS and control groups reported similar amounts of time engaged in various activities, 
including vigorous, moderate, and light activity, as well as sleeping or reclining, for 
typical weekdays or weekend days. These findings were consistent with those of 
Álvarez-Blasco et al. (42), Ahmadi et al. (45), and Graff et al. (46), who also noted no 
differences in overall physical activity among Spanish, Iranian, and Brazilian women 
with or without PCOS. Wright et al. (36) noted that women with PCOS reported greater 
sitting time. Unlike the findings in an Australian cohort (44), this difference did not 
reach significance (P = 0.064). Wright et al. (36) did not detect differences in physical 
activity among PCOS and control groups when the data were analyzed by BMI 
categories (i.e., normal weight, overweight, and obese). 
By using 7-d activity records, Barr et al. (43) showed that the majority of women 
with PCOS (74%) in their UK study reported achieving 30 min of daily moderate-
intensity activity. This was consistent with the UK national recommendations for 
healthy living (58). Approximately half of the overweight and obese women with PCOS 
did not achieve the recommended 60 min of daily moderate-intensity activity (43). The 
authors admit that a self-selected sample might not have yielded a representative sample 
of women with PCOS because their approach may have overestimated physical activity 
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due to the inclusion of highly motivated individuals. This study did not include 
comparisons with healthy age- and BMI-matched controls. Rather, Barr et al. (43) 
examined the potential for differences in physical activity among normal weight and 
overweight women with PCOS. They noted that normal weight women with PCOS 
reported longer durations of moderate-intensity physical activity compared with 
overweight and obese women with PCOS of the same age. Coupled with their findings 
of lower glycemic index diets in normal weight women with PCOS, this study supported 
that diet and physical activity behaviors were associated with BMI among women with 
PCOS.  
The emerging data about physical activity levels in women with PCOS are 
challenging to interpret because none of the studies used the same physical activity 
evaluation tool. The limitations for the methods used merit consideration. Wright et al. 
(36) used the Paffenbarger Physical Activity Questionnaire, which has been primarily 
validated in mixed-gender populations (59). It is uncertain whether this tool provides an 
accurate measure of physical activity for pre- and perimenopausal women with PCOS. 
Álvarez-Blasco et al. (42) and Ahmadi et al. (45) evaluated physical activity on the basis 
of an assessment of exercise habits by using interview questions. The validity of this 
approach is uncertain because the details regarding the validation of their interview tools 
were not provided. The 7-d activity records used by Barr et al. may be considered a 
more accurate quantification of physical activity since because is minimal dependence 
on memory, in contrast to the 7-d self-recall implemented in the Australian study (43). 
However, 7-d activity records place greater burden on participants, which can impact 
the reporting accuracy. Graff et al. (46) was the only research group to eliminate recall 
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bias and use pedometers, which objectively quantified 6 d of physical activity among 
participants. Graff et al. reported no difference in physical activity levels between 
women with or without PCOS. Although these data are strengthened by their inclusion 
of an objective measure of physical activity, we are unaware of any validation study on 
the pedometer model that was used. Moreover, pedometers may have low accuracy 
when assessing energy expenditure (60). Future studies would benefit from a 
combination of objective and subjective instruments in the situation that the objective 
tool may malfunction in the field. Information on perceptions of physical activity may 
also have relevance when used in conjunction with objective measures. 
SUMMARY AND FUTURE RECOMMENDATIONS 
It is important to recognize that studies assessing diet and physical activity of 
women with PCOS used broad definitions for PCOS. This creates a challenge when 
interpreting the literature because the PCOS group comprise of several distinct clinical 
phenotypes. Most research groups used criteria supported by the American Society for 
Reproductive Medicine and the European Society of Human Reproduction and 
Embryology, known as the Rotterdam criteria (61), which yield heterogeneous PCOS 
phenotypes. Hormonal and metabolic differences exist among these clinical phenotypes, 
which may serve as confounding factors when examining lifestyle variables (62,63). As 
Graff et al. (46) demonstrated, there may be distinct differences in dietary intake among 
clinical phenotypes of PCOS. This is consistent with repeated reports that women with 
milder variants of PCOS have improved metabolic status and different health risks 
compared with those with more severe phenotypes (64,65). Researchers must establish 
 26 
 
a clear distinction between PCOS status to provide an accurate comparison of lifestyle 
habits between women with and without clinical variants of PCOS. 
Energy balance is an important determinant of weight that has not been 
adequately explored in women with PCOS. Few studies performed concomitant 
assessments of physical activity when examining dietary intake in women with PCOS. 
Future studies would be strengthened by the addition of objective tools to measure 
physical activity (e.g., accelerometers), which can provide an unbiased account of 
energy expenditure. Although there are emerging data on the associations between 
biochemical markers and dietary intake, more of these analyses are needed in PCOS 
populations to develop hypotheses related to potential predictors of dietary intake and 
physical activity in women with PCOS. Dietary interventions featuring weight loss were 
shown to have a positive effect on reproductive outcomes (27,30,31,48). However, 
methods to maintain weight loss should be further examined. Researchers should 
consider the interaction between environmental influences, personal beliefs, and 
biological variables in women with PCOS to fully understand influences on diet and 
physical activity behaviors. Experts have suggested that depression and/or low self-
esteem place women with PCOS at higher risk of emotional eating and decreased 
exercise, which contribute to a long-term positive energy balance and weight gain (66). 
By examining and understanding these associations, it may be possible to identify 
potential key intervention targets with a high likelihood for success in the PCOS 
population. The roles of race and ethnicity also merit further consideration. There is 
existing evidence supporting racial disparities in reproductive function among women 
with PCOS (67,68). Because only a few studies disclosed the race of their participants, 
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we were unable to draw any conclusions regarding any potential influence of race on 
dietary intake or physical activity.  
CONCLUSIONS 
This review is the first to our knowledge to summarize the literature on dietary 
intake and physical activity in women with and without PCOS and to provide 
recommendations to strengthen research within this area. There are emerging global 
data that women with PCOS have different dietary intakes compared with women 
without PCOS. Although the limited number of studies in the United States suggest that 
dietary intake is similar to that of women without PCOS irrespective of BMI (35,36), 
both studies recommend that diet and its effect on metabolic outcomes be more 
thoroughly examined in this population. These recommendations were based on the 
observation that differences existed in the consumption of certain foods among women 
with PCOS (e.g., high glycemic index), despite similarities in overall energy or nutrient 
intake. Moreover, notable differences in dietary intake were evident in women with 
PCOS when BMI was taken into consideration. Internationally, most studies indicate 
higher energy intakes in women with PCOS, with excessive saturated fat and inadequate 
fiber consumption. However, there appears to be no significant differences in self-
reported physical activity between women with and without PCOS. The use of objective 
tools may be the next step to determine energy expenditure in this population. Moving 
forward, we recommend that researchers incorporate life stage and clinical phenotypes 
into their analysis when examining dietary intake and physical activity in the PCOS 
population. Larger sample sizes with sufficient power to discern the impact of BMI and 
clinical phenotype will also serve to strengthen future studies. 
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Supplementary Table S1.1. Summary of cross-sectional study characteristics used in 
narrative review1  
Characteristics Summary 
 
Mean Age Range 
 
22.7 to 46.7 years 
 
Mean BMI Range 
 
23.0 to 35.2 kg/m2 
 
Race Distribution 
 
White: 83 to 97% 
Black: 10 to 13% 
Other: 3 to 13% 
 
Countries (N, number of studies) 
 
Australia (N = 1) 
Brazil (N = 2) 
Iran (N = 1) 
Italy (N = 1) 
Spain (N = 1) 
Taiwan (N = 1) 
United Kingdom (N =1) 
United States (N = 2)  
 
PCOS Definitions (N, number of studies) 
 
NIH (N=4) 
Rotterdam (N=4) 
Other/Unknown (N= 2) 
 
PCOS Sample Size Range 
 
22 to 409 participants 
 
Diet Assessments (N, number of studies) 
 
Food frequency questionnaire (N = 4) 
Food records (N = 4) 
24-hour recall (N = 2) 
 
Number of Studies Compared with 
Government Recommended 
Guidelines 
 
3 studies (no US studies) 
 
Physical Activity Assessments 
 
Physical activity questionnaire (N =2) 
Interviews (N = 1) 
Records (N =1) 
Pedometer (N = 1) 
 
Limitations  
 
Older population 
Objective instruments not used to measure  
    physical activity 
Not many studies compared with government 
    recommended guidelines 
1 Not all studies included information about these characteristics, summary results are based on 
available data.  
 
Abbreviations: BMI, Body Mass Index 
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CHAPTER 2: USUAL DIETARY INTAKE AND PHYSICAL ACTIVITY 
LEVELS OF WOMEN WITH POLYCYSTIC OVARY SYNDROME (PCOS) IN 
THE CARDIA WOMEN’S STUDY (CWS)  
Working Manuscript 
Plan to Submit: October 31, 2017 to Journal of Nutrition 
ABSTRACT 
Background: Current evidence supports adoption of healthy diet and physical activity 
(PA) behaviors in PCOS patients, given positive effects on their physical and emotional 
well-being. However, an improved understanding of the associations between dietary 
and PA behaviors with PCOS is needed to develop tailored interventions for this 
population.  
Objective: This study investigated the cross-sectional associations between diet and PA 
behaviors with PCOS. Associations between these behaviors and isolated PCOS 
features, as well as any modifying effect of race, were also examined. 
Methods: Of the 748 women who participated in the Coronary Artery Risk 
Development in Young Adults (CARDIA) Women’s Health Study, 40 were classified 
as having PCOS, 104 had isolated hyperandrogenism (IH) and 75 had isolated 
oligomenorrhea (IO). The remaining 529 participants comprised the reference group. 
Diet quality was computed using the Alternative Healthy Eating Index 2010 (AHEI-
2010) and self-reported PA was measured using a validated interviewer-administered 
questionnaire. Multinomial logistic regression analyses examined the associations 
between diet and PA (exposure variables) and the PCOS, IH, and IO outcomes, 
adjusting for age, race, total energy intake, and education. The threshold for statistical 
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significance was set at P<0.10 because of the low number of outcomes available for 
analysis.  
Results: The mean age was 25.4 (SD 3.6) years and 46.8% of participants were black. 
In considering dietary quality using the AHEI total score and subscores, there was little 
to no association of total score with odds of the outcomes. For the subscores, a lower 
intake of red and processed meat was associated with lower odds of PCOS (OR = 0.90; 
90% confidence interval, 0.81-0.99). In analyses of vegetable consumption, there was 
evidence for effect modification by race; a higher vegetable intake score was associated 
with lower odds of PCOS in black women only [β=-0.33 (SE 0.19); Pinteraction=0.08]. In 
contrast, a higher score on whole grain consumption was positively associated with odds 
of PCOS [β=0.29 (SE 0.15); Pinteraction=0.08] and IO [β=0.21 (SE 0.12); Pinteraction=0.07] 
in black women, but little to no association was found in white women. There was little 
to no association of macro- or micronutrients, or of PA, with PCOS, IH or IO.  
Conclusions: Food groups, but not nutrient composition or PA, were associated with 
PCOS, and findings varied by race. Longitudinal studies evaluating the preventive 
impact of better diet quality are needed to establish the temporal direction of diet and 
PA behaviors on the development and progression of PCOS, and our findings suggest 
there may be differences by race.  
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INTRODUCTION 
Little is understood about the role of diet and physical activity (PA) in the 
development of polycystic ovary syndrome (PCOS), a complex disorder characterized 
by oligomenorrhea, hyperandrogenism and/or polycystic ovaries (1). Anovulatory 
infertility is a common consequence of PCOS (2), yet represents only one of many 
health concerns that can impact PCOS patients across the lifespan (3,4). In particular, 
PCOS is closely associated with metabolic complications (such as hyperinsulinemia and 
abdominal obesity), which are hypothesized to propagate androgen production and 
impair ovarian function (5). Observational studies have linked poorer diet composition 
and lower PA levels to features of PCOS (higher antral follicle count and biochemical 
androgens) and surrogate markers of infertility (lower progesterone concentrations, self-
reported infertility) (6–16). These findings are consistent with about 5 studies that 
reported differences in total energy (17–21) and fat (17,18,21–23) intake between 
women with and without PCOS. Of the six studies that investigated PA, one study found 
women with PCOS reported longer sitting intervals than the comparison group (19). 
The other studies, with smaller sample sizes, reported no associations between diet and 
PA with PCOS (24), leaving this an area of current controversy.  
Mixed evidence for the association of diet and PA with PCOS may be partly 
attributed to the differences in the diagnostic criteria for PCOS between studies. PCOS 
defined by the combined presence of oligomenorrhea and androgen excess  defines the 
most severe manifestation of the syndrome [National Institutes of Health (NIH) criteria; 
(25)]. Though women with isolated features of oligomenorrhea and hyperandrogenism 
do not meet NIH PCOS diagnostic criteria, these women are considered to be at risk for 
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the development of PCOS, particularly if they later experience common physiological 
stressors (for example, weight gain) (4,26). Thus, understanding how diet and PA 
associate with both PCOS and the isolated features of PCOS (IH and IO) may generate 
further hypotheses about the role of diet and PA in the development of PCOS.  
Race and ethnicity influence the likelihood of adverse metabolic outcomes 
associated with PCOS (27–32). Studies of U.S. women with PCOS reported a higher 
odds and/or prevalence of abnormal fasting glucose concentrations (28,31), obesity, and 
hypertension (29,30) in black women with PCOS compared to white women with 
PCOS. A recent consensus statement from the European Society of Human 
Reproduction and Embryology (ESHRE) and the American Society for Reproductive 
Medicine (ASRM) pointed out these racial differences and emphasized the importance 
of investigating the best management practices for PCOS across races and ethnicities 
(3). The majority of studies reporting the associations of diet and physical activity with 
PCOS do not investigate whether associations vary by race, highlighting an important 
research gap. 
General dietary modifications for weight loss are currently recommended to 
treat or prevent adverse reproductive and metabolic outcomes in overweight and obese 
women with PCOS (5,33,34). Despite the unique metabolic and reproductive 
complications associated with PCOS, there are no specific dietary or PA 
recommendations for PCOS patients (35). A demonstration of specific differences in 
health-related behaviors between women with and without the isolated features of 
PCOS would help inform potential treatment recommendations. The primary objective 
of this study was to investigate associations between dietary and PA behaviors with 
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PCOS, to consider whether these associations were similar in black and white women, 
and to examine the consistency of association when the outcome is an isolated feature 
of PCOS (i.e., either hyperandrogenism alone or oligomenorrhea alone).  
METHODS 
Study Design and Sample 
The research questions were addressed in the Coronary Artery Risk 
Development in Young Adults (CARDIA) multi-center longitudinal prospective cohort 
study. From 1985 to 1986, CARDIA investigators enrolled 5115 men and women, ages 
18 to 30 years of age residing in one of four cities: Birmingham, AL; Chicago, IL; 
Minneapolis, MN; and Oakland, CA. Participants visited research centers at years 2, 5, 
7, 10, 15 and 20 after the initial examination (year 0), with a 72% retention rate at year 
20. Anthropometry (e.g., height, weight) and venipuncture were performed at each 
examination. Details about additional CARDIA procedures are described elsewhere 
(36). At year 16 (2002-2003), a subset of women were enrolled in an ancillary study 
(CARDIA Women’s Study; CWS) that investigated associations among androgens, 
polycystic ovaries and cardiovascular risk factors. Women were eligible if they had 
participated in the year 15 examination, had at least one ovary and were not pregnant. 
Eighty-six percent (n = 1163) of eligible women in the CARDIA cohort enrolled in the 
CWS (ages 34 – 46 years). As part of CWS, participants completed questionnaires about 
their reproductive health history and the occurrence of unwanted hair growth when they 
were between the ages of 20 and 39 years, an age range that coincided with years 0 and 
2 of the CARDIA study. Exclusion criteria for this current study included missing data 
on PCOS features (n = 294), pregnancy and/or breastfeeding at year 2 (n=103), and 
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implausible total energy (kcal) intake (defined as <600 and >6000 kcal) (n=18). The 
sample for the cross-sectional study reported herein comprised 748 women (64%) from 
the CWS cohort who had dietary and PA data collected at year 0 of the CARDIA study. 
The Institutional Review Board at each CARDIA research site approved the study 
protocol and all participants provided written informed consent.  
Group Definitions 
Participants were classified into four mutually exclusive groups: 1) PCOS; 2) 
isolated hyperandrogenism (IH); 3) isolated oligomenorrhea (IO); and 4) reference (i.e., 
participants in the CARDIA CWS study with neither PCOS, IH, nor IO). National 
Institutes of Health (NIH) criteria [both oligomenorrhea (irregular menstrual cycles) and 
hyperandrogenism (clinical and/or biochemical)] were used to identify women with 
PCOS. Women were considered to have oligomenorrhea if they reported menstrual 
cycle lengths ≥ 34 days during their 20s and 30s on the year 16 reproductive history 
questionnaire. Women were considered to have hyperandrogenism if they reported 
unwanted hair growth at two or more regions of the body (with the exception of the 
lower leg and/or underarm) during their 20s and 30s on the year 16 reproductive  history 
questionnaire, or, if there was evidence of biochemical hyperandrogenemia in serum 
samples taken at year 2. Biochemical hyperandrogenemia was defined as total 
testosterone (T) ≥ 76 ng/dL and/or free T ≥ 0.69 ng/dL; cut points were defined by the 
95th percentile of androgen concentrations in CWS women with regular menstrual 
cycles (20 to 30 days) and no symptoms of unwanted hair growth during their 20s or 
30s (N=415). Androgens and sex hormone binding globulin were assayed by the 
OB/GYN Research and Diagnostic Laboratory at the University of Alabama, 
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Birmingham as previously described (37). Women who had only one of the two PCOS 
criteria were classified as either IH or IO. Women with regular menstrual cycles and no 
evidence of hyperandrogenism comprised the reference group.  
Data Collection 
Diet and physical activity measurements 
Year 0 dietary data, collected using the interviewer-administered CARDIA Diet 
History, were studied given the close proximity to the year 2 androgen concentrations 
(38). Participants reported their dietary intake in the past 28 days, including the 
frequency and amount of food consumption and methods of food preparation. Forty-six 
food and beverage subgroups were defined by the Nutrient Data Software for Research 
(NDSR; University of Minnesota, Minneapolis, MN). The intake of each food or 
beverage intake subgroup was calculated by summing the number of daily servings of 
items included in the subgroup.  
Diet quality was scored using the Alternate Healthy Eating Index 2010 (AHEI-
2010). The AHEI-2010 includes 11 dietary components (seven food groups, four 
nutrient groups) that have been linked to multiple adverse health outcomes, including 
cardiovascular disease and diabetes (39). Each dietary component score ranged from 
zero to ten, with a higher score representing a healthier diet. The total AHEI-2010 score 
was calculated as the sum of all 11 components and ranged from 0 to 110 (higher score 
represents more optimal quality diet). The 46 NDSR food and beverage subgroups were 
sorted into the seven AHEI-2010 food groups (Supplemental Figure S2.1). Higher 
intakes of vegetables, fruits, whole grains, nuts/legumes, long chain omega 3 fatty acids 
(eicosapentaenoic and docosahexaenoic acids; EPA+DHA), polyunsaturated fatty acids 
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(PUFAs without EPA+DHA) were assigned higher scores. Sugar-sweetened beverages 
and fruit juices, red and processed meats, trans-fats and sodium were assigned scores 
on a reverse scale due to their association with adverse health outcomes (thus, higher 
scores indicate lower consumption). Given the complex relation of alcohol to health 
outcomes, women who consumed 0.5 to 1.5 drinks/day were assigned the highest score 
(score of 10), women who consumed >1.5 drinks/day were assigned the lowest scores, 
and non-drinkers were assigned a score of 2.5.  
Self-reported PA data were collected during year 0 with the CARDIA Physical 
Activity History questionnaire, which asked about the frequency of 13 types of 
moderate and vigorous intensity activities in the past year (40,41). This questionnaire 
was adapted and simplified from the Minnesota Leisure Time Physical Activity 
Questionnaire. The PA score of each category was calculated by multiplying the 
frequency and intensity of each activity in that category and then computing the sum 
across all included activities. Activity scores were expressed as ‘exercise units’ (EU) 
since the questionnaire did not contain separate questions on the duration of each 
activity. However, a score of approximately 100 EU is equivalent to a vigorous exercise 
class that meets two to three hours a week for half a year (42).  
Sociodemographic and clinical measurements 
Sociodemographic data (age, race, education) were collected at year 0 using 
interviewer-administered questionnaires. Participants changed into light clothing and 
removed their shoes prior to anthropometric measurements taken by trained research 
staff. Weight was obtained using a digital scale (Detecto model 439; Webb City, MO) 
and measured to the nearest 0.2 pounds. Height was collected using a vertical mounted 
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ruler and measured to the nearest 0.5 centimeters. Body mass index (BMI) was 
calculated as weight in kilograms divided by height in meters, squared.  
Statistical Analyses  
Statistical analyses were performed using SAS 9.4 (SAS Institute, Cary NC). 
The statistical significance threshold was set at P < 0.05 for the bivariate analyses. The 
t-test was used to test the difference in the means of continuous variables across groups, 
and χ2 tests were used to test categorical variable differences by group. Fully adjusted 
multinomial logistic regression models estimated the association of dietary and PA 
(continuous) variables with the odds of PCOS, IH and IO after adjusting for age and 
BMI (continuous), and race (categorical). To investigate whether associations between 
health-related behaviors with combined and isolated features of PCOS varied by race, 
regression models were extended to include interaction terms between race and the 
dietary and PA variables. The significance level threshold for logistic regression models 
was set at P < 0.10 due to the small sample size in the PCOS group (43).  A focus on 
effect sizes and confidence intervals (CI) to address the precision of the estimates is 
supported by the American Psychological Association (44). Sensitivity analyses omitted 
women on oral contraceptives from the reference group.  
RESULTS 
Participant Characteristics 
Among the 748 participants included in this analysis, 40 (5.3%) women were classified 
as PCOS, 104 (13.9%) as IH, 75 (10.0%) as IO, and 529 comprised the reference group. 
Mean age and BMI were similar across the four groups (Table 2.1 and Supplemental 
Table S2.1).  Compared to the reference group, there were lower proportions of black 
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women in the PCOS and IO groups, and a higher proportion of women with advanced 
degrees in the PCOS group (P < 0.05).  
Association of Dietary Intake and PA with PCOS 
 Multinomial logistic regression models identified one food group that was 
statistically significantly associated with PCOS (Table 2.2). A higher AHEI-2010 red 
and processed meat intake score was associated with a lower odds of PCOS in the 
partially adjusted model [OR 0.90 (90% CI: 0.81, 0.99); P = 0.05]. A one-unit increase 
in AHEI-2010 red and processed meat scores is equivalent to a decrease of one serving 
per week, thus lower red and processed meat intake was associated with a lower odds 
of PCOS. Although the coefficient for red and processed meat intake did not reach the 
statistical significance threshold in the fully adjusted model [OR 0.92 (90% CI: 0.83, 
1.01); P = 0.15], the effect size was similar between models. There were no significant 
associations of individual macro- or micronutrients, or PA with the odds of PCOS 
(Supplemental Table S2.2). 
The consideration of whether the association of food group variables with PCOS 
differed by race (Table 2.3) was tested next. We found that a higher AHEI-2010 
vegetable score was associated with a lower odds of PCOS, but only in black women 
[β=-0.33 (SE 0.19); Pinteraction=0.08]. A one-unit increase in AHEI-2010 vegetable score 
is consistent with an increase of one serving of vegetables per day, and was associated 
with 27% lower odds of PCOS in black participants. Differential associations by race 
were found for AHEI-2010 whole grain scores [βinteraction=0.29 (SE 0.15); 
Pinteraction=0.05] such that half a serving of whole grains per day was associated higher 
  
Table 2.1. Characteristics of participants in the CARDIA Women’s Study cohort by group1 
Variable PCOS  (n = 40) 
IH  
(n = 104) 
IO  
(n = 75) 
Reference  
(n = 529) 
Age, years  24.7 ± 3.6 25.6 ± 3.8 25.4 ± 3.8 25.4 ± 3.6 
Black, n (%) 11 (27.5)2 57 (54.8) 26 (34.7)2 256 (48.4) 
Center, n (%)     
   Birmingham, Alabama 8 (20.0) 22 (21.6) 14 (18.7) 125 (23.9) 
   Chicago, Illinois 5 (12.5) 27 (26.5) 18 (24.0) 117 (22.4) 
   Minneapolis, Minnesota 10 (25.0) 28 (27.5) 15 (20.0) 125 (23.9) 
   Oakland, California 17 (42.5) 25 (24.5) 28 (37.3) 156 (29.8) 
Education, n (%) 
   High School or Lower 8 (20.0) 2 40 (38.5) 29 (38.7) 177 (33.5) 
   College 21 (52.5) 55 (52.9) 39 (52.0) 312 (59.0) 
   Advanced Degree 11 (27.5) 9 (8.7) 7 (9.3) 40 (7.6) 
BMI (kg/m2)  25.5 ± 5.9 26.3 ± 6.82 25.0 ± 5.8 24.6 ± 5.7 
Unwanted Hair, n (%) 33 (82.5)2 60 (57.7)2 0 (0.0) 0 (0.0) 
Menstrual Cycle ≥ 34 Days, n (%) 40 (100.0)2 0 (0.0) 75 (100.0)2 0 (0.0) 
Total Testosterone, ng/dL 78.4 ± 65.32 79.9 ± 101.92 35.9 ± 17.5 34.1 ± 17.7 
Free Testosterone, ng/dL 0.7 ± 0.62 0.7 ± 1.22 0.3 ± 0.2 0.2 ± 0.2 
TBG, ng/dL  26.8 ± 12.42 26.9 ± 14.82 32.8 ± 15.8 33.7 ± 15.4 
1Groups are defined according to reproductive variables as PCOS, IH, IO or none of the three (reference group); data are expressed as mean (SD) or N (% 
within each group). Statistical Test: Independent T-Tests or Chi Square  
2P < 0.05 (each group vs. reference group) 
 
Abbreviations: BMI, Body Mass Index; IH, Isolated Hyperandrogenism (elevated testosterone and/or hirsutism at 2 sites or more); IO, Isolated 
Oligomenorrhea (≥34 days in menstrual cycle); PCOS, Polycystic Ovary Syndrome (hyperandrogenism and oligomenorrhea); Reference (neither PCOS nor 
hyperandrogenism nor oligomenorrhea); TBG, Total Binding Globulin 
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Table 2.2. Multinomial logistic regression models estimating the associations of AHEI-
2010 scores with odds of PCOS, IH or IO for women in the CARDIA Women’s Study 
cohort 
AHEI-2010 Subcomponent 
Scores Partial Model
1 Full Model2 
 Odds Ratio 90% CI Odds Ratio 90% CI 
Vegetables      
   PCOS 0.94 0.84, 1.06 0.95 0.85, 1.07 
   IH 1.01 0.94, 1.09 1.02 0.94, 1.09 
   IO 1.03 0.95, 1.12 1.03 0.95, 1.12 
 
Fruits  
    
   PCOS 0.96 0.85, 1.08 0.97 0.87, 1.09 
   IH 1.04 0.97, 1.12 1.05 0.98, 1.13 
   IO 1.00 0.92, 1.09 1.01 0.92, 1.09 
 
Whole Grains  
    
   PCOS 0.98 0.86, 1.11 0.99 0.87, 1.13 
   IH 0.93 0.86, 1.02 0.94 0.86, 1.03 
   IO 0.94 0.85, 1.04 0.95 0.86, 1.05 
 
SSB, Fruit Juice  
    
   PCOS 1.04 0.95, 1.14 1.05 0.96, 1.16 
   IH 1.03 0.96, 1.10 1.03 0.96, 1.10 
   IO 1.01 0.93, 1.08 1.01 0.94, 1.09 
 
Nuts and Legumes  
    
   PCOS 1.00 0.92, 1.09 1.00 0.92, 1.10 
   IH 0.98 0.93, 1.04 0.98 0.92, 1.04 
   IO 0.95 0.89, 1.02 0.95 0.89, 1.02 
 
Red, Processed Meats  
    
   PCOS 0.903 0.81, 0.99 0.92 0.83, 1.02 
   IH 1.00 0.93, 1.07 1.01 0.94, 1.08 
   IO 0.99 0.91, 1.06 1.00 0.92, 1.08 
 
trans-Fat  
    
   PCOS 0.91 0.70, 1.18 0.88 0.68, 1.15 
   IH 1.00 0.85, 1.18 0.98 0.83, 1.16 
   IO 0.93 0.77, 1.13 0.92 0.76, 1.11 
 
Long Chain Omega 3 Fats  
   PCOS 1.00 0.89, 1.11 1.01 0.91, 1.13 
   IH 1.05 0.98, 1.12 1.06 0.99, 1.13 
   IO 1.05 0.97, 1.13 1.05 0.97, 1.14 
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Table 2.2. Multinomial logistic regression models estimating the associations of AHEI-
2010 scores with odds of PCOS, IH or IO for women in the CARDIA Women’s Study 
cohort 
AHEI-2010 Subcomponent 
Scores Partial Model
1 Full Model2 
 Odds Ratio 90% CI Odds Ratio 90% CI 
PUFA  
   PCOS 0.99 0.86, 1.13 1.00 0.87, 1.14 
   IH 1.07 0.98, 1.16 1.07 0.98, 1.17 
   IO 1.05 0.95, 1.17 1.05 0.95, 1.17 
 
Sodium  
    
   PCOS 0.94 0.79, 1.12 0.95 0.80, 1.13 
   IH 0.99 0.89, 1.10 0.99 0.89, 1.11 
   IO 0.97 0.86, 1.10 0.98 0.86, 1.11 
 
Alcohol  
    
   PCOS 1.03 0.93, 1.13 1.05 0.95, 1.15 
   IH 1.06 1.00, 1.13 1.073 1.01, 1.14 
   IO 0.98 0.91, 1.05 0.98 0.91, 1.05 
 
Total AHEI-2010 Score 
 
  
  
   PCOS 0.99 0.96, 1.02 1.00 0.97, 1.02 
   IH 1.01 0.99, 1.03 1.01 1.00, 1.03 
   IO 1.00 0.98, 1.02 1.00 0.98, 1.02 
1Partially adjusted model adjusted for covariates: age, race, total energy intake, education 
2Fully adjusted model adjusted for covariates in partial model plus BMI 
3P < 0.10 (each group vs. reference group) 
 
Abbreviations: AHEI, Alternative Healthy Eating Index; IH, Isolated Hyperandrogenism (elevated 
testosterone and/or hirsutism at 2 sites or more); IO, Isolated Oligomenorrhea (≥34 days in menstrual 
cycle); PCOS, Polycystic Ovary Syndrome (hyperandrogenism and oligomenorrhea); PUFA, 
Polyunsaturated Fatty Acid; SSB, Sugar-sweetened Beverages 
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Table 2.3. Summary of statistically significant race-diet interactions in multinomial logistic regression models estimating the associations of 
AHEI-2010 food groups with PCOS 
Variables All women1 Black2 White3 
 βinteraction (SE) Pinteraction Odds Ratio 90% CI Odds Ratio 90% CI 
AHEI-2010 subcomponent 
score:  
      
 
Vegetables  
      
   PCOS -0.33 (0.19) 0.08 0.73 0.54, 0.98 1.37 1.02, 1.84 
 
Whole Grains  
      
   PCOS 0.29 (0.15) 0.05 1.31 1.05, 1.65 0.76 0.61, 0.96 
   IO 0.21 (0.12) 0.07 1.21 1.02, 1.43 0.83 0.70, 0.99 
 
SSB, Fruit Juice  
      
   IO 0.16 (0.09) 0.08 1.14 1.01, 1.29 0.88 0.77, 0.99 
1Adjusted for independent effect of race. Baseline group = White.  
2Black sample sizes: PCOS N = 11, IO N = 26, Reference N = 256 
3White sample sizes: PCOS N = 29, IO N = 49, Reference N = 273 
 
Abbreviations: AHEI, Alternative Healthy Eating Index; IO, Isolated Oligomenorrhea (≥34 days in menstrual cycle); PCOS, Polycystic Ovary Syndrome 
(hyperandrogenism and oligomenorrhea); SSB, Sugar-sweetened Beverages 
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odds of PCOS in black women [OR 1.21 (90% CI: 1.00, 1.47)], but a lower odds of 
PCOS in white women [OR 0.90 (90% CI: 0.77, 1.05)]. Sensitivity analyses in which 
women with PCOS were compared to non-OC users in the reference group (thus 
omitting all women in the reference group who were using oral contraceptives) 
confirmed results from the primary analyses, with the exception of the caffeine intake—
PCOS association (Supplementary Table S2.3). A significant interaction of caffeine 
intake and race was found in sensitivity analyses, but the effect size was considered 
trivial [βinteraction=0.00 (SE 0.00); Pinteraction=0.08].  
Association of Dietary Intake and PA with Isolated IH and/or Isolated IO 
 A 1-unit higher AHEI-2010 alcohol intake score was associated with a 7% 
greater odds of IH in fully adjusted models (OR=1.07, 90% CI: 1.01, 1.14; P = 0.07; 
Table 2.2). However, a continuous variable for alcohol intake (grams/day) had little to 
no association with IH [OR = 1.03, (90% CI: 0.99, 1.02); P = 0.74], suggesting that the 
association demonstrated by the AHEI score may be reflecting a nonlinear association. 
Magnesium intake was associated with the odds of IH, but the estimated effect sizes 
were trivial in both the partially and fully adjusted models [OR = 1.00, (90% CI: 1.00, 
1.00); P < 0.10]. No other statistically significant diet and/or PA associations with IO 
and/or IH were detected (Supplemental Table S2.2).  
Race modified the association of dietary quality with the odds of IO (Table 2.3). 
Similar to the findings for the PCOS outcome, an increase in half serving of whole grain 
intake was associated with a higher odds of  IO in black women, but a lower odds of IO 
in white women [βinteraction=0.21 (SE 0.12); Pinteraction=0.07]. A healthier AHEI-2010 
sugar-sweetened beverage and fruit juice score (one serving decrease per week) was 
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associated with higher odds of IO in black women only [βinteraction=0.16 (SE 0.09); 
Pinteraction=0.08], but the interaction was not confirmed in the sensitivity analysis 
[βinteraction=0.04 (SE 0.13); Pinteraction=0.15]. Significant race interactions with vitamin C, 
zinc, and caffeine were identified in the sensitivity analyses for IH, but the interaction 
effect sizes were considered trivial (Supplementary Table S2.3).   
DISCUSSION 
This study investigated whether diet and/or PA were associated with PCOS, a 
topic that is timely given the growing emphasis on using health-related behavioral 
modifications to treat and prevent PCOS (5). The identification of specific dietary and 
PA factors that differ between women with and without PCOS would lead to targets for 
tailored interventions. Cross-sectional analyses in the large biracial CARDIA cohort 
study revealed that a higher intake of red and processed meat was associated with higher 
risk of PCOS. Further, diet patterns showed differential associations with PCOS by race 
with black women demonstrating lower odds of PCOS with higher vegetable and with 
lower whole grain intake. Our analyses of total daily energy, macro- and micronutrient 
intake, and PA between women with and without PCOS did not find differences 
between women with and without PCOS. Collectively, our study supports the 
conclusion that food groups, but not nutrient composition or PA, were associated with 
PCOS.  
Food groups were associated with the odds of PCOS. A one-unit increase in 
AHEI-2010 red and processed meat scores, which is consistent with a decrease of one 
serving per week, was associated with a 10% lower risk of PCOS in the partially 
adjusted model. Although there was no significant association between PCOS and red 
 55 
 
and processed meat intake in the fully adjusted model, the addition of BMI as a covariate 
may have resulted in overadjustment. A potential mechanism by which red meat 
consumption may increase the risk of PCOS includes the adverse effects of consuming 
nitrosamines and advanced glycation end products, two substrates shown to destroy 
pancreatic insulin-secreting beta cells and contribute to insulin resistance (45,46). Red 
and processed meat consumption has been shown to be associated with higher fasting 
glucose and/or insulin concentrations in several animal and human trials (47–49). In 
particular, nitrosamine-induced insulin resistance and compensatory hyperinsulinemia 
are posited to contribute to the pathogenesis of androgen excess and disordered 
folliculogenesis in PCOS (49). Despite systemic resistance to the metabolic effects of 
insulin, the ovaries remain sensitive to insulin whose actions include augmenting 
androgen biosynthesis (50) and increasing bioavailable androgens. Further, insulin 
appears to inhibit follicular maturation in PCOS by inhibiting granulosa cell 
proliferation and interfering with estrogen and progesterone production at later stages 
of folliculogenesis (50). Future longitudinal studies should examine changes in red and 
processed meat intake and the subsequent risk of PCOS.   
To our knowledge, no other studies have examined the modifying effect of race 
in the context of health-related behaviors in PCOS. We observed that associations 
between aspects of diet quality with PCOS and isolated PCOS features differed between 
black and white women. An improved understanding of how race impacts the 
pathogenesis of PCOS is important, given that there are racial differences in the risk of 
glucoregulatory and cardiometabolic conditions in black versus white PCOS patients 
(28–31) – impairments that can be modified by healthy dietary and PA behaviors. Two 
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of our findings were paradoxical: a higher whole grain intake and a lower sugar-
sweetened beverage and fruit juice intake were associated with a higher odds of PCOS 
and/or IO for black women. Given that these two dietary patterns are typically 
associated with better health outcomes (51), our findings stratified by race might have 
been caused by differences in how black and white participants interpreted items on the 
CARDIA dietary history. This hypothesis explanation is consistent with results from a 
validation study, where the nutrient correlations between the questionnaire and mean 
nutrient values from seven 24 hour recalls were lower in black than white CARDIA 
participants (38).  
This study did not identify any differences in macro- and micronutrient intake 
between women with and without PCOS. These findings are consistent with previous 
US (22,52) and international studies (23,53,54) that reported no differences in total 
energy and/or macro- or micronutrient intake between women with and without PCOS. 
The similarity of our finding to other US studies may reflect our common use of the 
NIH diagnostic criteria to define the presence of PCOS; with other studies outside the 
U.S. often using a different definition of PCOS (18,20,21,23) thus identifying a case 
group that is inherently different to the one studied herein. Our study of relatively 
younger women taken together with other US studies of older women (22) suggests that 
there are no differences in total daily energy intake between women with and without 
PCOS during the reproductive and peri-menopausal years. The results from our study 
conflict with three previous studies that identified higher carbohydrate intake (ranging 
from 31 to 43 grams) in women with PCOS than the comparison groups (17,18,22). The 
conflicting evidence may be explained by differences in the outcome definition, data 
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collection methods, sample characteristics, and statistical approaches. Additionally, the 
CARDIA cohort was purposively sampled by race, allowing us to test interactions of 
diet and PA with race, in contrast to prior studies that either combined races into one 
group and/or were less diverse.  
In addition to investigating whether the diet—PCOS and/or the PA—PCOS 
associations vary by race, we evaluated the associations between diet and PA with 
clinical and/or biochemical markers of androgen excess to understand whether 
syndrome features were associated with diet and/or PA.  Our findings for the OA 
outcome are at odds with two longitudinal cohort studies that reported a greater intake 
of carbohydrate and folic acid were associated with a reduced risk of anovulatory 
infertility (9,10). In contrast, our study agrees with findings of a longitudinal cohort 
study of B vitamins as predictors of self-reported anovulatory infertility, which reported 
no significant associations (10). Furthermore, the association of diet and PA with PCOS 
and its isolated features were not consistent, which may be due to heterogeneity in the 
IH and IO groups (55). For example, cycle irregularity can manifest secondary to stress 
and nutrient deficiency (56), and not only as an indicator of PCOS risk.  
There was little to no association of PA behaviors with PCOS, which is 
consistent with previous studies that noted no differences in self-reported moderate and 
vigorous intensity PA between women with and without PCOS (24). Consistent with 
previous studies that investigated PA in adult women with PCOS (19–22,53), our 
findings do not support the hypothesis that women with PCOS engage in less moderate 
and vigorous PA (57). Other researchers reported differences in PA patterns in women 
with PCOS (i.e. longer sitting intervals), which have been associated with increased risk 
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of all-cause mortality (58). The CARDIA measurement of PA did not capture patterns 
of exercise types across time, and further research using objective PA data are needed 
to provide more unbiased estimates of the association between PA behaviors and the 
development of PCOS.  
Strengths of this study include the use of a biracial cohort, which enabled us to 
examine how health-related behaviors and PCOS associations differed by race. Reverse 
causality as an explanation of the findings is unlikely because diet and PA data were 
collected prior to widespread recognition of PCOS with the establishment of formal 
NIH (1990) criteria for PCOS. However, our study was limited by the use of self-
reported menstrual cycle history and clinical signs of androgen excess that were not 
confirmed with clinical assessments. The generalizability of our results may also be 
restricted to the classic and most severe clinical phenotype of PCOS (defined as 
hyperandrogenism and irregular menses) since ovarian data were not available to 
determine the presence of polycystic ovarian morphology, which would have enabled 
the detection of subtler variants of PCOS.  
Previous studies have identified potential nutrient predictors for anovulatory 
infertility (9,10), but associations between food groups and PA with PCOS remained 
largely unexplored. Though macro- and micronutrients are important components of the 
diet, evaluation of diet quality provides further knowledge about the potential targets 
for intervention since alterations in foods and/or dietary patterns, rather than nutrients, 
may be easier for patients to follow in their diet. Overall, results from this study revealed 
that lower red and processed meat intake was associated with a lower odds of PCOS. 
This study also found preliminary evidence that associations between food groups and 
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PCOS may differ by race. Findings from this study are formative and provide the basis 
for new hypotheses regarding the role of dietary behaviors on the development of PCOS 
to inform targeted interventions for PCOS patients.  
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Supplemental Figure S2.1. Food groups from the NDSR (Nutrient Data Software for 
Research) that were collapsed into AHEI-2010 food groups, after ensuring the 
approach was consistent with the Willet food frequency questionnaire (FFQ).  
 
 
 
 
 
  
 
 
Supplementary Table S2.1. Diet and physical activity for all women in the CARDIA Women’s Study cohort by group1 
Variable PCOS (n = 40) IH (n = 104) IO (n = 75) Ref (n = 529) 
Nutrient     
Energy (kcal /d) 2229.3 ± 879.4 2312.6 ± 981.1 2170.3 ± 925.7 2246.7 ± 912.3 
Total Carbohydrate (g/d) 260.0 ± 108.2 270.7 ± 122.6 258.5 ± 114.9 262.5 ± 111.0 
   Fiber (g/d) 4.9 ± 2.3 5.2 ± 3.0 5.1 ± 3.3 5.0 ± 2.8 
Total Protein (g/d) 83.3 ± 29.7 84.7 ± 36.8 78.1 ± 32.4 82.7 ± 35.8 
Total Fat (g/d) 93.3 ± 43.2 97.1 ± 46.7 90.4 ± 45.9 94.2 ± 44.7 
   Cholesterol (mg/d) 357.2 ± 178.8 357.7 ± 165.7 325.2 ± 159.2 354.2 ± 207.4 
   Total SFA (g/d) 35.3 ± 18.0 35.5 ± 17.0 33.6 ± 18.3 35.4 ± 17.7 
   Total MUFA (g/d) 34.6 ± 16.8 35.8 ± 18.7 32.6 ± 16.9 34.5 ± 17.3 
   Total PUFA (g/d) 16.6 ± 7.3 18.8 ± 10.3 17.8 ± 12.1 17.5 ± 9.0 
   Omega 3 (mg/day) 77.3 ± 93.2 96.3 ± 125.1 77.9 ± 78.3 83.4 ± 129.4 
Vitamin A (IU/d) 10450.2 ± 8330.0 10453.8 ± 8623.8 11464.6 ± 12917.5 10612.7 ± 11420.3 
Vitamin C (mg/d) 231.6 ± 373.2 292.8 ± 386.7 273.7 ± 452.9 249.1 ± 445.1 
Vitamin D (mcg /d) 7.0 ± 4.1 8.5 ± 6.9 7.0 ± 4.9 7.4 ± 6.7 
Alpha Tocopherol Equivalents 
(mg/d) 21.1 ± 62.3 21.0 ± 55.2 11.6 ± 9.2 16.6 ± 44.1 
Sodium (mg/d) 3412.6 ± 1561.3 3383.1 ± 1472.6 3265.2 ± 1518.3 3298.8 ± 1530.7 
Calcium (mg/d) 1098.3 ± 520.0 1151.1 ± 830.3 1030.4 ± 509.8 1084.4 ± 673.1 
Phosphorus (mg/d) 1454.2 ± 500.8 1474.2 ± 637.9 1403.3 ± 584.5 1459.7 ± 629.7 
Thiamin (mg/d) 2.0 ± 0.9 2.7 ± 2.8 2.0 ± 0.9 2.4 ± 2.4 
Potassium (mg/d) 3075.7 ± 1148.9 3195.1 ± 1577.9 3048.2 ± 1276.9 3120.1 ± 1361.8 
Riboflavin (mg/d) 2.5 ± 1.0 3.1 ± 2.9 2.4 ± 1.1 2.8 ± 2.5 
Niacin (mg/d) 24.5 ± 8.9 31.2 ± 24.2 24.2 ± 11.0 27.7 ± 23.5 
Iron (mg/d) 20.0 ± 9.2 21.8 ± 16.6 19.0 ± 10.0 21.7 ± 33.0 
Copper (mg/d) 2.5 ± 1.4 3.0 ± 2.0 2.8 ± 1.8 2.7 ± 1.9 
Magnesium (mg/d) 332.2 ± 168.9 356.5 ± 260.8 308.8 ± 126.3 324.2 ± 149.8 
Zinc (mg/d)  14.5 ± 6.3 18.2 ± 12.7 16.4 ± 8.9 16.2 ± 11.7 
Folic Acid (mcg/d) 565.9 ± 1248.4 507.9 ± 773.2 385.6 ± 275.9 470.7 ± 1922.4 
Caffeine (mg/d) 263.1 ± 289.4 279.2 ± 452.2 231.9 ± 320.6 268.2 ± 585.1 
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Supplementary Table S2.1. Diet and physical activity for all women in the CARDIA Women’s Study cohort by group1 
Variable PCOS (n = 40) IH (n = 104) IO (n = 75) Ref (n = 529) 
AHEI-20102     
   Vegetables Score 5.0 ± 2.7 5.0 ± 2.7 5.2 ± 2.8 5.0 ± 2.8 
   Fruits Score 3.5 ± 2.2 3.7 ± 2.9 3.5 ± 2.7 3.5 ± 2.5 
   Whole Grains Score 3.3 ± 2.0 2.8 ± 2.1 2.9 ± 2.1 3.1 ± 2.3 
   SSB, Fruit Juice Score 2.3 ± 3.1 1.7 ± 2.9 1.9 ± 2.9 1.7 ± 2.9 
   Nuts and Legumes Score 4.7 ± 3.4 4.5 ± 3.5 4.1 ± 3.3 4.6 ± 3.5 
   Red, Processed Meats Score 4.6 ± 3.1 4.7 ± 3.4 5.2 ± 3.3 5.0 ± 3.1 
   trans-Fat Score 3.8 ± 0.9 3.8 ± 1.0 3.8 ± 1.2 3.9 ± 1.1 
   Long Chain Omega 3 Fats Score 3.0 ± 2.6 3.5 ± 3.0 3.2 ± 2.9 3.1 ± 2.6 
   PUFA Score 5.8 ± 1.6 6.2 ± 2.1 6.1 ± 2.2 5.9 ± 2.1 
   Sodium Score 5.6 ± 3.0 5.6 ± 3.0 5.9 ± 3.1 5.8 ± 3.0 
   Alcohol Score 6.3 ± 2.9 6.2 ± 2.7 5.7 ± 2.8 5.8 ± 3.0 
   Total AHEI-2010 Score 47.3 ± 11.6 47.8 ± 12.0 47.5 ± 11.7 47.2 ± 11.6 
Physical Activity     
   Moderate Exercise Units 137.8 ± 101.9 126.2 ± 100.9 124.9 ± 99.5 126.3 ± 98.5 
   Heavy Exercise Units 243.6 ± 175.2 233.8 ± 198.8 252.9 ± 262.6 218.2 ± 191.3 
   Total Exercise Units 381.4 ± 217.4 360.0 ± 267.2 377.8 ± 324.8 344.5 ± 257.0 
Abbreviations: IH, Isolated Hyperandrogenism (elevated testosterone and/or hirsutism at 2 sites or more); IO, Isolated Oligomenorrhea (≥34 days in 
menstrual cycle); IU, International Units; MUFA, Monounsaturated Fatty Acids; PCOS, Polycystic Ovary Syndrome (hyperandrogenism and 
oligomenorrhea); PUFA, Polyunsaturated Fatty Acids; SFA, Saturated Fat; SSB, Sugar-sweetened Beverages 
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Supplemental Table S2.2. Multinomial logistic regression models estimating the 
associations of macro- and micronutrients with odds of PCOS, IH or IO for women in the 
CARDIA Women’s Study cohort 
Variables Partial Model1 Full Model2 
 Odds Ratio 90% CI Odds Ratio 90% CI 
Total Carbohydrate (g/d)     
   PCOS 1.00 0.99, 1.01 1.00 0.99, 1.01 
   IH 1.00 1.00, 1.00 1.00 1.00, 1.00 
   IO 1.00 1.00, 1.01 1.00 1.00, 1.01 
Fiber (g/d)     
   PCOS 0.92 0.81, 1.05 0.94 0.82, 1.07 
   IH 1.04 0.96, 1.12 1.04 0.97, 1.13 
   IO 1.03 0.95, 1.13 1.04 0.95, 1.13 
Total Protein (g/d)     
   PCOS 1.00 0.98, 1.02 1.00 0.98, 1.02 
   IH 1.00 0.99, 1.01 1.00 0.99, 1.01 
   IO 0.99 0.98, 1.00 0.99 0.97, 1.00 
Total Fat (g/d)     
   PCOS 1.01 0.99, 1.02 1.01 0.99, 1.03 
   IH 1.00 0.99, 1.01 1.00 0.99, 1.01 
   IO 1.00 0.99, 1.01 1.00 0.99, 1.02 
Cholesterol (mg/d)     
   PCOS 1.00 1.00, 1.00 1.00 1.00, 1.00 
   IH 1.00 1.00, 1.00 1.00 1.00, 1.00 
   IO 1.00 1.00, 1.00 1.00 1.00, 1.00 
Total SFA (g/d)     
   PCOS 1.01 0.97, 1.04 1.01 0.97, 1.05 
   IH 0.98 0.96, 1.00 0.98 0.96, 1.01 
   IO 0.99 0.97, 1.02 0.99 0.97, 1.02 
Total MUFA (g/d)     
   PCOS 1.03 0.99, 1.07 1.03 0.99, 1.07 
   IH 1.00 0.98, 1.03 1.00 0.98, 1.03 
   IO 1.00 0.97, 1.03 1.00 0.97, 1.03 
Total PUFA (g/d)     
   PCOS 0.98 0.93, 1.04 0.98 0.93, 1.04 
   IH 1.02 0.99, 1.05 1.02 0.99, 1.05 
   IO 1.03 1.00, 1.06 1.03 0.99, 1.06 
Omega 3 (mg/day)     
   PCOS 1.00 1.00, 1.00 1.00 1.00, 1.00 
   IH 1.00 1.00, 1.00 1.00 1.00, 1.00 
   IO 1.00 1.00, 1.00 1.00 1.00, 1.00 
Vitamin A (IU/d)     
   PCOS 1.00 1.00, 1.00 1.00 1.00, 1.00 
   IH 1.00 1.00, 1.00 1.00 1.00, 1.00 
   IO 1.00 1.00, 1.00 1.00 1.00, 1.00 
 72 
 
Supplemental Table S2.2. Multinomial logistic regression models estimating the 
associations of macro- and micronutrients with odds of PCOS, IH or IO for women in the 
CARDIA Women’s Study cohort 
Variables Partial Model1 Full Model2 
 Odds Ratio 90% CI Odds Ratio 90% CI 
Vitamin C (mg/d)     
   PCOS 1.00 1.00, 1.00 1.00 1.00, 1.00 
   IH 1.00 1.00, 1.00 1.00 1.00, 1.00 
   IO 1.00 1.00, 1.00 1.00 1.00, 1.00 
Vitamin D (mcg /d)     
   PCOS 0.97 0.92, 1.03 0.98 0.92, 1.03 
   IH 1.02 1.00, 1.05 1.03 1.00, 1.05 
   IO 0.98 0.94, 1.02 0.98 0.95, 1.02 
Alpha Tocopherol Eq (mg/d) 
   PCOS 1.00 1.00, 1.01 1.00 1.00, 1.01 
   IH 1.00 1.00, 1.01 1.00 1.00, 1.01 
   IO 0.99 0.98, 1.01 0.99 0.98, 1.01 
Sodium (mg/d)     
   PCOS 1.00 1.00, 1.00 1.00 1.00, 1.00 
   IH 1.00 1.00, 1.00 1.00 1.00, 1.00 
   IO 1.00 1.00, 1.00 1.00 1.00, 1.00 
Calcium (mg/d)     
   PCOS 1.00 1.00, 1.00 1.00 1.00,1.00 
   IH 1.00 1.00, 1.00 1.00 1.00, 1.00 
   IO 1.00 1.00, 1.00 1.00 1.00, 1.00 
Phosphorus (mg/d)     
   PCOS 1.00 1.00, 1.00 1.00 1.00, 1.00 
   IH 1.00 1.00, 1.00 1.00 1.00, 1.00 
   IO 1.00 1.00, 1.00 1.00 1.00, 1.00 
Thiamin (mg/d)     
   PCOS 0.82 0.63, 1.08 0.83 0.64, 1.09 
   IH 1.06 0.99, 1.12 1.06 1.00, 1.13 
   IO 0.86 0.73, 1.03 0.87 0.73, 1.03 
Potassium (mg/d)     
   PCOS 1.00 1.00, 1.00 1.00 1.00, 1.00 
   IH 1.00 1.00, 1.00 1.00 1.00, 1.00 
   IO 1.00 1.00, 1.00 1.00 1.00, 1.00 
Riboflavin (mg/d)     
   PCOS 0.87 0.70, 1.07 0.88 0.71, 1.08 
   IH 1.05 0.98, 1.11 1.05 0.99, 1.12 
   IO 0.87 0.74, 1.01 0.87 0.75, 1.02 
Niacin (mg/d)     
   PCOS 0.98 0.96, 1.01 0.98 0.96, 1.01 
   IH 1.01 1.00, 1.01 1.00 1.00, 1.01 
   IO 0.99 0.97, 1.00 0.99 0.97, 1.01 
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Supplemental Table S2.2. Multinomial logistic regression models estimating the 
associations of macro- and micronutrients with odds of PCOS, IH or IO for women in the 
CARDIA Women’s Study cohort 
Variables Partial Model1 Full Model2 
 Odds Ratio 90% CI Odds Ratio 90% CI 
Iron (mg/d)     
   PCOS 0.99 0.98, 1.01 1.00 0.98, 1.01 
   IH 1.00 0.99, 1.01 1.00 0.99, 1.01 
   IO 0.99 0.98, 1.01 0.99 0.98, 1.01 
Copper (mg/d)     
   PCOS 0.85 0.67, 1.08 0.86 0.67, 1.10 
   IH 1.07 0.97, 1.18 1.08 0.98, 1.19 
   IO 1.04 0.93, 1.18 1.05 0.93, 1.18 
Magnesium (mg/d)     
   PCOS 1.00 1.00, 1.00 1.00 1.00, 1.00 
   IH 1.003 1.00, 1.00 1.003 1.00, 1.00 
   IO 1.00 1.00, 1.00 1.00 1.00, 1.00 
Zinc (mg/d)      
   PCOS 0.96 0.92, 1.01 0.96 0.92, 1.01 
   IH 1.01 1.00, 1.03 1.02 1.00, 1.03 
   IO 1.00 0.98, 1.02 1.00 0.98, 1.02 
Folic Acid (mcg/d)     
   PCOS 1.00 1.00, 1.00 1.00 1.00, 1.00 
   IH 1.00 1.00, 1.00 1.00 1.00, 1.00 
   IO 1.00 1.00, 1.00 1.00 1.00, 1.00 
Caffeine (mg/d)     
   PCOS 1.00 1.00, 1.00 1.00 1.00, 1.00 
   IH 1.00 1.00, 1.00 1.00 1.00, 1.00 
   IO 1.00 1.00, 1.00 1.00 1.00, 1.00 
1Partially adjusted model adjusted for covariates: age, race, total energy intake, education 
2Fully adjusted model adjusted for covariates: age, race, total energy intake, education, and BMI 
3Overall significance level P < 0.10 (each group vs. reference group) 
 
Abbreviations: Eq, Equivalent; IH, Isolated Hyperandrogenism (elevated testosterone and/or 
hirsutism at 2 sites or more); IO, Isolated Oligomenorrhea (≥34 days in menstrual cycle); IU, 
International Units; MUFA, Monounsaturated Fatty Acid; PCOS, Polycystic Ovary Syndrome 
(hyperandrogenism and oligomenorrhea); PUFA, Polyunsaturated Fatty Acid; SFA, Saturated Fatty 
Acid 
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Supplementary Table S2.3. Significant race-specific multinomial logistic regression models estimating the associations of diet with 
reproductive status reported in the sensitivity analysis1 
Variables Overall2 Black3 White4 
 β (SE) Pinteraction Odds Ratio 90% CI Odds Ratio 90% CI 
AHEI-2010       
Vegetables Score       
   PCOS -0.44 (0.26) 0.09 0.79 0.61, 1.01 1.27 0.99, 1.64 
Whole Grains Score       
   PCOS 0.51 (0.20) 0.06 1.29 1.04, 1.60 0.78 0.63, 0.96 
   IO 0.26 (0.16) 0.08 1.18 1.01, 1.39 0.85 0.72, 0.99 
SSB, Fruit Juice Score       
   IO 0.04 (0.13) 0.15 1.11 0.99, 1.24 0.90 0.80, 1.01 
Nutrients       
Vitamin C (mg)       
   IH 0.00 (0.00) 0.08 1.00 1.00, 1.00 1.00 1.00, 1.00 
Zinc (mg)       
   IH 0.02 (0.03) 0.09 0.98 0.97, 1.00 1.02 1.00, 1.03 
Caffeine (mg)       
   PCOS 0.00 (0.00) 0.08 1.00 1.00, 1.00 1.00 1.00, 1.00 
   IH 0.00 (0.00) 0.05 1.00 1.00, 1.00 1.00 1.00, 1.00 
1 Sensitivity analysis in which women on oral contraceptives were excluded from the reference group 
2Adjusted for independent effect of race. Baseline group = White. Sensitivity analysis: removed participants on OCP from the reference group 
3Black sample sizes: PCOS N = 11, IO N = 26, Reference N = 112 
4 White sample sizes: PCOS N = 29, IO N = 49, Reference N = 129 
 
Abbreviations: IH, Isolated Hyperandrogenism (elevated testosterone and/or hirsutism at 2 sites or more); IO, Isolated Oligomenorrhea (≥34 days in 
menstrual cycle); PCOS, Polycystic Ovary Syndrome (hyperandrogenism and oligomenorrhea); SSB, Sugar-sweetened Beverages 
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CHAPTER 3: COMPARISON OF DIET AND PHYSICAL ACTIVITY 
BEHAVIORS BETWEEN WOMEN WITH AND WITHOUT POLYCYSTIC 
OVARY SYNDROME (PCOS) 
Working Manuscript 
ABSTRACT 
Background: There is conflicting evidence about whether diet and physical activity 
(PA) behaviors differ between women with and without polycystic ovary syndrome 
(PCOS). Specific differences in health-related behavior could explain the propensity for 
obesity and serve as targets to design tailored interventions in PCOS. 
Objective: To investigate the cross-sectional associations between diet and PA with 
PCOS.  
Methods: A semi-structured interview was conducted with 89 participants (PCOS, 
n=50 and non-PCOS reference n=39) to collect sociodemographic and reproductive 
health history data, in conjunction with the following assessments: 1) a fasting blood 
draw to measure reproductive hormones; 2) a transvaginal ultrasound scan to evaluate 
ovarian morphology; 3) hirsutism scoring and anthropometry; 4) an on-line food 
frequency questionnaire and dietary interview to assess dietary intake, 5) accelerometry 
to capture PA over a minimum of four days. Diet quality was evaluated using the 
Healthy Eating Index 2010. Binomial logistic regression analyses (adjusting for age, 
total calories, and/or BMI) were performed to estimate associations between diet and 
PA with PCOS. The statistical significance threshold was set at P < 0.10 to detect 
significant associations in a small sample size.  
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Results: Higher HEI-2010 empty calories scores were positively associated with odds 
of PCOS after adjusting for age, total energy intake, and BMI [OR = 1.07 (90% CI: 
1.01, 1.12); P =0.04]. A higher intake of niacin, vitamin B6, vitamin B12, zinc, and iron 
were also associated with odds of PCOS. No differences in macronutrient intake nor PA 
were noted between women with and without PCOS.  
Conclusions: A healthier diet, as defined by a higher intake of B vitamins and lower 
intake of empty calories, was positively associated with PCOS. Whether consumption 
of better quality diets in women with PCOS results from advice after receiving a PCOS 
diagnosis should be determined.  
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INTRODUCTION 
Polycystic ovary syndrome (PCOS) is a broad-spectrum endocrine disorder that 
is diagnosed by a combination of oligo/amenorrhea, hyperandrogenism, and/or 
polycystic ovaries (1). PCOS affects approximately 7 to 18% of reproductive-aged 
women globally (2–4) and represents a severe healthcare-related economic burden in 
the United States (US) (5). Obesity is known to worsen reproductive and metabolic 
profiles in PCOS (6), which is particularly concerning since up to 80% of PCOS patients 
are considered to be overweight or obese (7,8). While preliminary evidence support that 
women with PCOS are more susceptible to weight gain (9), controversy exists on 
whether obesity and/or dietary and physical activity (PA) behaviors contribute to the 
development of PCOS (8,10). Poor dietary intake has been associated with PCOS 
features, such as hyperandrogenemia and polycystic ovaries (11–14), as well as self-
reported infertility (15–19). However, evidence on whether PCOS patients consume 
poorer diets and/or participate in shorter intervals of PA activities than women without 
PCOS remains mixed (20).  
The inconsistent evidence about whether diets and PA differ in women with and 
without PCOS may be dependent on the diagnostic criteria used to define PCOS (20). 
Studies in the US that have examined dietary and PA behaviors in PCOS have used the 
National Institutes of Health (NIH) criteria, which does not consider polycystic ovarian 
morphology as a diagnostic criterion (21). This approach omits other distinct PCOS 
phenotypes commonly seen in clinical settings and limits the generalizability of the 
study results (21). Additionally, different measurement approaches may contribute to 
the conflicting data. Studies have used a variety of instruments to collect dietary (e.g., 
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food records, recalls, questionnaires) and PA data (e.g., questionnaires, interview). 
Overall, PA data have been based on self-report and can be biased by the recall period 
or social desirability (22). Objective tools to measure PA (e.g., accelerometers) have 
rarely been implemented in the area of PCOS (23,24), which could help to address 
controversy in this area (20).  
General dietary and PA modifications are recommended as the first-line therapy 
to treat overweight and obese women with PCOS (25,26). However, studies have 
reported lower participation with self-help programs in this patient population (27). To 
successfully influence behavior change, studies outside of PCOS have shown that 
incorporation of health strategies into existing practices could improve compliance 
(28,29). Current evidence from other countries suggests that PCOS patients exceed 
government recommendations for fat intake, while not meeting fiber, potassium and 
vitamin E dietary guidelines (30–32). However, comparisons between current health-
related behaviors of PCOS patients and government recommendations have not been 
examined in the US. To that end, we investigated the current diet and PA level of PCOS 
patients in the US and compared these behaviors with those without PCOS to identify 
factors that could serve as potential targets for tailored PCOS intervention. 
METHODS 
This case-comparison study included data that were collected as part of three 
separate protocols between January 2013 and April 2017 (ClinicalTrials.gov Identifiers: 
NCT01859663, NCT01927432, NCT01785719). Institutional Review Boards (IRB) 
approved the study protocols. All participants provided written informed consent. 
Participants were recruited to these protocols from the general population using paper 
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and electronic advertising in Tompkins, Monroe, New York and Bronx counties, NY. 
Women were eligible to participate if they were of reproductive age (defined as 18 to 
45 years) and had clear visualization of their ovaries on ultrasonography. Exclusion 
criteria included use of insulin-sensitizing medications and/or statins within three 
months of study participation; presence of medical conditions known to interfere with 
reproductive or metabolic function (such as hyperprolactinemia, diabetes, untreated 
thyroid dysfunction and premature ovarian failure); absence of both diet and PA data; 
evidence of implausible energy intake (defined as <600 and >6000 calories/day); and 
inability to determine reproductive status due to missing data.  
Study Procedures 
Participants were screened for eligibility during a semi-structured interview in 
which they estimated their average menstrual cycle length (MCL) in the past year, and 
underwent a transvaginal ultrasound scan of the ovaries to ascertain visibility of the 
ovaries and stage of cycle. If eligible, women were invited to return to the participating 
clinical research center either during the early follicular phase (i.e. between days 2 and 
7 of menses) if they had a regular MCL or at their convenience if they had unpredictable 
cycles. Clinical assessments at the follow-up visit included a fasting blood draw to 
measure reproductive hormones; a transvaginal ultrasound scan to evaluate ovarian 
morphology; a physical exam to assess degree of hirsutism, vitals and anthropometry; 
and dietary and physical activity assessments to quantify health-related behaviors.  
Participants wore light clothing and removed their shoes prior to anthropometric 
assessments. Height was measured using a standard stadiometer to the nearest 0.5 cm 
and weight was taken using a calibrated digital scale to the nearest 0.1 kg. Body mass 
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index was calculated as weight in kilograms divided by height in meters squared. 
Participants were asked to confirm hirsutism scores suggested by investigators using the 
modified Ferriman-Gallwey scoring system (33), as previously described (34). Blood 
was processed for serum, and stored at -80ºC until the time of analyses. Serum was sent 
to the Brigham Research Assay Core (Boston, MA), as part of the Centers for Disease 
Control and Prevention Hormone Standardization Program, and assayed for total 
testosterone using liquid chromatography-tandem mass spectrometry (CV ± 6.4%).  
Ovaries were scanned from the inner to outer margins in the longitudinal plane 
by experienced ultrasonographers. De-identified cineloops throughout each ovary were 
exported and analyzed offline using Santesoft DICOM Editor (Emmanouil 
Kannellopoulus, Athens, Greece). Reliable estimates of follicle number per ovary 
(FNPO), follicle number in the largest cross-sectional plane of the ovary (FNPS), and 
ovarian volume (OV) were obtained using the grid system approach as previously 
described (35). Mean FNPO, FNPS and OV values were calculated by averaging values 
of the left and right ovary. Follicle numbers were rounded to the nearest whole number 
and OV to the nearest decimal place. FNPS was used to phenotype four participants 
(4.5%) due to missing FNPO and OV data.  
Nutrient and diet quality data were collected using VioScreen™ (VioCare, Inc., 
Princeton, NJ), a validated web-based food frequency questionnaire (FFQ) that assesses 
habitual diet over the past three months (36). The Nutrition Data System for Research 
software (V42; Nutrition Coordinating Center, University of Minnesota, Minneapolis, 
MN) was used to calculate nutrient and food intake. Diet quality was assessed with the 
Healthy Eating Index 2010 (HEI-2010) (37). The HEI-2010 comprised of 12 dietary 
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components that were associated with health promotion (total fruit, whole fruit, total 
vegetables, greens and beans, whole grains, dairy, total protein foods, seafood and plant 
proteins, and fatty acids) and adverse health outcomes (refined grains, sodium, and 
empty calories as defined by energy from solid fats, alcohol and added sugars). Higher 
scores reflect more optimal diet quality within each dietary component in accordance to 
the 2010 US Dietary Guidelines for Americans. Total HEI-2010 scores were computed 
by aggregating the scores across dietary components; total scores ranged from 0 to 100 
(higher score represents adherence to government dietary recommendations). Semi-
structured diet interviews were conducted by a registered dietitian who asked 
participants to describe changes in dietary practice and weight trajectories over time. To 
collect objective PA data, participants were asked to wear Actigraph triaxial 
accelerometers GT3X (27 g; 3.8 cm x 3.7 cm x 1.8 cm) and wGT3X+ (19g; 4.6 cm x 
3.3 cm x 1.5 cm) at the left hip with a maximum acceleration sampling rate of 50 Hertz 
and without a low frequency extension (Actigraph LLC, Pensacola, FL) for seven days. 
Physical activity data were included if the participant wore the accelerometer for at least 
four days – where an entire day was defined as wear for at least 10 hours. Raw data 
from accelerometers were processed to generate wear minutes from vector magnitude 
counts using the Sasaki algorithm with the internally developed AutocalcMET Excel 
model (38). Minutes spent within moderate and vigorous activities were reported due to 
their known health benefits (39).  
Group definitions 
The Rotterdam consensus criteria (having at least two of three PCOS features) 
was used to classify patients with PCOS (40). Oligo/amenorrhea was defined as self-
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reported unpredictable MCL that averaged ≥36 days in the year prior to study 
enrollment. Women were considered to have hyperandrogenism if they were hirsute 
(defined as modified Ferriman-Gallwey score ≥7) (33)  and/or if they had elevated 
fasting serum total testosterone (TT) concentrations (defined as ≥65.4 ng/dL). These 
thresholds were generated by the investigators based on the 95th percentile of women 
with predictable MCL that were enrolled across our studies. Polycystic ovarian 
morphology was characterized by mean FNPO ≥25 per ovary (41) or mean FNPS ≥9 
(42). The remaining participants were placed in the comparison group.  
Statistical Analyses  
Statistical analyses were performed using SPSS 23.0 (IBM, Armonk, NY). 
Results for bivariate analyses were considered significant at P<0.05. Clinical and health-
related behavioral data were compared between the PCOS and comparison groups using 
independent t-tests and χ2 analyses. Binomial logistic regression models reported as 
odds ratios (OR) were used to explore associations between diet and PA (continuous) 
variables with PCOS status (categorical). For each exposure variable, Model 1 adjusted 
for age, total energy intake (continuous variables), while Model 2 was extended to 
include BMI (continuous variable). Significance level threshold for the logistic 
regression analyses were set at P <0.10 due to the small sample size (43). Effect sizes 
and confidence intervals (CI) were also reported to provide information on the precision 
of estimates according to American Psychological Association recommendations (44).  
RESULTS  
Demographics and clinical characteristics  
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Eighty-nine participants were included in the study, and comprised of 50 
(56.2%) women classified as PCOS and 39 (43.8%) as reference (Figure 3.1). The 
majority of the study sample was Caucasian and was categorized as overweight or obese 
[n=60 (69.8%)]. A small proportion of women in the entire sample used oral 
contraceptive pills (OCPs) [n=7 (7.9%)]. Relative to the comparison group, women with 
PCOS were significantly younger and had higher BMIs (Table 3.1). The PCOS group 
had longer mean MCL, greater degrees of hyperandrogenism, and ovarian 
dysmorphology, compared to women without PCOS (P ≤0.006). In this study, 54% of 
women in the PCOS group self-reported a previous diagnoses of PCOS by a healthcare 
professional in contrast to 13% of women in the comparison group. 
Dietary intake and diet quality  
The PCOS group exceeded Acceptable Macronutrient Distribution Range total 
fat recommendations as established by US guidelines (>35% of daily total energy). 
Women with PCOS also consumed greater amounts of sodium than the US Dietary 
Reference Intake (>2,300 mg/day), and did not meet fiber (<25 g/day) and potassium 
(<4,700 mg/day) recommendations, similar to the reference group. Women with and 
without PCOS had similar macro-and micronutrient intake in their diets, while the 
PCOS group scored higher in the HEI-2010 empty calories component. There were no 
differences in total energy intake between women with and without PCOS. Mean (SD) 
data for nutrient composition, diet quality and PA levels are presented in Table 3.2. 
 When adjusting for age, total calories and/or BMI, HEI-2010 empty calories 
scores continued to be positively associated with risk of PCOS (Table 3.3). Binomial 
logistic regression analyses also reported select B vitamins and minerals were positively 
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Figure 3.1. Participant flowchart. Flow diagram of the process through which participants 
were classified into PCOS and comparison groups. 
 
Abbreviations: FSH, follicle stimulating hormone; PA, physical activity TSH, thyroid 
stimulating hormone; PCOS, polycystic ovary syndrome
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Table 3.1. Characteristics for all women in the study1 
  Study Groups 
Variable Overall  (n = 89) 
PCOS  
(n = 50) 
Comparison 
 (n = 39) P 
Age, years  27.4 ± 6.0 26.0 ± 5.4 29.2 ± 6.3 0.01 
Hispanic, n (%) 12 (14.3) 5 (10.6) 7 (18.9) 0.45 
Race, n (%)     
   Black 12 (14.0) 6 (12.2) 6 (16.2) 0.67 
   White 60 (69.8) 36 (73.5) 24 (64.9) 
   Other 14 (16.3) 7 (14.3) 7 (18.9) 
BMI, kg/m2   29.8 ± 7.6 31.6 ± 8.5 27.5 ± 5.7 <0.01 
BMI, n (%)       
   Healthy 29 (32.6) 13 (26.0) 16 (41.0) 0.17 
   Overweight 18 (20.2) 9 (18.0) 9 (23.1) 
   Obese 42 (47.2) 28 (56.0) 14 (35.9) 
Highest Completed Education, n (%) 
   High School or Lower 15 (27.8) 7 (35.0) 8 (23.5) 0.13 
   College 25 (46.3) 11 (55.0) 14 (41.2) 
   Advanced Degree 14 (25.9) 2 (10.0) 12 (35.3) 
Reproductive History     
On OCP (Yes), n (%) 7 (7.9) 3 (6.0) 4 (10.3) 0.36 
Mean Menstrual Cycle Length 
(days) 
64.4 ± 75.9 95.3 ± 96.8 32.7 ± 12.8 <0.01 
Mean Ovarian Volume (mL) 10.5 ± 5.7 12.3 ± 5.7 8.1 ± 4.7 <0.01 
Mean FNPO (2 to 9 mm) 33.6 ± 22.4 44.5 ± 23.8 20.5 ± 10.5 <0.01 
Total AFC 69.8 ± 44.3 88.8 ± 47.0 43.5 ± 20.9 <0.01 
Total Testosterone (ng/dL) 51.9 ± 45.8 62.8 ± 58.3 38.3 ± 12.4 <0.01 
Total Hirsutism Score 6.1 ± 4.9 7.5 ± 5.3 4.2 ± 3.6 <0.01 
1Data are expressed as mean ± SD or n (% of those with data in each group). Statistical Test: 
Independent T-Tests or Chi Square. Comparison group (remaining women not classified as PCOS) 
2Overall significance level P < 0.05 
 
Abbreviations: AFC, Antral Follicle Count; BMI, body mass index; OCP, Oral contraceptive pill; 
PCOS, Polycystic Ovary Syndrome (Rotterdam Criteria); FNPO, Follicle Number Per Ovary 
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Table 3.2. Nutrient intake, diet quality, and physical activity for all women in the study1 
   Study Groups 
Variable Overall (n = 89) DRI PCOS (n = 50) Comparison (n = 39) P 
Energy (kcal /d) 2098.1 ± 901.5 - 2107.9 ± 887.7 2085.5 ± 930.2 0.91 
Total Carbohydrate (g/d) 254.6 ± 116.0 RDA: 130  253.6 ± 110.8 255.9 ± 123.7 0.93 
   Glycemic Index 514.6 ± 243.1  520.9 ± 240.6 506.5 ± 249.2 0.78 
   Glycemic Load 132.5 ± 69.2  134.3 ± 67.2 130.3 ± 72.3 0.79 
   Total sugars (g/d) 116.4 ± 65.9  115.9 ± 63.1 117.0 ± 70.2 0.94 
   Fiber (g/d) 22.9 ± 9.3 RDA: 25  22.4 ± 9.0 23.5 ± 9.8 0.58 
Total Protein (g/d) 80.5 ± 34.2 RDA: 46  81.7 ± 33.6 79.0 ± 35.3 0.72 
Total Fat (g/d) 83.6 ± 38.4 - 85.2 ± 40.3 81.4 ± 36.2 0.65 
   Cholesterol (mg/d) 279.4 ± 157.4 - 291.6 ± 165.2 263.8 ± 147.6 0.41 
   Total SFA (g/d) 27.2 ± 14.8 - 27.4 ± 15.3 27.0 ± 14.3 0.90 
   Total MUFA (g/d) 32.3 ± 14.6 - 33.1 ± 15.9 31.2 ± 13.0 0.54 
   Total PUFA (g/d) 17.1 ± 7.9 - 17.6 ± 8.2 16.5 ± 7.7 0.51 
   Omega 3 (mg/day) 1.8 ± 0.9 - 1.9 ± 0.9 1.8 ± 0.9 0.86 
   Trans-fat (g/d) 2.8 ± 2.2  3.0 ± 2.5 2.5 ± 1.6 0.31 
Vitamin A (IU/d) 14298.6 ± 11056.8 UL: 10,000  13977.9 ± 11566.0 14709.7 ± 10502.7 0.76 
Thiamin (mg/d) 1.7 ± 0.7 EAR: 0.9 1.8 ± 0.7 1.6 ± 0.7 0.30 
Riboflavin (mg/d) 2.2 ± 0.9 EAR: 0.9 2.3 ± 0.8 2.1 ± 1.0 0.39 
Niacin (mg/d) 22.4 ± 9.0 EAR: 11 23.8 ± 8.6 20.6 ± 9.1 0.09 
Vitamin B6 (mg/d) 2.0 ± 0.7 AI: 1.2-1.3 2.1 ± 0.7 1.9 ± 0.7 0.10 
Vitamin B12 5.3 ± 2.9 AI: 2.4 5.7 ± 2.9 4.7 ± 2.7 0.08 
Vitamin C (mg/d) 126.3 ± 72.4 EAR: 60  127.4 ± 76.7 124.9 ± 67.4 0.87 
Vitamin D (mcg /d) 5.3 ± 3.2 EAR: 10 5.4 ± 3.2 5.1 ± 3.3 0.70 
Alpha Tocopherol Eq (mg/d) 19.6 ± 8.4 EAR: 12 20.7 ± 8.7 18.2 ± 7.9 0.15 
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Table 3.2. Nutrient intake, diet quality, and physical activity for all women in the study1 
   Study Groups 
Variable Overall (n = 89) DRI PCOS (n = 50) Comparison (n = 39) P 
Sodium (mg/d) 3748.4 ± 1703.0 RDA: 1500 3792.8 ± 1694.2 3691.5 ± 1734.8 0.78 
Calcium (mg/d) 1050.4 ± 468.2 EAR: 800 1035.9 ± 421.4 1069.0 ± 527.2 0.74 
Phosphorus (mg/d) 1349.7 ± 542.5 EAR: 580 1339.2 ± 518.3 1363.1 ± 578.7 0.84 
Potassium (mg/d) 3007.8 ± 1103.7 RDA: 4700 2992.3 ± 1080.1 3027.8 ± 1147.3 0.88 
Iron (mg/d) 15.6 ± 6.4 EAR: 8.1 16.5 ± 6.1 14.4 ± 6.7 0.13 
Copper (mg/d) 1.5 ± 0.5 EAR: 0.7 1.5 ± 0.5 1.4 ± 0.6 0.87 
Magnesium (mg/d) 342.5 ± 120.4 EAR: 255-265  334.5 ± 110.1 352.9 ± 133.3 0.48 
Zinc (mg/d)  12.4 ± 5.1 EAR: 6.8 13.2 ± 5.1 11.4 ± 5.0 0.11 
Folic Acid (mcg/d) 562.9 ± 228.1 - 597.1 ± 218.5 519.2 ± 235.5 0.11 
Caffeine (mg/d) 162.6 ± 145.0 - 153.0 ± 140.6 174.9 ± 151.4 0.48 
HEI-2010 Scores 2  Max Score    
Fruit 3.5 ± 1.6 5 3.5 ± 1.7 3.6 ± 1.5 0.66 
Whole Fruit 3.8 ± 1.6 5 3.9 ± 1.6 3.7 ± 1.6 0.67 
Vegetables 4.1 ± 1.1 5 4.1 ± 1.2 4.1 ± 1.1 0.87 
Green Beans 3.5 ± 1.7 5 3.5 ± 1.8 3.6 ± 1.7 0.88 
Whole Grains 4.9 ± 3.0 10 4.7 ± 3.1 5.2 ± 3.0 0.47 
Dairy 6.2 ± 2.6 10 6.1 ± 2.5 6.4 ± 2.8 0.58 
Protein Foods 4.5 ± 0.8 5 4.5 ± 0.8 4.5 ± 0.8 0.82 
Seafood and Plant Proteins 3.9 ± 1.5 5 3.8 ± 1.6 4.0 ± 1.5 0.65 
Fatty Acids 5.2 ± 3.1 10 5.5 ± 3.2 4.9 ± 2.9 0.33 
Refined Grains 8.3 ± 2.3 10 8.2 ± 2.4 8.6 ± 2.1 0.44 
Sodium 2.9 ± 2.5 10 2.8 ± 2.4 3.0 ± 2.6 0.67 
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Table 3.2. Nutrient intake, diet quality, and physical activity for all women in the study1 
   Study Groups 
Variable Overall (n = 89) DRI PCOS (n = 50) Comparison (n = 39) P 
Empty Calories 7.3 ± 8.1 20 9.4 ± 8.03 4.8 ± 7.6 <0.01 
Total HEI-2010 Score 58.3 ± 14.1 100 59.9 ± 14.6 56.3 ± 13.4 0.24 
Physical Activity      
Moderate Exercise (min/day) 55.2 ± 23.8 - 55.5 ± 24.2 55.0 ± 23.9 0.93 
Vigorous  Exercise (min/day)  7.5 ± 9.3 - 8.2 ± 8.5 6.9 ± 10.0 0.59 
Total Moderate and Vigorous 
Exercise (min/day) 
62.7 ± 27.9 - 63.8 ± 27.0 61.9 ± 29.0 0.80 
1Data are expressed as mean (SD). Statistical Test: Independent T-Tests. Comparison group (remaining women not classified as PCOS) 
2 Higher score represents better quality for all components 
3Overall significance level P < 0.05 
 
Abbreviations: DRI, Dietary Reference Intake; EAR, Estimated Average Requirement; Eq, Equivalent; HEI, Healthy Eating Index; IU, International Units; 
MUFA, Monounsaturated Fatty Acid; PCOS, Polycystic Ovary Syndrome (Rotterdam Criteria); PUFA, Polyunsaturated Fatty Acid; RDA, Recommended 
Daily Allowance; SFA, Saturated Fatty Acid; UL, Upper Limit 
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Table 3.3. Multinomial logistic regression models estimating the association of diet and 
physical activity with PCOS1 
Variables 
Model 1: 
Age, Total Kcal 
Model 2: 
Age, Total Kcal, BMI 
 Odds Ratio 95% CI 
Odds 
Ratio 95% CI 
Energy (kcal/d)     
   PCOS 1.00 1.00, 1.00 1.00 1.00, 1.00 
Total Carbohydrate (g/d)     
   PCOS 0.99 0.98, 1.01 1.00 0.98, 1.01 
Glycemic Index     
   PCOS 1.00 1.00, 1.00 1.00 1.00, 1.00 
Glycemic Load     
   PCOS 1.00 0.99, 1.02 1.00 0.98, 1.02 
Total Sugar     
   PCOS 1.00 0.99, 1.01 1.00 0.99, 1.01 
Fiber (g/d)     
   PCOS 0.98 0.93, 1.02 1.00 0.95, 1.05 
Total Protein (g/d)     
   PCOS 1.01 0.98, 1.04 1.01 0.98, 1.03 
Total Fat (g/d)     
   PCOS 1.02 0.99, 1.05 1.02 0.99, 1.05 
Cholesterol (mg/d)     
   PCOS 1.00 1.00, 1.00 1.00 1.00, 1.00 
Total SFA (g/d)     
   PCOS 1.03 0.96, 1.10 1.01 0.94, 1.09 
Total MUFA (g/d)     
   PCOS 1.03 0.98, 1.08 1.04 0.98, 1.09 
Total PUFA (g/d)     
   PCOS 1.05 0.96, 1.16 1.06 0.96, 1.17 
Omega 3 (mg/day)     
   PCOS 0.95 0.47, 1.92 1.20 0.58, 2.49 
Trans-fat (g/day)     
   PCOS 1.47 1.00, 2.17 1.30 0.88, 1.92 
Vitamin A (IU/d)     
   PCOS 1.00 1.00, 1.00 1.00 1.00, 1.00 
Thiamin (mg/d)     
   PCOS 2.62 0.94, 7.33 2.25 0.76, 6.64 
Riboflavin (mg/d)     
   PCOS 1.81 0.94, 3.48 1.43 0.72, 2.88 
Niacin (mg/d)     
   PCOS 1.121 1.04, 1.22 1.111 1.02, 1.20 
Vitamin B6 (mg/d)     
   PCOS 2.30* 1.06, 5.00 2.471 1.09, 5.58 
Vitamin B12 (mg/d)     
   PCOS 1.251 1.04, 1.51 1.20 0.99, 1.45 
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Table 3.3. Multinomial logistic regression models estimating the association of diet and 
physical activity with PCOS1 
Variables 
Model 1: 
Age, Total Kcal 
Model 2: 
Age, Total Kcal, BMI 
 Odds Ratio 95% CI 
Odds 
Ratio 95% CI 
Vitamin C (mg/d)     
   PCOS 1.00 0.99, 1.01 1.00 1.00, 1.01 
Vitamin D (mcg /d)     
   PCOS 1.03 0.90, 1.18 1.02 0.88, 1.18 
Alpha Tocopherol Eq 
(mg/d) 
    
   PCOS 1.03 0.98, 1.09 1.05 0.99, 1.11 
Sodium (mg/d)     
   PCOS 1.00 1.00, 1.00 1.00 1.00, 1.00 
Calcium (mg/d)     
   PCOS 1.00 1.00, 1.00 1.00 1.00, 1.00 
Phosphorus (mg/d)     
   PCOS 1.00 1.00, 1.00 1.00 1.00, 1.00 
Potassium (mg/d)     
   PCOS 1.00 1.00, 1.00 1.00 1.00, 1.00 
Iron (mg/d)     
   PCOS 1.101 1.01, 1.20 1.09 0.99,1.20 
Copper (mg/d)     
   PCOS 0.86 0.27, 2.71 1.45 0.42, 4.94 
Magnesium (mg/d)     
   PCOS 1.00 0.99, 1.00 1.00 0.99, 1.00 
Zinc (mg/d)      
   PCOS 1.181 1.04, 1.34 1.151 1.01, 1.31 
Folic Acid (mcg/d)     
   PCOS 1.001 1.00, 1.00 1.00 1.00, 1.00 
Caffeine (mg/d)     
   PCOS 1.00 1.00, 1.00 1.00 1.00, 1.00 
HEI-2010 Scores     
Fruit     
   PCOS 0.90 0.70, 1.15 1.02 0.78, 1.34 
Whole Fruit     
   PCOS 1.06 0.83, 1.36 1.21 0.92, 1.60 
Vegetables     
   PCOS 1.02 0.72, 1.43 1.31 0.89, 1.93 
Green Beans     
   PCOS 0.96 0.76, 1.21 1.11 0.85, 1.44 
Whole Grains     
   PCOS 0.94 0.83, 1.06 0.97 0.85, 1.10 
Dairy     
   PCOS 0.98 0.85, 1.12 0.91 0.77, 1.06 
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Table 3.3. Multinomial logistic regression models estimating the association of diet and 
physical activity with PCOS1 
Variables 
Model 1: 
Age, Total Kcal 
Model 2: 
Age, Total Kcal, BMI 
 Odds Ratio 95% CI 
Odds 
Ratio 95% CI 
Protein Foods     
   PCOS 0.89 0.57, 1.39 0.99 0.63, 1.57 
Seafood and Plant Proteins 
   PCOS 0.87 0.68, 1.11 0.95 0.73, 1.23 
Fatty Acids     
   PCOS 1.05 0.92, 1.20 1.11 0.96, 1.28 
Refined Grains     
   PCOS 0.94 0.80, 1.11 0.95 0.80, 1.13 
Sodium     
   PCOS 0.97 0.84, 1.13 0.97 0.83, 1.14 
Empty Calories      
   PCOS 1.071 1.02, 1.12 1.071 1.01, 1.12 
Total HEI-2010 Scores     
   PCOS 1.01 0.99, 1.04 1.03 0.99, 1.06 
Physical Activity      
Moderate Exercise      
   PCOS 1.00 0.98, 1.02 1.00 0.98, 1.02 
Vigorous Exercise      
   PCOS 1.01 0.96, 1.06 1.02 0.96, 1.07 
Total Moderate and Vigorous Exercise  
   PCOS 1.00 0.98, 1.02 1.00 0.98, 1.02 
1Overall significance level P < 0.10 due to exploratory analysis (vs. Comparison) 
 
Abbreviations: Eq, Equivalent; HEI, Healthy Eating Index; IU, International Unit; MUFA, 
Monounsaturated Fatty Acid; PCOS, Polycystic Ovary Syndrome (hyperandrogenism and 
oligomenorrhea); PUFA, Polyunsaturated Fatty Acid; SFA, Saturated Fatty Acid 
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associated with PCOS. Higher intake of niacin (vitamin B3), vitamin B6, and zinc were 
associated with greater odds of PCOS in Models 1 and 2 (P≤0.08). In Model 1, an 
increase of 1 mg/day in vitamin B12 or iron intake was associated with 10 to 25% 
greater odds of having PCOS (P≤0.08). The main effects of vitamin B12 and iron were 
comparable between Models 1 and 2, yet results from Model 2 did not reach statistical 
significance. No other food groups and macro- or micronutrients were associated with 
PCOS. 
Results from dietary interviews in a subset of participants confirmed findings 
that women with PCOS altered their eating behaviors. A higher proportion of 
participants in the PCOS group (21 of 33 interviews; 64%) reported attempting to 
increase intake of fiber and whole grains and/or limit refined sugar and fat than the 
reference group (10 of 23 interviews; 43%). Additionally, participants with PCOS 
described that they altered their diet due to health markers related to PCOS (e.g., weight 
gain, elevated triglycerides and glucose concentrations) (data not shown).  
Physical activity  
Women with and without PCOS met the 2008 PA guidelines for performing 150 
minutes of moderate and/or 75 minutes of vigorous activity over 4 to 7 days (Table 3.2). 
No significant differences were observed in the duration spent in moderate and/or 
vigorous activities between the PCOS and comparison groups. There were also no 
significant associations detected between markers of PA and PCOS after adjusting for 
age, total calories and/or BMI (Table 3.3). 
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DISCUSSION 
The objectives of this study were to understand the current diet and PA behavior 
of women with PCOS, and contrast these results with women without PCOS. By 
understanding the current dietary and PA behaviors in PCOS patients, potential targets 
for PCOS-specific interventions could be identified and integrated into existing 
practices. Our cross-sectional analyses revealed that women with PCOS did not meet 
US dietary recommendations for fat (% total energy/day), fiber (g/day), and potassium 
(mg/day). These findings agreed with two prior studies conducted outside the US that 
noted PCOS patients exceeded US and United Kingdom government recommendations 
on fat intake (30,32) and/or did not meet fiber (30,32) and potassium guidelines (32). 
High fat and low fiber and potassium intake have been linked to increased risk of 
cardiovascular disease (45) – an adverse outcome that is more likely to develop in 
women with PCOS than the general population (46). Despite these findings, we 
observed no association between total energy intake and PCOS, a finding that was 
consistent with two other studies conducted in the US (47,48). While the mounting 
cross-sectional evidence suggests that higher total energy intake is not associated with 
PCOS, we are unable to conclude whether this pattern is present for participants during 
their earlier reproductive years.   
The current study confirmed that women with PCOS had healthier diets 
compared to women without PCOS. Our study revealed that a 1.6% decrease in total 
energy intake from sugar, fat, and alcohol was associated with a 7.0% increase in odds 
of PCOS. Higher intake of niacin, vitamin B6, and zinc were positively associated with 
PCOS in Models 1 and 2, while significant associations between vitamin B12 and iron 
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with PCOS were only observed in the Model 1. However, estimates of vitamin B12 and 
iron with PCOS were similar between the Models 1 and 2, suggesting that the addition 
of BMI as a covariate may lead to overadjustment in the regression analyses. Our 
findings paralleled results reported by Moran et al. (2013), in which the PCOS group 
reported better diet quality scores than a non-PCOS group (31). We hypothesize that 
our findings may be attributed to a greater proportion of women with PCOS changing 
their health-related behaviors, which was corroborated by our review of data from the 
diet interviews. Fewer empty calories and higher intake of B vitamins, iron, and zinc 
were significantly associated with PCOS, suggesting that patients with PCOS may have 
adopted specific dietary recommendations provided by either physicians and/or social 
media. Clinicians often provide government dietary recommendations, such as reducing 
healthy snacks, to encourage weight loss in overweight and obese PCOS patients 
(26,49,50). This may explain why the PCOS group in our study consumed fewer calories 
from solid fat, alcohol, and added sugars. The benefits of B vitamins, iron and zinc have 
also been encouraged in recent years on popular patient websites due to associations 
with markers of cardiovascular disease and diabetes (51), which is a preferred source of 
information for women with PCOS (52–55). Notably, an emphasis has been placed on 
consuming greater amounts of B vitamins to reduce homocysteine concentrations (an 
amino acid linked with cardiovascular disease) (56,57). 
Outside of dietary recommendations, increasing PA is another fundamental 
strategy to achieve weight loss and treat PCOS symptoms (50). Our study found that 
women in the PCOS group met the recommended national PA guidelines, though we 
noted no significant associations between minutes spent in moderate and vigorous PA 
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with PCOS. These findings were consistent with five studies that detected no differences 
in self-reported moderate and vigorous PA between women with and without PCOS 
(31,32,47,58,59). A single study that measured PA using accelerometers also noted no 
significant differences in sedentary levels of obese adolescents with and without PCOS 
(24), suggesting that physical activity levels may not differ between women with and 
without PCOS across the reproductive life course. That said, we are aware of one study 
that reported longer sitting intervals in women with PCOS compared to the reference 
group (31). Differences in the patterns and types of PA and sedentary behaviors may 
exist between women with and without PCOS. However, future research involving 
assessments of PA patterns is ultimately needed to corroborate the relevance of these 
findings.  
This study had several strengths. This was the first US study to use Rotterdam 
diagnostic criteria and new morphological criteria for PCOS when examining dietary 
and PA behaviors of the PCOS population, an approach recommended by the National 
Institutes of Health Evidence-based Methodology steering committee for clinical and 
research settings (21). Through this approach, we were able to capture the health-related 
behavior of women across all variants of PCOS, thereby improving the clinical 
applicability of our results. Our study was also among the first to use US government 
recommended benchmarks (60,61) to assess whether PCOS patients met nutrition needs 
and physical activity guidelines. This evaluation was particularly informative since 
these recommendations were created to reduce risk of chronic disease and are often 
indicators of healthy behaviors (39,60). However, our study was limited by the small 
sample size of women in the control group and by its cross-sectional design. Though 
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we identified potential associations between dietary and PA behaviors with PCOS, the 
temporal relationship has yet to be established. We also excluded women who were 
previously diagnosed with other chronic diseases due to institutional regulations, thus 
restricting the generalizability of our results to a healthier sample of PCOS patients.  
 Our findings build upon previous evidence to confirm a relationship between 
dietary intake and PCOS. Overall, women with PCOS met US dietary and PA 
guidelines, while higher intake of B vitamins, zinc, and iron, and fewer empty calories 
were associated with PCOS. These results suggest that women with PCOS may adopt 
certain healthy dietary and PA behaviors after receiving a PCOS diagnosis. However, 
these results also highlight a need for future longitudinal cohort studies to assess dietary 
and PA exposures to PCOS-related outcomes at earlier stages of the reproductive life 
course, particularly during adolescence. The early identification of dietary and PA 
factors that may promote or hasten progression to PCOS are needed to develop tailored 
preventative strategies for this chronic disorder.   
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PART TWO PREFACE 
 
The narrative review in Part One also identified the importance of understanding the 
psychosocial influences on lifestyle behaviors of PCOS patients. To encourage behavior 
change, health-related knowledge, personal beliefs and environmental influences are 
often incorporated in interventions at research and clinical settings. Data were collected 
on health-related knowledge status, beliefs about health, and perceptions directed 
toward healthcare providers for the following specific aims:  
 
AIM 1: To compare health-related knowledge, beliefs, and self-efficacy between 
women with and without PCOS.  
This aim was addressed in Chapter 4.  
 
AIM 2: To compare perceptions of trust and social support from healthcare 
providers (medical experiences) between women with and without PCOS.  
This aim was addressed in Chapter 5.  
 
AIM 3: To examine whether trust towards physicians varied between general and 
PCOS health concerns in PCOS patients.  
This aim was addressed in Chapter 5.  
 
Both instruments were internally developed and validated using a nationwide US 
sample. Details on the reliability and validation analyses, as well as the final drafts of 
both instruments, are presented in Appendices B and C. This chapter yielded two 
primary research manuscripts. 
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CHAPTER 4: HEALTH-RELATED KNOWLEDGE, BELIEFS, AND SELF-
EFFICACY IN WOMEN WITH POLYCYSTIC OVARY SYNDROME 
Submitted, with Decision to Revise, Resubmit: August 2017 by Human Reproduction 
* Lin AW, Dollahite JS, Sobal, Lujan ME. Health-related knowledge, beliefs, and self-efficacy in women 
with polycystic ovary syndrome.  
ABSTRACT 
Study question: Do health-related knowledge, beliefs, and self-efficacy differ between 
women with and without polycystic ovary syndrome (PCOS)? 
Summary answer: Women with PCOS felt at greater risk for adverse health outcomes, 
yet believed diet and PA behaviors were less beneficial to prevent weight gain relative 
to a comparison group. 
What is known already: Dietary and physical activity interventions are often used to 
treat PCOS, but there are high attrition rates and less engagement in self-help methods. 
It is unclear whether there are unique psychosocial considerations in PCOS that should 
be incorporated into these interventions. 
Study design, size, duration: This cross-sectional study enrolled 475 women with and 
without PCOS who were recruited through flyers and online advertisements across the 
United States. 
Participants/materials, setting, methods: Participants were females who lived in the 
United States (mean age: 28.1 ± 5.4 years). Participants were considered to have PCOS 
if they responded affirmatively about whether they were previously diagnosed with 
PCOS by a healthcare provider. The remaining women were placed in the comparison 
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group. A reliable and valid online instrument about health-related knowledge, beliefs, 
and self-efficacy was administered to these participants.  
Main results and the role of chance: Most women with PCOS had a basic 
understanding of nutrition (96%), but had misconceptions about diagnostic criteria for 
PCOS (≤86%). PCOS was associated with greater perceived susceptibility for disease 
and weight gain and poorer perceived control over these health outcomes (all P≤0.05), 
in relation to the comparison group. Women with PCOS also perceived fewer benefits 
of healthy behaviors on weight gain (P=0.03) with less than half of the PCOS group 
attempting to follow government diet recommendations (47%). There were no 
differences in the self-efficacy of dietary behaviors between groups.   
Limitations, reasons for caution: It is likely that participant self-selection occurred 
due to the nature of recruitment in this study. Additionally, most of the sample identified 
as having European ancestry, which reduces the generalizability of the results.  
Wider implications of the findings: These findings provide evidence that behavioral 
interventions should incorporate the unique psychosocial considerations associated with 
PCOS to encourage patient participation in health interventions.  
Study funding/competing interest(s): This manuscript was partially supported by 
Cornell University Human Ecology Alumni Association and College of Agriculture and 
Life Sciences Alumni Association. The authors have no competing interests.  
Trial registration number: NCT01859663 
Keywords: Health Behaviors, PCOS, Psychosocial, Counseling
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INTRODUCTION 
Polycystic ovary syndrome (PCOS) is a complex endocrine disorder whose symptoms 
and co-morbidities have far-reaching implications for the health of women across the 
lifespan  (Fauser et al., 2012).  Rotterdam criteria for PCOS define the condition by the 
presence of at least two of three features: 1) oligo- or amenorrhea; 2) hyperandrogenism; 
and 3) polycystic ovarian morphology (Rotterdam ESHRE/ASRM-Sponsored PCOS 
Consensus Workshop Group, 2004). Using these criteria, PCOS affects up to 10% of 
reproductive-aged women globally (Bozdag et al., 2016) and is established as an 
independent risk factor for cardiovascular disease, diabetes, infertility, endometrial 
cancer, and obesity (Fauser et al., 2012). Consequently, diet and physical activity (PA) 
modifications are recommended to treat PCOS symptoms and/or prevent the 
development of these adverse health outcomes (Harrison et al., 2011; Moran et al., 
2009; Fauser et al., 2012). Women with PCOS are frequently provided general 
behavioral advice, such as reducing high caloric and/or fat foods, and incorporating 
more PA (Humphreys and Costarelli, 2008; Jeanes et al., 2009). Prior research has 
revealed that women with PCOS perceive these general diet and PA recommendations 
to be useful, but simultaneously vague and insufficient (Humphreys and Costarelli, 
2008; Gibson-Helm et al., 2014). Dissatisfaction with current recommendations suggest 
more targeted multidisciplinary interventions are needed to address barriers to adopting 
healthy practices in women with PCOS.  
Studies in obese populations have established that effective interventions 
integrate a multidisciplinary approach (Ross et al., 2010; Montesi et al., 2016). A major 
component of this approach is the use of theories to understand the patient’s health-
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related knowledge, beliefs and self-efficacy (Ross et al., 2010). Social Cognitive Theory 
(SCT) and the Health Belief Model (HBM) are two theories used in clinical and research 
settings to encourage behavior change (Bandura, 2004; Anderson et al., 2007; 
Deshpande et al., 2009). Social Cognitive Theory examines the interaction between 
personal, environmental, and behavioral factors, emphasizing self-efficacy (Bandura, 
2004). The Health Belief Model can be implemented in conjunction with SCT to 
examine beliefs toward a disease and/or a behavior (Janz and Becker, 1984). Both 
theories maintain the assumption that cognitive (e.g., health-related knowledge) and 
affective (e.g., health-related beliefs, self-efficacy) factors are prerequisites for behavior 
change (Janz and Becker, 1984; Bandura, 2004). This assumption is supported by 
several studies involving women without PCOS wherein knowledge, beliefs, and self-
efficacy (psychosocial constructs) were shown to influence adoption of behavioral 
modifications (Bunting and Boivin, 2007; Lo et al., 2015; Stacey et al., 2015; Teixeira 
et al., 2015). 
It remains unclear whether experiences related to PCOS impart additional 
psychosocial considerations when designing behavioral interventions. Unique concerns 
associated with PCOS may explain the high attrition rates in intervention studies 
(Sorensen et al., 2012; Mutsaerts et al., 2013) and less engagement in self-help methods 
(Jeanes et al., 2009; Kozica et al., 2013). Currently, there is limited understanding about 
the actual health-related knowledge, beliefs and self-efficacy of women with PCOS, and 
whether PCOS is associated with poor perceptions of health behaviors. The few studies 
published to date report conflicting evidence about whether women with PCOS have 
different health-related beliefs relative to women without PCOS, despite experiencing 
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poorer overall health and greater impairment from adverse health outcomes (Moran et 
al., 2010; Kozica et al., 2013). To address this knowledge gap, we compared health-
related knowledge, beliefs, and self-efficacy between women with PCOS and a 
comparison group.  
MATERIALS AND METHODS 
Ethics Approval  
The study was approved by the Institutional Review Board at Cornell University and all 
participants provided informed consent. 
Participants 
This project was an ancillary study of a larger observational investigation of the 
differences in diet and physical activity in women with and without PCOS 
(ClinicalTrials.gov Identifier: NCT01859663). Women were initially recruited through 
flyers posted in clinics throughout Tompkins County, New York, and through online 
local advertisements. Subsequently, recruitment was extended more broadly using 
several electronic platforms nationwide (Twitter, Facebook, Reddit, ResearchMatch).  
Inclusion criteria were female, 18 to 38 years of age, US residents, and self-
reported history of predictable menstrual cycles or self-reported physician diagnosis of 
PCOS. Exclusion criteria included incomplete surveys (defined as less than half of the 
instrument completed), implausible (defined as <16 kg/m2 or >80 kg/m2) or missing 
body mass index (BMI) values, diagnosis of major chronic disease (such as diabetes, 
kidney disease, and/or thyroid conditions), and/or a history of isolated oligo-amenorrhea 
(defined as unpredictable menstrual cycles and/or menstrual cycle length <20 or >35 
days without a PCOS diagnosis). A participant was considered to have PCOS if she 
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responded ‘yes’ to the item: “Have you been diagnosed with PCOS by a medical 
professional?” Participants who responded ‘no’ and reported predictable menstrual 
cycles between 20 and 35 days were included in the comparison group. As such, PCOS 
status was based on self-report and not confirmed with clinical and/or biochemical data. 
This approach has been used in other studies (Kozica et al., 2013; Gibson-Helm et al., 
2016) with the understanding that self-report may lead to random misclassification and 
an underestimate of true effect sizes. The large sample size employed in this study, and 
the validity of self-reported PCOS status as described by others (Teede et al., 2013), 
were expected to reduce random misclassification bias.  
Procedure 
The Instrument for PCOS: Knowledge, Health-Related Beliefs, and Self-Efficacy (I-
PCOSK) was developed as an online instrument (Qualtrics©, Provo, UT, USA) over a 
21-month period (June 2014 to March 2016). The final instrument was comprised of 77 
items designed using SCT and HBM constructs to assess 1) reproduction-, nutrition-, 
and PCOS-related knowledge, 2) beliefs about health outcomes and confidence in 
dietary and PA behaviors, and 3) self-evaluation of current behaviors (Supplemental 
Table S4.1). The majority of items were formatted as multiple choice questions or five-
point rating scales. Items related to beliefs about the severity and inevitability of adverse 
health outcomes and evaluation of dietary and PA behaviors were assessed on a 
continuous scale (1=‘disagree’ to 5=‘agree’). For items about perceived susceptibility 
to adverse health outcomes, a value of 1 indicated ‘much lower than average’ and 5 
indicated ‘much higher than average.’ Higher values on items assessing health-related 
worries denoted greater occurrences of worrying about adverse health outcomes 
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(1=‘never’ to 5=‘almost all the time’). For self-efficacy, higher values indicated greater 
confidence to perform a given dietary behavior (1=‘cannot do’ to 5=‘certainly can do’). 
Additional details about the development and validation of the I-PCOSK are presented 
in the Appendix B.  
Statistical Analyses  
Statistical analyses were performed using SPSS 23.0 (IBM, Armonk, NY, USA), 
with the significance level threshold set at P<0.05. Differences in demographics, self-
reported anthropometrics, and health-related knowledge between women in the PCOS 
and comparison groups were analyzed with independent t-tests and/or Fisher’s exact 
tests. Linear regression methods estimated the associations between PCOS status 
(exposure) with health-related beliefs and self-efficacy (outcomes). Each valid item in 
the I-PCOSK was analyzed as a separate regression model. Multiple linear regression 
models were adjusted for potential confounders: age (continuous), BMI (categorical), 
and highest completed education level (categorical). Unadjusted and adjusted model 
estimates were compared to confirm the presence of covariates. Due to the potentially 
high interrelatedness of the items, a correction for multiple comparisons across models 
was not used (Rothman, 1990).  
RESULTS 
Women across the US (n=786) responded to electronic advertisements for the self-
administered I-PCOSK and 475 (69%) were eligible to participate in the study (Figure 
4.1). The study sample was comprised of female adults who were primarily white, with 
at least a high school education (Table 4.1). The sample size exceeded the target 
recruitment goal (N = 150), which was calculated to provide 86% power to detect a 1-
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Figure 4.1. Participant flowchart. Flow diagram of the process through which 
participants were classified into PCOS and comparison groups. 
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Table 4.1. Characteristics of I-PCOSK participants   
Characteristics PCOS
a 
(n = 255) 
Comparison 
(n = 220) P 
Age (years) 29.3 ± 4.7 26.7 ± 5.7 <0.01 
Race (%)    
   Asian 11 (4.3) 13 (5.9) 
0.65 
   Black  18 (7.1) 14 (6.4) 
   White 200 (78.5) 169 (77.2) 
   Latina 14 (5.5) 8 (3.7) 
   Other  12 (4.7) 15 (6.8) 
Highest Education (%)    
   ≤  High School Degree 71 (27.8) 74 (33.6) 
0.01 
   Associate’s Degree 30 (11.8) 26 (11.8) 
   College Graduate 91 (35.7) 92 (41.8) 
   Advanced Degree 63 (24.7) 28 (12.7) 
BMI Categories (%)    
   Underweight (< 18.5 kg/m2) 4 (1.6) 8 (3.6) 
<0.01 
   Normal (18.5- < 25 kg/m2) 47 (18.4) 122 (55.5) 
   Overweight (25- < 30 kg/m2) 51 (20.0) 51 (23.1) 
   Obese (≥ 30 kg/m2) 153 (60.0) 39 (17.7) 
Data are expressed as mean ± SD, n (%). Significance level P < 0.05 between PCOS and comparison 
groups. Abbreviations: PCOS, Polycystic ovary syndrome. 
 
a Prompt used to determine PCOS status: “Have you been diagnosed with PCOS by a medical 
professional?” 
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unit difference in measures of knowledge, beliefs and self-efficacy (scale). Women with 
PCOS (n=255) were older, more likely to be obese and to have an advanced degree 
relative to the comparison group (n=220, P <0.01). Those excluded from the analysis 
(n=311) were ineligible due to having a major chronic disease (n =124), submitting 
incomplete surveys (n=78), reporting a history of oligo-amenorrhea without a PCOS 
diagnosis (n=50), being ≤ 18 and ≥ 38 years old (n = 37), and/or meeting other exclusion 
criteria (n=22).  
Health-related Knowledge in PCOS and Relation to the Comparison Group 
A majority of women with PCOS (>76%) correctly answered knowledge items related 
to ovarian physiology and function (Figure 4.2). Most of the participants with PCOS 
(96%) also accurately identified at least one food group containing fiber and one 
national nutrition recommendation. When responding to items about PCOS, participants 
correctly answered items about evidence-based adverse health outcomes and treatments 
(Figure 4.3), but did not consistently identify components of established diagnostic 
criteria for PCOS. Features that were incorrectly identified as diagnostic criteria 
included sudden weight gain (64%), insulin resistance (81%) and trouble losing weight 
(86%). Relative to the comparison group, a greater percentage of the PCOS group 
correctly answered items related to knowledge of female reproductive hormones (Figure 
4.2). By contrast, there were no differences in nutrition-related knowledge between the 
two groups.  
Health-Related Beliefs in PCOS and Relation to the Comparison Group  
The PCOS group reported high scores for perceived severity of cardiovascular disease, 
diabetes, and endometrial cancer, indicating that these outcomes were considered to
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Figure 4.2. Correct responses on reproductive- and nutrition-related knowledge. Percentage of correct responses on reproductive- 
and nutrition-related knowledge in the PCOS and comparison groups (PCOS n = 255; Comparison n = 250). Asterisks represent 
significantly different responses between groups (P ≤ 0.01). 
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Figure 4.3. Responses on PCOS-related Knowledge. Percentage of “yes” responses on PCOS-related knowledge in the PCOS group 
(n = 255).  
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be serious health issues for this group (Table 4.2). Women with PCOS also reported 
they were at higher risk of developing adverse health outcomes. However, overall scores 
on the occurrence of worrying about cardiovascular disease and diabetes for this group 
fell between “hardly ever” and “usually” [2.55 (SD 1.19) and 3.21 (SD 1.13), 
respectively]. Women with PCOS were likely to believe that cardiovascular disease, 
diabetes, and weight gain were preventable (mean scores ≥3.90), but not endometrial 
cancer and infertility (mean scores ≤2.60). These beliefs were further corroborated by 
their responses that a healthy diet and/or physical activity would reduce their risk for 
adverse health outcomes, except for endometrial cancer and infertility (Table 4.2). 
Nevertheless, the PCOS group was ambivalent about the importance of meeting diet 
and physical activity government recommendations. Sixty-four percent reported they 
searched for the MyPlate guidelines on the Internet and fewer (47%) attempted to follow 
these recommendations, which was consistent with how the PCOS group rated the 
overall quality of their diet and lifestyle [3.12 (SD 1.00) and 2.86 (SD 1.04), 
respectively.  
The PCOS group perceived greater severity of and susceptibility to endometrial 
cancer relative to the comparison group in both the unadjusted and adjusted regression 
models (Table 4.3). The addition of age, BMI, and education to the adjusted model did 
not appreciably alter estimates from the unadjusted model. Women with PCOS felt more 
susceptible to adverse health outcomes and were more concerned about developing 
cardiovascular disease and diabetes relative to the comparison group (P<0.01). 
Although the PCOS group reported poorer perceived control over cardiovascular 
disease and weight gain, this pattern was not observed for endometrial cancer and 
  
Table 4.2. Health-related beliefs and self-efficacy scores in the PCOS group from the nationwide distribution (n = 255) 
Item Prompt PCOS Range of Scales (1 to 5) 
Health-Related Beliefs 
________________ is a very serious problem.  
Heart disease* 5.00 ± 0.00 
1 (disagree) to 5 (agree) Diabetes* 5.00 ± 0.00 
Endometrial cancer* 5.00 ± 0.00 
Compared to most people your age and weight in the United States, what would you say your chances are of getting:  
Heart disease 3.61 ± 1.11 
1 (much lower than average) to  
5 (much higher than average) 
Diabetes 4.01 ± 1.05 
Endometrial cancer 3.50 ± 1.11 
Weight gain 4.29 ± 0.95 
During the past year, how often have you thought about your chances of getting:  
Heart disease 2.55 ± 1.19 
1 (never) to 5 (almost all the time) 
Diabetes 3.21 ± 1.13 
There is a lot I can do to prevent getting: 
Heart disease* 4.00 ± 1.00 
1 (disagree) to 5 (agree) 
Diabetes* 4.00 ± 1.00 
Endometrial cancer  2.61 ± 1.14 
Weight gain* 4.00 ± 2.00 
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Table 4.2. Health-related beliefs and self-efficacy scores in the PCOS group from the nationwide distribution (n = 255) 
Item Prompt PCOS Range of Scales (1 to 5) 
Infertility  2.47 ± 1.15 
It is important for me to meet government ________________ recommendations.  
Diet 3.11 ± 1.26 
(1 disagree) to 5 (agree) 
Physical activity 3.71 ± 1.28 
________________ will reduce my risk of ________________. 
Healthy diet: Heart disease* 5.00 ± 1.00 
1 (disagree) to 5 (agree) 
Healthy diet: Diabetes* 5.00 ± 1.00 
Healthy diet: Endometrial cancer  2.77 ± 1.22 
Healthy diet: Weight gain* 5.00 ± 1.00 
Healthy diet: Infertility  2.73 ± 1.24 
Physical activity: Heart disease* 5.00 ± 1.00 
Physical activity: Diabetes* 5.00 ± 1.00 
Physical activity: Endometrial cancer  2.73 ± 1.27 
Physical activity: Weight gain* 5.00 ± 1.00 
Physical activity: Infertility  2.80 ± 1.28 
In general, how healthy is your overall ________________? 
Diet 3.12 ± 1.00 
1 (poor) to 5 (excellent) 
Lifestyle 2.86 ± 1.04 
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Table 4.2. Health-related beliefs and self-efficacy scores in the PCOS group from the nationwide distribution (n = 255) 
Item Prompt PCOS Range of Scales (1 to 5) 
Self-Efficacy: Please select how confident you are in your ability to do the following things FOR THE NEXT MONTH. 
Incorporate low fat foods into my diet.* 4.00 ± 2.00 
1 (cannot do) to 5 (certainly can do) 
Incorporate low salt foods into my diet.* 4.00 ± 2.00 
Decrease the amount of refined sugar in my diet.* 4.00 ± 2.00 
Eat more high fiber foods.* 5.00 ± 1.00 
Eat smaller portions at dinner.* 4.00 ± 2.00 
Control my eating on weekends. 3.84 ± 1.07 
Resist eating too much when there are many different kinds of 
food available. 3.72 ± 1.05 
Resist eating when I am at a party. 3.37 ± 1.23 
Resist eating when I am anxious or nervous. 3.58 ± 1.13 
Resist eating when I am depressed or feel down. 3.41 ± 1.18 
Resist eating when I am angry or irritable. 3.73 ± 1.11 
Resist eating when I experience failure. 3.66 ± 1.11 
Data are expressed as mean ± SD or median ± IQR (*). Abbreviations: PCOS, Polycystic ovary syndrome  
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Table 4.3. Differences in health-related beliefs and self-efficacy scores of the PCOS group (n = 255) in relation to the comparison group (n = 
250) from the nationwide distribution 
Item: Abbreviated Prompts Unadjusted β (SE) P Unadjusted  Adjusted β (SE)a P Adjusted 
Health-Related Beliefs 
________________ is a very serious problem.  
Heart disease 0.01 (0.05) 0.78 0.03 (0.05) 0.63 
Diabetes 0.03 (0.05) 0.54 -0.01 (0.05) 0.80 
Endometrial cancer 0.14 (0.06) 0.02 0.16 (0.07) 0.02 
Compared to most people your age and weight in the United States, what would you say your chances are of getting:  
Heart disease 1.16 (0.10) <0.01 0.83 (0.11) <0.01 
Diabetes 1.59 (0.10) <0.01 1.25 (0.11) <0.01 
Endometrial cancer 1.02 (0.10) <0.01 0.89 (0.11) <0.01 
Weight gain 1.60 (0.09) <0.01 1.05 (0.09) <0.01 
During the past year, how often have you thought about your chances of getting:  
Heart disease 0.71 (0.10) <0.01 0.47 (0.11) <0.01 
Diabetes 1.25 (0.10) <0.01 0.93 (0.11) <0.01 
There is a lot I can do to prevent getting: 
Heart disease -0.21 (0.08) 0.01 -0.19 (0.09) 0.04 
Diabetes -0.16 (0.08) 0.05 -0.19 (0.09) 0.05 
Endometrial cancer  0.10 (0.10) 0.34 0.09 (0.12) 0.43 
Weight gain -0.52 (0.09) <0.01 -0.44 (0.10) <0.01 
Infertility  0.28 (0.11) 0.08 0.20 (0.12) 0.10 
It is important for me to meet government ________________ recommendations.  
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Table 4.3. Differences in health-related beliefs and self-efficacy scores of the PCOS group (n = 255) in relation to the comparison group (n = 
250) from the nationwide distribution 
Item: Abbreviated Prompts Unadjusted β (SE) P Unadjusted  Adjusted β (SE)a P Adjusted 
Diet 0.07 (0.12) 0.56 0.20 (0.13) 0.13 
Physical activity 0.15 (0.12) 0.21 0.38 (0.13) <0.01 
________________ will reduce my risk of ________________. 
Healthy diet: Heart disease -0.12 (0.07) 0.08 -0.06 (0.08) 0.43 
Healthy diet: Diabetes -0.10 (0.07) 0.13 -0.10 (0.08) 0.22 
Healthy diet: Endometrial cancer  -0.16 (0.11) 0.15 -0.12 (0.13) 0.34 
Healthy diet: Weight gain -0.27 (0.08) <0.01 -0.19 (0.09) 0.03 
Healthy diet: Infertility  0.11 (0.11) 0.32 0.15 (0.13) 0.25 
Physical activity: Heart disease -0.05 (0.07) 0.48 -0.03 (0.08) 0.72 
Physical activity: Diabetes -0.02 (0.07) 0.79 -0.05 (0.08) 0.53 
Physical activity: Endometrial cancer  -0.13 (0.12) 0.26 -0.09 (0.13) 0.48 
Physical activity: Weight gain -0.24 (0.07) <0.01 -0.18 (0.08) 0.03 
Physical activity: Infertility  0.13 (0.12) 0.26 0.08 (0.13) 0.54 
In general, how healthy is your overall ________________? 
Diet -0.15 (0.09) 0.10 0.04 (0.10) 0.72 
Lifestyle -0.32 (0.09) <0.01 -0.11 (0.10) 0.27 
Self-efficacy: Please select how confident you are in your ability to do the following things FOR THE NEXT MONTH. 
Incorporate low fat foods into my diet. 0.14 (0.10) 0.89 0.13 (0.11) 0.24 
Incorporate low salt foods into my diet. 0.07 (0.10) 0.51 0.10 (0.12) 0.40 
Decrease the amount of refined sugar in my diet. 0.14 (0.09) 0.14 0.20 (0.10) 0.06 
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Table 4.3. Differences in health-related beliefs and self-efficacy scores of the PCOS group (n = 255) in relation to the comparison group (n = 
250) from the nationwide distribution 
Item: Abbreviated Prompts Unadjusted β (SE) P Unadjusted  Adjusted β (SE)a P Adjusted 
Eat more high fiber foods. 0.09 (0.08) 0.25 0.14 (0.09) 0.14 
Eat smaller portions at dinner. 0.17 (0.10) 0.08 0.17 (0.11) 0.13 
Control my eating on weekends. -0.06 (0.10) 0.57 0.05 (0.11) 0.62 
Resist eating too much when there are many different kinds of food 
available. 0.09 (0.10) 0.35 0.19 (0.11) 0.09 
Resist eating when I am at a party. -0.06 (0.11) 0.61 -0.04 (0.12) 0.73 
Resist eating when I am anxious or nervous. -0.04 (0.11) 0.70 0.09 (0.12) 0.44 
Resist eating when I am depressed or feel down. -0.07 (0.11) 0.51 0.06 (0.12) 0.61 
Resist eating when I am angry or irritable. -0.20 (0.10) 0.05 -0.06 (0.11) 0.60 
Resist eating when I experience failure. -0.09 (0.10) 0.38 0.06 (0.11) 0.62 
Significance level P < 0.05. Abbreviations: PCOS, Polycystic ovary syndrome  
a Adjusted model: Independent variable: PCOS status (Reference category: comparison group); Dependent variable: I-PCOSK item; Covariates: age, BMI, 
education. 
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infertility as evidenced by the regression models. Women with PCOS were less likely 
to agree that a healthy diet or physical activity could reduce risk of weight gain relative 
to the comparison group (both P = 0.03), though the PCOS group placed greater 
importance in meeting national physical activity recommendations [adjusted model, 
β=0.38 (SE 0.13), P<0.01]. No differences were observed in how both groups rated their 
diet when accounting for age, BMI, and education level.   
Health-Related Self-efficacy in PCOS and Relation to the Comparison Group 
Women with PCOS were confident in their ability to incorporate low-fat, low-
sodium and high-fiber food products, restrict refined sugar in the diet and eat smaller 
portions of food (Table 4.2). Although women with PCOS did not score as confidently 
on items related to resisting cues to eating compared to confidence to change one’s diet, 
mean scores fell between “possibly can do” and “certainly can do.” No significant 
differences were observed in self-efficacy scores on items related to diet modification 
and resistance to eating cues between the PCOS and comparison groups in either the 
unadjusted or adjusted models (Table 4.3).  
DISCUSSION 
Objectives of this study were to investigate health-related knowledge, beliefs and self-
efficacy in women with PCOS. The PCOS group demonstrated basic understanding of 
female reproduction, current national diet recommendations and PCOS-related health 
risks and treatments. However, a majority of the women with PCOS did not correctly 
identify established PCOS diagnostic criteria. Overall, women with PCOS had 
significantly less optimal health-related beliefs relative to the comparison group but did 
not differ in their health-related self-efficacy.  
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Our study provides evidence that women with PCOS have some misconceptions 
surrounding criteria used to diagnose this condition. The high percentage of women who 
identified unestablished criteria as diagnostic may reflect current disagreements and/or 
confusion related to the actual clinical spectrum of PCOS among clinicians and 
researchers (Azziz, 2006; Teede et al., 2014). In a recent publication documenting the 
PCOS diagnosis experience, a significant proportion of patients reported formal 
assessments by three or more health professionals occurring over several years prior to 
obtaining a formal diagnosis (Gibson-Helm et al., 2016). The relatively long time to 
diagnosis and interaction with multiple specialists would be expected to engender some 
degree of confusion among patients related to how their diagnosis was ultimately 
established.  
In particular, features related to body weight were selected as a diagnostic for 
PCOS by many women in this study, which may explain why the PCOS population was 
less likely to engage in self-help methods (Jeanes et al., 2009; Kozica et al., 2013). In a 
recent qualitative study with obese participants, those who expected failure with weight 
loss experienced more unsuccessful attempts (Hollywood and Ogden, 2016). Similarly, 
we hypothesize that women with PCOS may become less motivated to adopt healthy 
behaviors if they feel they are predisposed to have weight issues. Our findings suggest 
that despite believing that healthy behaviors decreases risk of weight gain, the PCOS 
group felt they had significantly poorer control over their weight relative to the 
comparison group and did not follow a self-described ‘good’ quality diet. Focusing on 
the known success of weight loss interventions in women with PCOS and providing 
strong encouragement about health-related issues from healthcare providers may 
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represent important targets for intervention when counseling women with PCOS about 
the benefits of behavior changes.  
Although informed about their elevated risk for adverse health outcomes, 
women with PCOS are provided with government diet recommendations for the general 
population (e.g., avoid high-fat meals, reduce intake of unhealthy snacks) that they 
perceive as inadequate (Cussons et al., 2005; Humphreys and Costarelli, 2008; Jeanes 
et al., 2009). Our study showed that the PCOS group was ambivalent about meeting 
government diet recommendations. Fewer than half of the PCOS group attempted to 
follow these recommendations, despite being more concerned about developing adverse 
health outcomes relative to the comparison group. 
 Our findings also point to potential incongruences between attitudes toward 
government recommendations and self-efficacy of behavior performance in PCOS. 
Namely, participants with PCOS reported higher scores on self-efficacy items related to 
general diet recommendations in contrast to other dietary behaviors, though they did not 
usually adopt these behaviors. Further investigation is needed to explore whether 
attitudes toward diet recommendations may explain why women with PCOS are not 
practicing these dietary behaviors despite having confidence that they could 
successfully adopt the recommendations.  
Endometrial cancer has emerged as a health concern for which women with 
PCOS may require further education. The PCOS group reported that they were more 
susceptible to endometrial cancer, but felt limited in their ability to prevent this 
condition. Despite consensus in the field that PCOS patients are at greater risk for 
endometrial cancer, very few clinicians reported this disease as their most important 
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concern compared to other adverse health outcomes for PCOS (Fauser et al., 2012; 
Conway et al., 2014). This finding is reflected in interviews with patients with PCOS 
who expressed receiving inadequate care for health outcomes outside of infertility 
(Weiss and Bulmer, 2011; Humphreys and Costarelli, 2008). Factors recognized to 
reduce risk of endometrial cancer (behavioral modifications, hormonal contraception) 
are prescribed to women with PCOS to treat their reproductive and metabolic 
complications (Cussons et al., 2005; Ding et al., 2016). However, our study suggests 
that women with PCOS may be unaware of the additional health benefits of these 
treatments.  
Strengths of this study include the multiple recruitment methods used to 
administer the questionnaire, allowing opportunities to reach a variety of potential 
respondents. We also employed statistical models that accounted for significant 
sociodemographic differences between groups enabling us to address the main effect of 
PCOS on psychosocial constructs. Our emphasis on “PCOS identity” is also an 
important strength. Previous studies outside of PCOS support the idea that identity 
influences health-related psychosocial factors and behaviors (Hooker et al., 2012; 
Grabowski, 2013).  The participants involved in this study self-identify as having PCOS 
based on diagnosis made by a medical professional and would be expected to consider 
a professional medical opinion as a valid basis for their PCOS diagnosis.  
Limitations include the study relying on participant self–selection particularly 
those with access to internet and interest in study participation, which can contribute to 
bias. Though the age and BMI distribution of our study sample was similar with an 
unselected US population of women with PCOS (Lo et al., 2006), most of the 
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participants also identified as non-Hispanic whites in contrast to a lower percentage of 
white women reported by Lo et al. (2006) (n=34%). This may reduce the 
generalizability of our results to other racial and ethnic groups. There is some evidence 
that the prevalence of PCOS and metabolic outcomes vary by race and ethnicity, which 
may create race-ethnic differences in health-related knowledge, beliefs, and self-
efficacy in PCOS (Williamson et al., 2001; Hillman et al., 2014). Generalizability of 
the results may also be limited due to the convenience sampling approach employed in 
this study. However, to our knowledge, there is currently no evidence that health-related 
beliefs associated with PCOS differ across geographical locations within the US.  
CONCLUSION 
Despite these limitations, findings from this cross-sectional study provide 
groundwork for further research in this area.  A future longitudinal cohort study would 
provide additional evidence about the temporal order between PCOS diagnosis and 
health-related beliefs. Few studies to date have identified potential psychosocial targets 
to improve attrition when designing weight loss interventions for PCOS. Our analyses 
support the conclusion that women with PCOS perceived themselves to be susceptible 
to adverse health outcomes and weight issues despite the adoption of healthy behaviors. 
A major theme emerging from this study is the importance of targeted diet and PA 
interventions for the PCOS population which addresses these unique perceptions. By 
directing multidisciplinary interventions to PCOS-specific issues, the high attrition in 
intervention studies and less engagement in self-help methods by patients may be 
addressed. Future studies are needed to examine how these psychosocial constructs can 
be successfully incorporated into targeted PCOS interventions with a multidisciplinary 
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healthcare team. Additionally, the interaction between obesity and PCOS should be 
further examined to determine whether there are different psychosocial considerations 
across the adiposity spectrum in women with PCOS. 
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Supplemental Table S4.1. Constructs in the I-PCOSK  
Constructs Definition Preliminary No. of  Items 
Retained No. 
of Items 
Knowledge Constructs 
      Reproduction Knowledge of facts about reproduction 4 4 
      Nutrition Knowledge of facts about nutrition 10 10 
      PCOSb Knowledge of facts about PCOS 20 20 
Belief Constructs 
    Perceived severity of health outcome Belief about the seriousness of a disease or condition 5 3 
    Perceived inevitability of health outcome a) Perceived control over disease or condition; 
 
b) Belief that diet and/or physical activity can prevent a 
disease or condition 
15 15 
    Perceived susceptibility of health outcome Belief about risk of developing a disease or condition 5 4 
    Worry about health outcome Concerns about developing a disease or condition 5 2 
   
    Evaluation of health behaviors 
 
a) Actions taken to improve physical health;  
 
b) Evaluation of importance of meeting health guidelines 
 
7 5 
Self-efficacy Construct 
   Self-efficacy for dietary behaviors Confidence about successfully performing a dietary behavior  19 13 
 
Total No. of Items 
 
91 77 
Abbreviations: No., Number; I-PCOSK, Instrument for Polycystic Ovary Syndrome: Knowledge, Health-Related Beliefs, and Self-Efficacy. 
a Total knowledge scores were only used in test-retest reliability analyses.  
b Only administered in participants with PCOS. 
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CHAPTER 5: PERCEPTIONS OF TRUST AND SOCIAL SUPPORT 
TOWARD HEALTHCARE PROVIDERS DIFFER BETWEEN WOMEN 
WITH AND WITHOUT POLYCYSTIC OVARY SYNDROME 
Plan to Submit: August 31, 2017 
* Lin AW, Bergomi EJ, Dollahite JS, Sobal J, Hoeger KM, Lujan ME. Perceptions of trust and social 
support toward healthcare providers differ between women with and without polycystic ovary syndrome.  
ABSTRACT 
BACKGROUND: Women with polycystic ovary syndrome (PCOS) have reported 
dissatisfaction with their early medical care, which may foster poor relationships 
between patients and their healthcare providers. Positive perceptions of trust and social 
support toward healthcare providers are associated with a strong patient-provider 
relationship, but have not been measured in a larger-scale study of patients with PCOS.  
OBJECTIVE: The objective of the study was to investigate whether perceptions of 
trust and social support toward physicians [primary care physicians (PCPs) and 
specialists] and/or other healthcare providers varied between women with and without 
PCOS.  
STUDY DESIGN: A reliable and valid online instrument surveying aspects of trust and 
social support toward healthcare providers was advertised through paper and electronic 
adverts across the United States. Women, between 18 and 38 years old, used five point 
rating scales to rate trust and social support toward healthcare providers within the last 
three years. Participants who responded that they had a previous diagnosis with PCOS 
were placed in the PCOS group, while the remaining women were included in the 
comparison group. Linear regression models accounting for age, BMI, and income were 
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used 1) to compare trust and social support between PCOS (N=134) and comparison 
groups (N=198) and 2) to ascertain associations between type of health concern with 
perceptions of trust and social support in the PCOS group.  
RESULTS:  PCOS was associated with greater distrust in the PCP’s opinion [β=0.38 
(SE 0.15); P<0.01], but also greater confidence about the PCP’s prioritization of general 
health concerns [β=0.31 (SE 0.13); P=0.04] relative to the comparison group. Patients 
with PCOS felt that the PCP spent less effort in treating PCOS health concerns [β=0.79 
(SE 0.19); P<0.001] and were less qualified to treat PCOS symptoms [β=-0.75 (SE 
0.17); P<0.001], in contrast to general health concerns. No significant associations were 
observed between having PCOS and trust in specialists. When examining social support, 
women with PCOS felt their healthcare providers argued with them more often relative 
to the comparison group [β=0.30 (SE 0.13); P=0.02]. 
CONCLUSION: Patient perceptions of trust and social support toward healthcare 
professionals differed between women with and without PCOS. Our findings support a 
need for improving trust and social support, particularly between patients with PCOS 
and PCPs. Future studies should confirm whether patients with PCOS view their 
medical experiences differently depending on the sub-specialty of the provider. 
Identifying areas for improvement in the patient-provider relationship may help to 
ensure continuity of care for patients with PCOS who require life-long surveillance to 
reduce reproductive and metabolic health risks.  
Keywords: healthcare, physicians, polycystic ovary syndrome, social support, 
specialization, trust 
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INTRODUCTION 
Patient perceptions of medical care have long been used to evaluate healthcare 
quality and inform clinical practice guidelines (Williams, 1994; Sitzia and Wood, 1997). 
The emphasis on understanding patient perception toward healthcare providers (such as 
beliefs on trust and social support) is attributed to its link with treatment adherence 
(Thom et al., 2004; Reblin and Uchino, 2008) – an important consideration when 
treating polycystic ovary syndrome (PCOS). PCOS is characterized by the presence of 
at least two of the following features: androgen excess, irregular menstrual cycles and/or 
polycystic ovarian morphology (Carmina, 2004), and its effects extend well beyond 
impaired reproductive function. Several metabolic abnormalities (such as obesity, 
increased prevalence of risk factors for cardiovascular disease and diabetes) are closely 
associated with PCOS and lifelong medical care is required to manage PCOS symptoms 
and mitigate long-term health complications (Fauser et al., 2012). As such, patients with 
PCOS are encouraged to engage in healthy dietary and physical activity (PA) behaviors, 
which improve the cardinal symptoms and metabolic status of PCOS. (Cussons et al., 
2005; Moran et al., 2009; Jarrett and Lujan, 2016). However, women with PCOS may 
face unique barriers that impede the adoption of these health-related behaviors due to 
their previous medical experiences (Sills et al., 2001; Gibson-Helm et al., 2016). The 
degree to which beliefs about trust and social support in healthcare providers contribute 
to these barriers is uncertain.  
There are few data evaluating the patient-provider relationship in PCOS 
(Gibson-Helm et al., 2016; Tomlinson et al., 2017). A substantial proportion of patients 
with PCOS across several countries reported feeling frustrated with their early medical 
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experiences (Gibson-Helm et al., 2016), resulting in negative feelings toward healthcare 
providers (Crete and Adamshick, 2011; Tomlinson et al., 2017). Further, patients’ 
perceptions of the quality of medical care appeared to vary between primary care 
physicians (PCPs) and specialists (Crete and Adamshick, 2011; Weiss and Bulmer, 
2011; Tomlinson et al., 2017). This observation is particularly relevant in the United 
States (US), where a gatekeeping approach involving PCPs operates within the 
healthcare system for access to specialist referrals (Forrest, 2003; Shi, 2012). Women 
with PCOS will likely require care from multiple healthcare providers across the life 
course, due to the evolution of their endocrine and metabolic symptoms with aging 
and/or changes to treatment goals at different life stages (Goodman et al., 2015; Gibson-
Helm et al., 2016).   
It is also unclear whether medical experiences related to PCOS influence patient 
perceptions during treatment for general medical concerns. Previous studies reported 
about patients’ perceptions of limited informational support provided about specific 
PCOS issues, but did not investigate other health concerns that are addressed during 
patient-provider interactions (Humphreys and Costarelli, 2008; Crete and Adamshick, 
2011; Gibson-Helm et al., 2016). Themes of emotional support have been only briefly 
discussed these studies, leaving this concept largely unexplored in this patient 
population. To that end, our primary objective was to examine whether there were 
differences in perceptions of trust and social support between women with and without 
PCOS with types of physicians (i.e., PCP, specialists) and/or other healthcare providers 
(i.e., nurse practitioners, physician assistants). Our secondary objective was to examine 
whether perceptions of trust in physicians varied between the types of health concerns 
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(i.e., general vs. PCOS-related). This study provides context about the current 
perceptions of medical care in women with PCOS with the goal of identifying factors 
which could be targeted to improve patients’ overall medical experiences.   
MATERIALS AND METHODS 
This project was registered as part of a larger observational study comparing 
health-related behaviors (i.e., diet, physical activity) in women with and without PCOS 
(ClinicalTrials.gov Identifier: NCT01859663). Flyers and online advertisements (i.e., 
Twitter, Facebook, Reddit, ResearchMatch) were used to recruit locally around 
Tompkins County, NY, and broadly across the United States (US). Participants met 
inclusion criteria if they reported that they were between 18-38 years of age, and either 
a history of predictable menstrual cycles (i.e., between 20 and 35 days) or an existing 
PCOS diagnosis. A participant was placed in the PCOS group if they responded 
affirmatively to the item, “Have you been diagnosed with PCOS by a medical 
professional?” Those who never received a PCOS diagnosis and reported predictable 
menstrual cycle lengths (i.e., 20 and 35 days) were placed in the comparison group. 
Participants were excluded if they had 1) incomplete surveys (less than half of the 
instrument), or reported 2) implausible or missing BMI (defined as < 16 kg/m2 or > 80 
kg/m2), 3) a major chronic disease, 4) a self-reported history of isolated oligomenorrhea 
(defined as unpredictable menstrual cycles and/or menstrual cycle length <20 or >35 
days without a PCOS diagnosis), and/or 5) non-US resident status. The Institutional 
Review Board approved the study protocol and all participants provided informed 
consent.  
I-PCOSM Instrument  
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The I-PCOSM (Instrument for Polycystic Ovary Syndrome: Medical 
Experiences) was distributed as a web-based instrument (Qualtrics, Provo, UT, USA) 
over a 2-year interval (August 2014 to August 2016). Details about the development 
and validation of the I-PCOSM are described in the Appendix C. After evaluating the 
validity and reliability of the I-PCOSM, the final instrument contained 28 items that 
assessed the recent medical experiences of women with PCOS within the last three years 
(Supplemental Table S5.1). Items related to trust in physicians were consistently worded 
across types of physicians (PCP or specialist) and health concerns (general or PCOS-
related). The PCOS group was presented with items on both types of health concerns, 
while the comparison group was only asked about general health issues. Responses to 
each I-PCOSM item were formatted as five-point rating scales. Response options on 
trust in physicians ranged from ‘strongly disagree’ to ‘strongly agree’, while the scales 
on social support ranged from ‘never’ to ‘always.’  
Statistical Analysis 
Data were analyzed with SPSS 23.0 (IBM, Armonk, NY, USA) and a P < 0.05 
was considered statistically significant. Demographic and anthropometric data were 
compared between PCOS and comparison groups using independent t-tests and Chi-
square analyses. To address the primary objective, multiple linear regression was used 
to examine associations between PCOS status (exposure) with trust and social support 
outcomes. Mixed-effects regression models were used to investigate whether trust 
towards physicians differed between types of health concerns. Given that each 
participant in the PCOS group had two observations for this secondary objective, 
participants were treated as a random effect in the mixed model. All regression models 
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were adjusted for age (continuous), BMI (categorical), and income (categorical). As a 
result of the high correlation between trust items, multiple comparison correction 
methods were not used in the analyses (Thom et al., 1999).  
RESULTS 
Of the 755 women that completed the I-PCOSM in the nationwide sample (Figure 5.1), 
332 (44%) met eligibility criteria for the PCOS (n=134) and the comparison groups 
(n=198) (Table 5.1). Excluded participants (n=423) were ineligible based on incomplete 
surveys (n=312), report of oligo-amenorrhea without a PCOS diagnosis (n=80), non-
US resident status (n=30), and/or implausible or missing BMI values (n=1). The eligible 
study sample included 262 (78.9%) white participants and 188 (56.6%) participants with 
a college degree. Most women were New York State residents (62.2%), with the 
remaining participants residing at different areas in the United States. Groups did not 
differ by age, race, education or BMI. By contrast, the PCOS group reported higher 
yearly household incomes relative to the comparison group (P < 0.001).  
Women with PCOS felt their physicians (both PCPs and specialists) were well 
qualified to treat general health concerns and were able to place patients’ medical needs 
above other considerations (Table 5.2). Overall, the PCOS group had positive beliefs 
regarding the physicians’ efforts to treat their general health concerns. While women 
with PCOS disagreed with the statement, “I sometimes distrust the recent specialized 
doctor's opinions and would like a second one” [2.47 (SD 1.16)], they had more neutral 
attitudes towards the PCP [3.05 (SD 1.16)]. These findings were confirmed with results 
from the multiple linear regression models (Table 5.3). Relative to the comparison 
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Figure 5.1. Participant flowchart. Flow diagram of the process through which 
participants were classified into PCOS and comparison groups.  
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Table 5.1. Characteristics of I-PCOSM participants   
Characteristics PCOS
a 
(n = 134) 
Comparison 
(n = 198) P 
Age (years) 28.2 ± 4.7 27.5 ± 5.5 0.22 
Race (%)    
   Asian 4 (3.0) 15 (7.6) 0.39 
   Black  8 (6.0) 15 (7.6)  
   White 112 (83.6) 150 (75.8)  
   Latina 2 (1.5) 3 (1.5)  
   Other  8 (6.0) 15 (7.6)  
Highest Education (%)    
   ≤  High School Degree 34 (25.4) 61 (30.8) 0.19 
   Associate’s Degree 16 (11.9) 33 (16.7)  
   College Graduate 54 (40.3) 75 (37.9)  
   Advanced Degree 30 (22.4) 29 (14.6)  
Household Yearly Income (%)    
   ≤ $19,999 19 (14.2) 57 (28.8) <0.001 
   $20,000 - $39,999 29 (21.6) 60 (30.3)  
   $40,000 - $59,999 16 (11.9) 30 (15.2)  
   $60,000 - $79,999 18 (13.4) 17 (8.6)  
   $80,000 - $99,999 35 (26.1) 16 (8.1)  
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Table 5.1. Characteristics of I-PCOSM participants   
Characteristics PCOS
a 
(n = 134) 
Comparison 
(n = 198) P 
   ≥ $100,000 17 (12.7) 18 (9.1)  
BMI Categories (%)    
   Underweight (< 18.5 kg/m2) 2 (1.5) 2 (1.0) 0.34 
   Normal (18.5-< 25 kg/m2) 46 (34.3) 74 (37.4)  
   Overweight (25-29.9 kg/m2) 23 (17.2) 46 (23.2)  
   Obese (≥ 30 kg/m2) 63 (47.0) 76 (38.4)  
Medical Visits in Past 3 Years: General Health 
Concerns    
   Seen by Primary Care Physician  112 (83.6) 164 (82.8) 0.88 
   Seen by Specialist 70 (52.2) 129 (65.2) 0.02 
Medical Visits in Past 3 Years: PCOS Health 
Concerns    
   Seen by Primary Care Physician  62 (46.3) NA NA 
   Seen by Specialist 81 (60.4) NA NA 
Data are expressed as mean ± SD or n (%). Significance level P < 0.05 between PCOS and comparison groups.  
a Prompt used to determine PCOS status: “Have you been diagnosed with PCOS by a medical professional?” 
 
Abbreviations: I-PCOSM, Instrument for Polycystic Ovary Syndrome: Medical Experiences; NA, Not applicable; PCOS, Polycystic ovary syndrome. 
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Table 5.2. Trust and social support scores in the polycystic ovary syndrome group (n = 134) 
Trust in Physicians General Concerns PCOS Concerns Scoring Range 
Primary Care Physicians 
I feel the recent Primary Doctor does not do    
   everything he/she should about my medical  
         care. 
2.67 ± 1.16 3.44 ± 1.38 1 = Strongly disagree 
2 = Disagree 
3 = Neutral 
4 = Agree 
5 = Strongly agree 
I sometimes distrust the recent Primary Doctor's     
   opinions and would like a second one. 
3.05 ± 1.16 3.19 ± 1.22 
I trust the recent Primary Doctor to put my  
   medical needs above all other considerations  
   when treating my medical problems. 
3.85 ± 1.00 3.78 ± 1.10 
The recent Primary Doctor is well qualified to  
   treat medical problems that I experience. 
4.08 ± 0.89 3.39 ± 1.43 
Specialistsa 
I feel the recent Specialized Doctor does not do  
   everything he/she should about my medical  
         care. 
2.26 ± 1.02 2.52 ± 1.16 1 = Strongly disagree 
2 = Disagree 
3 = Neutral 
4 = Agree 
5 = Strongly agree 
I sometimes distrust the recent Specialized  
   Doctor's opinions and would like a second one. 
2.47 ± 1.16 2.50 ± 1.16 
I trust the recent Specialized Doctor to put my  
   medical needs above all other considerations  
   when treating my medical problems. 
3.74 ± 0.94 3.83 ± 0.99 
The recent Specialized Doctor is well qualified to  
   treat medical problems that I experience. 
4.13 ± 0.85 4.02 ± 0.92 
Social Support from Healthcare Providersb General and/or PCOS Concerns Scoring Range 
How often...   
Do they give you advice or information about  
   health (whether you want it or not)? 
4.18 ± 0.78 1 = Never 
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Table 5.2. Trust and social support scores in the polycystic ovary syndrome group (n = 134) 
Do they give you advice or information about  
   nutrition (whether you want it or not)? 
3.41 ± 1.17 2 = Rarely 
3 = Sometimes 
4 = Usually 
5 = Always 
Do they give you advice or information about  
   PCOS (whether you want it or not)? 
3.25 ± 1.11 
Do they give you reassurance, encouragement and  
   emotional support (affection) concerning your  
   health? 
2.84 ± 1.23 
Do they listen to and try to understand your  
        worries about your health? 
3.42 ± 1.08 
Can you relax and be yourself around them? 3.05 ± 1.15 
Can you open up to them if you need to talk about  
   your worries about your health? 
3.34 ± 1.17 
How…   
Satisfied are you with the emotional support  
   provided? 
3.04 ± 1.17 1 = Never 
2 = Rarely 
3 = Sometimes 
4 = Usually 
5 = Always 
Often do they argue with you relating to your  
   health? 
1.67 ± 0.98 
Often do they criticize you relating to your    
         health? 
1.81 ± 1.01 
Often do they let you down when you are  
         counting on them? 
2.01 ± 1.08 
Often do they withdraw from discussions or try  
          to change the topic away from your health? 
1.46 ± 0.86 
Data are expressed as mean ± SD 
a Examples include gynecologists, endocrinologists, dermatologists.  
b Includes physicians, nurse practitioners, physician assistants 
 
Abbreviations: PCOS, Polycystic ovary syndrome 
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Table 5.3.  Differences in trust and social support scores between PCOS (n = 134) and comparison groups (n = 198)  
Trust in Physicians     
Primary Care Physicians (PCOS vs Comparison Group)a Unadjusted β (SE) PUnadjusted Fully Adjusted β (SE) PAdjusted 
I sometimes distrust the recent Primary Doctor's opinions and  
          would like a second one. 0.34 (0.14) 0.02 0.38 (0.15) <0.01 
I trust the recent Primary Doctor to put my medical needs      
          above all other considerations when treating my medical  
          problems. 
0.35 (0.12) 0.01  0.31( 0.13) 0.04 
The recent Primary Doctor is well qualified to treat medical  
          problems that I experience. 0.24 (0.11) 0.03 0.22 (0.11) 0.05 
Primary Care Physicians (General vs. PCOS Concerns)b Partial Adjusted β (SE) PPartial Fully Adjusted β (SE) PAdjusted 
I feel the recent Primary Doctor does not do everything  
          he/she should about my medical care. 0.81 (0.20) < 0.001 0.79 (0.19) < 0.001 
The recent Primary Doctor is well qualified to treat medical  
          problems that I experience. -0.75 (0.17) < 0.001 -0.75 (0.17) < 0.001 
Social Support from Healthcare Providersac Unadjusted β (SE) PUnadjusted Fully Adjusted β (SE) PAdjusted 
How often do they argue with you relating to your health? 0.30 (0.12) 0.02 0.30 (0.13) 0.02 
Significance level P < 0.05.  
 
a Adjusted models: Independent variable: PCOS (Reference category: comparison group); Dependent variable: I-PCOSM item; Covariates: age, BMI, 
income.  
b Adjusted mixed model: Independent variable: PCOS (Reference category: general health issues); Dependent variable: I-PCOSM item; Covariates: 
participant (partial and fully adjusted), age, BMI, income (fully adjusted) 
c Includes physicians, nurse practitioners, physician assistants 
 
Abbreviations: PCOS, Polycystic ovary syndrome 
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group, women with PCOS experienced greater distrust in the opinions offered by the 
PCP but reported greater confidence in the PCP’s prioritization of their general health 
concerns. PCOS was also positively associated with patient’s trust in the PCP’s 
qualifications to treat general health concerns (P<0.02), albeit this association became 
non-significant after adjusting for covariates. No significant associations were observed 
between PCOS status and trust in specialists.  
Women with PCOS provided favorable scores when asked about their trust in 
specialists regarding PCOS-related concerns (Table 5.2). Similar to perceptions about 
general health concerns, women with PCOS agreed that the PCPs were able to prioritize 
PCOS medical needs [3.78 (SD 1.10)] but had neutral feelings about their PCP’s 
qualifications to treat PCOS [3.39 (SD 1.43)]. The PCOS group’s responses to items 
relating to the PCPs efforts to treat and advise on PCOS concerns suggested they were 
not completely satisfied with their interactions with the PCP [3.44 (SD 1.38) and 3.19 
(SD 1.22)]. Results from the mixed model confirmed that the PCOS group felt their PCP 
placed less effort in treating PCOS issues compared to general health concerns (Table 
5.3). Moreover, women with PCOS were less likely to believe that their PCP was well 
qualified to treat PCOS concerns relative to general health concerns (P<0.001). The 
adjustment for potential covariates did not appreciably alter the estimates of these 
associations.  
The PCOS group reported that they usually received general health advice 
(informational support) from healthcare providers, but did not usually receive specific 
information about nutrition and PCOS (Table 5.2). Women with PCOS reported that 
they rarely had negative encounters with their healthcare providers, yet were only 
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sometimes satisfied with the emotional support provided during their medical care. The 
limited satisfaction may be attributed to the patients’ inability to usually relax and 
discuss their health concerns with their healthcare providers [3.05 ± 1.15 and 3.34 ± 
1.17], as well as the patients’ perception that healthcare providers only sometimes 
comprehended their health concerns [3.42 ± 1.08]. When examining differences in 
perceptions of social support by mixed models, the PCOS group reported that their 
healthcare providers were more inclined to argue about health-related issues relative to 
the comparison group (Table 5.3).  
DISCUSSION 
To our knowledge, this was the first study to directly investigate the perceptions 
of trust and social support with healthcare providers in a sample of women with PCOS. 
Our data support the conclusion that women with PCOS believe that their PCPs are well 
qualified to treat general health concerns, but are less qualified to address issues related 
to PCOS. Accordingly, PCOS was associated with greater distrust of the PCP’s opinions 
to treat PCOS concerns, but this association was not observed with specialists. Women 
with PCOS were only somewhat satisfied with the provision of emotional support 
experienced during medical visits and felt they had more arguments with their 
healthcare providers about their health concerns compared to the comparison group.  
Differences in trust between study groups emerged only when medical 
experiences with PCPs were evaluated, suggesting that patient perceptions may differ 
between PCP and specialists. We hypothesize that PCPs face greater feelings of distrust 
because they are at the front-line of healthcare delivery (Forrest, 2003) and generally 
provide referrals when encountering medical conditions outside their usual scope of 
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practice (Mehrotra et al., 2011). However, the absence of significant associations 
between PCOS and trust items related to specialists should not be interpreted to mean 
that all types of specialized care are associated with better perceptions of trust. The I-
PCOSM did not distinguish patient experiences by physician sub-specialty, leaving this 
as an important area of future research. The need for more research in this area was 
emphasized by recent findings of varying levels of knowledge between reproductive 
endocrinologists and gynecologists (Dokras et al., 2017) and the substantial lag period 
between PCOS symptom onset and diagnosis by multiple healthcare providers (Gibson-
Helm et al., 2016).  
This study showed that women with PCOS only sometimes received information 
about PCOS, per se, and the beneficial dietary and PA behaviors, which is consistent 
with previous findings that patients with PCOS are provided with limited information 
from their healthcare providers (Humphreys and Costarelli, 2008; Crete and 
Adamshick, 2011; Gibson-Helm et al., 2016; Tomlinson et al., 2017). Further, we also 
noted that women with PCOS were only sometimes satisfied with the emotional support 
provided by their healthcare providers, which was closely linked to poor perceptions of 
receiving encouragement about their health. Among the few qualitative studies that have 
examined the concept of emotional support, interviews revealed that women with PCOS 
perceived a lack of empathy and experienced greater frequency of arguments with their 
physicians (Weiss and Bulmer, 2011; Tomlinson et al., 2017). Tomlinson et al. 
(Tomlinson et al., 2017) identified conflicts stemming from disagreements about 
whether PCOS symptoms would alleviate with age and on the necessity of specialist 
referrals. Our demonstration that PCOS was associated with greater arguments about 
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health-related issues relative to the comparison group support these earlier findings. 
Collectively, results across studies reveal the healthcare provider should address 
different aspects of social support (informational and emotional) to improve the PCOS 
patient-provider relationship.  
Strengths of this study include the systematic approach used to develop and 
ensure the validity and reliability of the I-PCOSM in a large study sample. Further, the 
main effect of PCOS on trust and social support toward healthcare providers was 
investigated after adjusting for several potential covariates to better reflect an 
approximation of the actual effect sizes between exposure and outcome variables. Also, 
this study relied on self-reported PCOS diagnosis – an approach that was shown to be 
reproducible in previous PCOS studies (Moran et al., 2013; Gibson-Helm et al., 2016). 
We did not collect specific information about androgenic symptoms to corroborate the 
self-reported diagnoses in our cohort. Rather, our approach relied on the concept of 
“self-identity” to address perceptions associated with having a medical condition – a 
factor known to influence health-related behaviors (Grabowski, 2013). We acknowledge 
that this study was limited by the possibility of self-selection bias particularly by those 
with Internet access and interest in study participation.  
Previous research has shown that patients who were most satisfied with their 
medical care were often the first to respond to surveys, but that evaluations became less 
affirmative through repeated prompting of initial non-responders (Barron et al., 2014). 
The I-PCOSM did not employ repeated prompts to ensure participants completed the 
survey, so it is possible that our survey primarily captured responses from individuals 
with more positive outlooks about their medical care. Compared to a study with an 
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unselected population (Lo et al., 2006), a greater percentage of women with PCOS in 
our study identified as white. This suggests that we may not have captured a 
representative sample of US women with PCOS and reduces the generalizability of the 
results to other racial and ethnic groups. There is some evidence that black women are 
less trusting of physicians than whites and more concerned about potential for harm in 
hospital-settings (Boulware, 2003). For these reasons, future research would benefit 
from evaluating perceptions across a more diverse spectrum of patients with PCOS. 
This study examined the current perceptions of medical care in the PCOS patient 
population and identified potential areas of improvement to enhance the patient-
provider relationships. Though delays in the diagnosis can be partly attributed to 
controversies with the PCOS diagnosis (Azziz, 2006), negative medical experiences can 
ultimately lead to feelings of greater dissatisfaction with healthcare providers (Gibson-
Helm et al., 2016). Providing strong informational and emotional support may help 
reduce feelings of distrust between patients and physicians. We also recommend the 
importance of strengthening the specialty-referral process and identifying patient cues 
for when a referral may be the optimal approach when diagnosing and/or treating 
women at risk for PCOS (Mehrotra et al., 2011; Gibson-Helm et al., 2016). Future 
studies should investigate and establish recommendations to improve the medical 
experiences of women with PCOS. Efforts to directly compare medical experiences by 
sub-specialty and how the PCOS diagnosis experience influences impressions of 
general medical care are needed. By investigating these questions, the far-reaching 
implications of PCOS medical experiences could be further understood with the goal of 
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ensuring quality and continuity of care for patients who require life-long surveillance to 
curb health risks related to chronic reproductive and metabolic dysfunction.  
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Supplementary Table S5.1. Constructs in the initial and final versions of the I-PCOSM  
Domains Preliminary No. of  Items 
Retained No. of 
Items 
Trust in Physicians: Seen within the past three yearsa 
   Primary Care Physicians 18 8 
   Specialistsb 18 8 
Social Support 
   Healthcare Providersc 12 12 
Total No. of Items 48 28 
a PCOS group was asked about general and/or PCOS health concerns; Comparison group was asked 
about general health concerns. Reverse scoring for items with negative statements.   
b Examples include gynecologists, endocrinologists, dermatologists.  
c Includes physicians, nurse practitioners, physician assistants 
 
Abbreviations: No., Number; I-PCOSM, Instrument for Polycystic Ovary Syndrome: Medical 
Experiences 
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AFTERWORD 
 
Though health-related behaviors and PCOS are closely linked with obesity, it is unclear 
whether certain dietary and PA behaviors predict risk of PCOS. Additionally, current 
health-related behaviors and psychosocial perspectives of PCOS patients have not been 
widely studied. We addressed these knowledge gaps by developing and conducting 
cross-sectional studies on dietary and PA behaviors and psychosocial beliefs in women 
with PCOS. The major findings and implications of this research are summarized below.  
 
Part 1: Associations between lifestyle behaviors with PCOS 
 Both studies observed that food groups, rather than total daily energy intake nor 
PA, were significantly associated with PCOS (as defined by both NIH and 
Rotterdam criteria). The CARDIA study (Chapter 2) determined that red meat 
and processed meat intake was positively associated with PCOS, while the case-
comparison study (Chapter 3) observed that better diets (as determined by 
higher B vitamins and lower empty calories) were associated with PCOS. 
Results from Chapter 3 suggest that women with PCOS may have altered their 
behaviors after their diagnosis. However, reverse causality was less likely to 
occur in the CARDIA study (Chapter 2) since data were collected prior to the 
establishment of the first formal diagnostic criteria for PCOS. Thus, we believe 
that it is more probable that health-related behavior results from Chapter 2 
address the etiology of PCOS compared to other cross-sectional studies that have 
examined health-related behaviors in PCOS to this point. 
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o Use of different approaches in scoring diet quality in Chapters 2 and 3 
were used given the differences in the instruments used to collect dietary 
intake data.  AHEI-2010 diet quality scores could not be implemented in 
Chapter 3 due to unavailable food subgroup data generated by the 
Vioscreen questionnaire. There are strengths and limitations to each 
approach. The AHEI-2010 scoring system is closely linked to adverse 
health outcomes associated with PCOS and there is less overlap between 
food groups. However, the AHEI-2010 does not consider dairy 
consumption and is not as widely used as the HEI-2010, an approach 
based on the 2010 US Dietary Guidelines. Despite the widespread use of 
the HEI-2010, certain food products can be counted twice among 
different food groups, thereby biasing the total score. Nevertheless, both 
are accepted approaches to assess diet quality.  
 Associations between food groups and PCOS varied across race, highlighting 
the need for future studies to further delineate race-specific associations between 
lifestyle behavior and PCOS. We recommend that future studies examine the 
external validity of our results using data outside of CARDIA given that race-
specific differences were observed with the validity of the CARDIA Diet 
History questionnaire.   
The focus on diet quality in this dissertation provides clinicians with the opportunity 
to directly translate study results into clinical practice by addressing food groups 
and interactions among food choices. It is possible that patient counseling on 
reducing red and processed meat intake may improve features of PCOS. However, 
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our studies were not designed to establish the temporal order of the relationship 
between diet and PCOS. Future longitudinal studies that recruit adolescents prior to 
the development of PCOS are needed in order to confirm whether lower red meat 
and processed meat can prevent or curb progression to PCOS. 
 
Part 2: Associations between health-related knowledge and beliefs with PCOS status. 
 The majority of PCOS patients incorrectly believed that weight gain, insulin 
resistance, and difficulty with losing weight were established criteria for 
diagnosing PCOS.   
 Though women with PCOS agreed that a healthy lifestyle would help reduce 
risk for heart disease, diabetes, and weight gain, they felt more susceptible to 
adverse health outcomes and perceived fewer health benefits of implementing 
lifestyle changes. 
 Less than half of the PCOS group attempted to follow US government diet 
recommendations. There were no differences in the self-efficacy of diet 
behaviors between PCOS and comparison groups.  
 PCOS patients felt that their primary care physicians (PCP) spent less effort 
and were less qualified to treat PCOS symptoms than general health concerns.  
 There was greater distrust of the PCP’s opinion to treat general health concerns 
in the PCOS group than the reference group, which may have contributed to 
more frequent arguments between PCOS patients and healthcare providers.  
 
Results from Chapters 3 and 4 build upon previous literature that suggest there are 
potential psychosocial targets for tailored interventions in PCOS. We hypothesize that 
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greater misconceptions about diagnosis and poorer health-related beliefs by the PCOS 
group (compared to the comparison group) suggest that clinicians should provide 
stronger informational and emotional support about PCOS. By improving patient-
provider communication about PCOS issues, a greater level of trust directed towards 
the PCPs’ opinions may also develop in the PCOS population. Additionally, trust 
between the patient and provider can be strengthened by clinicians tailoring their 
recommendations to PCOS-specific health issues (e.g., endometrial cancer, infertility) 
to demonstrate their understanding about PCOS concerns while encouraging 
performance of these health-related behaviors. Future longitudinal cohort or 
experimental study designs are needed to substantiate these findings.  
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APPENDIX A 
IMPACT OF ACCELEROMETER DATA REDUCTION ALGORITHM 
SELECTION IN REPRODUCTIVE-AGED WOMEN* 
Submitted: April 15, 2017 to Journal of Science and Medicine in Sport 
*Lin AW, Larsen D, Hsu AC, Luna S, Chin SM, Parry SA, Hoeger KM, Lujan ME. Impact of 
accelerometer data reduction algorithm selection in reproductive-aged women.  
ABSTRACT 
Objectives: Physical activity (PA) estimates obtained from recent accelerometer data 
reduction algorithms have not been compared in reproductive-aged women. We 
investigated whether the accelerometer counts from the Crouter, Sasaki and Santos-
Lozano algorithms: 1) reported significantly different PA estimates; 2) interacted with 
weight and age to modify PA estimates; and 3) provided different prevalence of adults 
meeting PA guidelines and/or associations between PA and clinical markers of 
metabolic status.  
Design: Cross-sectional. 
Methods: Accelerometer data were collected from 29 women and processed through 
three algorithms using an in-house Excel model to generate wear minute data. Mixed-
effects linear regression models and bivariate correlation analyses were used to examine 
associations between accelerometer data with weight, age or clinical markers of 
metabolic status across algorithms.  
Results: The Crouter algorithm estimated significantly more wear minutes in Moderate 
intensity compared to the Sasaki and Santos-Lozano algorithms [+384(SE 33) and 
+356(SE 33) min]. Significant interactions between the Crouter algorithm with weight 
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and age were observed in Sedentary/Light and Moderate wear minutes, with the Santos-
Lozano algorithm as the reference (all pinteraction≤0.001). Algorithm selection also 
provided inconsistent findings in the prevalence of adults meeting PA guidelines and 
associations between Sedentary/Light and Moderate PA estimates with truncal fat and 
systolic blood pressure.  
Conclusions: Recently proposed data reduction algorithms varied in their estimates of 
PA in women of reproductive age. Algorithm selection interacted with weight and age 
to influence PA estimates, contributing to inconsistent findings in the prevalence of 
women who met PA guidelines and associations between PA and clinical markers.  
INTRODUCTION  
Objective measures of physical activity (PA) garnered from accelerometers are 
used widely in research to capture the impact of PA on human health.1,2 Accelerometer 
counts can be converted into different types of PA estimates, such as time spent within 
variable PA intensities (wear minutes).3 PA is typically classified into intensity 
categories, with higher intensity activities assigned greater metabolic equivalent (MET) 
values: Sedentary (MET=1), Light (MET >1 to <3), Moderate (MET 3 to <6) or 
Vigorous (MET ≥6).4 These PA estimates are later applied to evaluate the prevalence 
of adults meeting national PA guidelines and/or gauge whether PA behaviors correlate 
with clinical markers and the overall health of a target population.1  
Selection of a regression model that converts count data (data reduction 
algorithm) into PA estimates can impact findings.1,5 Algorithm selection has been 
shown to influence wear minute classification into different MET intensities, thereby 
providing inconsistent prevalence estimates of adults that meet PA recommendations.6,7 
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Prior studies have compared algorithms developed using counts from one plane given 
the nature of the technology available at that time.4,6,8 However, evidence suggests that 
vector magnitude (VM) counts, which use data collected from three different planes, 
may yield more precise data since a greater range of motion is captured5,9, though this 
concept is still controversial.10,11 By continuing to use older algorithms, data captured 
by newer accelerometers may be underutilized despite advancements in the field.12 
Three data reduction algorithms have emerged within the last seven years: the 
2010 Crouter two-regression model, the Sasaki algorithm and the Santos-Lozano 
algorithm.6,9,13 The Crouter and Sasaki algorithms have been cited most frequently, in 
part due to the recent development of the Santos-Lozano algorithm. We are unaware of 
any published studies that have directly compared PA estimates among these three 
recent algorithms in women of reproductive age. Multiple studies have shown that 
women are less physically active compared to men14–16 and are more likely to engage in 
unstructured and intermittent PA (such as household cleaning and walking).17,18 Since 
the Crouter algorithm differentiates between walk/run and lifestyle activities to 
calculate PA, it is possible this two-regression model provides significantly different 
PA estimates in a female population compared to other recently developed algorithms. 
Additional factors, such as weight and age, may also impact PA estimates across 
algorithms.12 However, the implications of these factors remain unknown when 
interpreting the health benefits of PA.  
To that end, the primary objectives of this study were to compare PA estimates 
across the Crouter, Sasaki and Santos Lozano algorithms in reproductive-aged women 
and to assess how algorithm selection impacts prevalence of meeting PA guidelines and 
 168 
 
associations with clinical markers of metabolic status. A secondary objective was to 
examine the modifying effect of weight and/or age on wear minutes derived from counts 
used across algorithms. We hypothesized that the Crouter algorithm would provide 
different wear minute classification compared to the other algorithms, contributing to 
inconsistent findings regarding meeting PA guidelines and associations with clinical 
markers across algorithms.   
METHODS 
Data were obtained from an observational study aimed at comparing diet and 
physical activity between women with and without polycystic ovary syndrome 
(ClinicalTrial.gov Identifier: NCT01859663). The study was approved by the 
Institutional Review Boards at Cornell University and University of Rochester, and all 
participants provided written informed consent. Female participants, ages 18 to 38 
years, were recruited in Tompkins and Monroe counties, New York. Exclusion criteria 
included not wearing the accelerometer for ≥ 4 days, participation in a diet or PA 
intervention and a weight exceeding 300 pounds. Of the 30 participants, one woman 
was excluded for not meeting the minimum requirement of valid wear days. Partial 
funding was provided by Cornell University Human Ecology Alumni Association, but 
they had no role in the finished manuscript.   
Triaxial accelerometer models GT3X (27 g; 3.8cm x 3.7cm x 1.8cm) and 
wGT3X+ (19g; 4.6cm x 3.3cm x 1.5 cm) were initialized to measure seven days of 
physical activity in 10-second intervals without a low frequency extension (Actigraph 
LLC, Pensacola, Florida, USA). Accelerometers were worn on an elastic belt around 
the left hip, except when involved in sleep or water-based activities. Acceleration 
 169 
 
sampling rates were set at either 30 or 50 Hertz. Participants recorded periods of wear 
and non-wear in a daily log to establish the accuracy of the accelerometer data. 
Accelerometer datasets were downloaded for participants using the commercial 
software ActiLife Version 6.5.4 (Actigraph, LLC, Pensacola, Florida, USA). Data 
derived from GT3X and wGT3X+ models were combined, given the previous 
demonstration of strong agreement between the two accelerometers models.19 Vector 
magnitude counts per minute (cpm) were generated using counts from three planes: 
vertical, medio-lateral and antero-posterior. The raw cpm were copied into an 
AutocalcMET Excel model developed in-house by the investigators to generate wear 
minutes across three recent data reduction algorithms simultaneously: Crouter, Sasaki 
and Santos-Lozano (all populations). 
The AutocalcMET model first categorized raw accelerometer cpm into wear and 
non-wear. Non-wear was assessed according to the method developed by Choi et al.20 
If participants reported wearing the accelerometer during sleep, daily logs were used to 
confirm non-wear periods. All non-wear cpm were converted to zero and excluded from 
analysis. Counts were excluded one minute before and after periods of non-wear to 
remove noise triggered by repositioning of the device. An entire day was categorized as 
non-wear if participants wore the accelerometer for less than 10 hours. The 
AutocalcMET model then converted each wear cpm into wear minutes for three MET 
intensity categories: Sedentary/Light, Moderate and Vigorous. Sedentary and Light 
activities were collapsed into one category to standardize pre-specified PA intensity 
category definitions across the three algorithms. Each minute of data was aggregated to 
provide total wear minutes for the participant across three data reduction algorithms for 
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each intensity. Intra-rater reliability was verified by an agreement analyses where the 
participants’ raw cpm were copied into the model twice, one week apart. Perfect 
agreement was noted between both weeks for wear minutes and within each MET 
intensity category (ICC = 1.0 for all results).  
Truncal body fat was estimated using whole body dual energy X-ray 
absorptiometry (Discovery QDR Series; Hologic Inc., Bedford, Massachusetts, USA), 
while weight was measured by a calibrated digital scale (Seca; Chino, California, USA). 
Fasting blood glucose (FBG) was analyzed from whole blood during a 2-hour oral 
glucose tolerance test (ACCU-CHEK ® Aviva; Roche Diagnostics, Indianapolis, 
Indiana, USA), while systolic blood pressure (SBP) was measured using an automated 
digital sphygmomanometer (LabTron 847 Series; Graham-Field, Atlanta, Georgia, 
USA).  
Statistical analyses were performed using SPSS 23.0 (IBM, Armonk, New York, 
USA) with the significance level threshold at p<0.05. Agreement in wear minutes 
between data reduction algorithms was determined using Cohen’s kappa statistics for 
individual participants and for the overall sample. Linear mixed-effects regression 
models were used to investigate wear minute differences (calculated from cpm) between 
the Santos-Lozano and other data reduction algorithms. Bonferroni correction method 
was applied to the partial models to compare across algorithms.21 Models were further 
adjusted to include weight, age and the interaction effects between cpm used in data 
reduction algorithms with these covariates. Adherence to the 2008 PA guidelines was 
analogous to performing 150 minutes of moderate and/or 75 minutes of vigorous 
activity over 4 – 7 days.22 Pearson’s correlations were used to examine associations 
 171 
 
between PA estimates and markers of metabolic status, including truncal fat (kg), FBG 
(mg/dL) and SPB (mmHg).  
RESULTS  
Table A.1 presents the descriptive characteristics of the participants included in 
the analyses. The study sample was comprised of young adult females (age range: 19 to 
36 years), with a weight range from 47 to 104 kg. Total wear time for the study sample 
averaged approximately 97 hours per week, and a majority of participants (76%) 
completed seven valid days of wear. Overall, participants spent the majority of their PA 
at Sedentary/Light intensity. 
The Crouter algorithm reported fewer wear minutes in Sedentary/Light intensity 
compared to Sasaki [-387(SE 31) min, p≤0.001] and Santos Lozano [-388(SE 31) min, 
p≤0.001] algorithms. For Moderate intensity, the Crouter algorithm reported additional 
wear minutes compared to the Sasaki and Santos-Lozano algorithms [+384(SE 33) and 
+356(SE 33) min; both p≤0.001], and more Vigorous wear minutes compared to the 
Santos-Lozano algorithm [+31(SE 6) min, p≤0.001]. The Sasaki and Santos-Lozano 
algorithms had comparable estimates of wear minutes in Sedentary/Light and Moderate 
intensities, but differed in their estimation of Vigorous intensity (29 min mean 
difference, p≤0.001). 
Agreement in wear minutes across data reduction algorithms was consistent with 
findings from the linear mixed-effects regression models. The range of wear minute 
agreement (κ) for each participant was widest when comparing estimates for the Crouter 
vs. Santos-Lozano algorithm (κ=0.18-0.84) followed by Crouter vs. Sasaki (κ=0.30-
0.73) and Sasaki vs. Santos-Lozano (κ=0.66-0.97) algorithms. Agreement in wear 
 172 
 
 
 
Table A.1. Descriptive characteristics of study sample (n = 29) 
Characteristics Overall 
Age (years) 29 ± 5 
Weight (kg) 74 ± 18 
Truncal fat mass (kg) 4 ± 7 
Fasting blood glucose (mg/dL) 81 ± 6 
Systolic blood pressure (mmHg) 76 ± 16 
Wear minutes per week in each MET intensity 
Sedentary/Light 
   Crouter algorithm 5014 ± 845 
   Sasaki algorithm 5401 ± 908 
   Santos-Lozano algorithm 5402 ± 931 
Moderate  
   Crouter algorithm 737 ± 278 
   Sasaki algorithm 352 ± 170 
   Santos-Lozano algorithm 380 ± 192 
Vigorous   
   Crouter algorithm 45 ± 43 
   Sasaki algorithm 42 ± 51 
   Santos-Lozano algorithm 13 ± 27 
Data are expressed as mean ± SD or n (%).  
Abbreviations: MET, metabolic equivalents 
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minutes for the overall sample was highest between the Sasaki vs. Santos-Lozano 
algorithm comparison (κ=0.84), followed by Crouter vs. Santos-Lozano (κ=0.58) and 
Crouter vs. Sasaki (κ=0.57). When examining the proportion of agreement in wear 
minutes for each intensity classification across all data reduction algorithms, there was 
almost perfect agreement for Sedentary/Light intensity (99%). Agreement was poorer 
in Moderate and Vigorous intensities, with less than 50% agreement with the Crouter 
vs. Sasaki and Crouter vs. Santos-Lozano algorithm comparisons. The Sasaki and 
Santos-Lozano algorithms exhibited better agreement, with consistent classification of 
wear minutes in Moderate (82% of the time) and Vigorous intensities (100% of the 
time). 
Wear minutes were significantly different between the Crouter and Santos-
Lozano algorithms across weight in Sedentary/Light and Moderate intensities (Table 
A.2, all pinteraction≤0.001). Similarly, differences in PA estimates across weight were 
detected between the Sasaki and Santos-Lozano algorithms (all pinteraction≤0.001). Age 
interacted with cpm used in the Crouter algorithm in Sedentary/Light and Moderate 
intensities (all pinteraction≤0.001). No significant interactions were found between cpm 
from any algorithm with weight and age within Vigorous intensity.  
The prevalence of women who met PA guidelines varied according to data 
reduction algorithm. The Crouter algorithm classified 100% of the sample as having 
met PA guidelines. The Sasaki and Santos-Lozano algorithms both reported a lower 
prevalence of meeting PA guidelines (90% of the sample), but disagreed on four 
individuals that did not meet PA guidelines (14%).  
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Table A.2. Mixed-effect estimates of wear minutes classified by MET intensity and 
accelerometer algorithms among reproductive-aged women: full model (n = 29)a 
Fixed effects   Sedentary/Light Moderate Vigorous 
 β SE β SE β SE 
Intercept 2884† 1155 762† 280 21 56 
Main effects       
   Algorithm       
      Crouter  733‡ 155 -819‡ 163 86 44 
      Sasaki  478† 155 -546‡ 163 68 44 
      Santos-Lozano  ref ref ref ref ref ref 
   Weight (kg) 18 9 -4 2 0 0 
   Age (years) 42 34 -4 8 0 2 
Interactions       
   Algorithm x weight       
      Crouter  -7‡ 1 7‡ 1 0 0 
      Sasaki  -5‡ 1 5‡ 1 0 0 
      Santos-Lozano  ref ref ref ref ref ref 
   Algorithm x age       
      Crouter  -20‡ 5 22‡ 5 -2 1 
      Sasaki  -3 5 5 5 -2 2 
      Santos-Lozano  ref ref ref ref ref ref 
†p<0.05; ‡p≤0.001. Abbreviations: MET, metabolic equivalents. 
a Model: Algorithm, weight and age interactions as fixed effects; Participant as random 
effect.   
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Algorithm selection influenced associations between wear minutes and clinical 
markers of metabolic status. Associations among estimates of Sedentary/Light wear 
minutes and SBP were consistent across all algorithms (Table A.3). Only the Moderate 
wear minutes as estimated by the Santos-Lozano algorithm were negatively correlated 
with truncal fat (r=-0.53, p≤0.01). No significant associations were observed with other 
PA intensity levels and features of metabolic status (e.g., FBG).  
DISCUSSION 
To the best of our knowledge, this was the first study to investigate agreement 
in PA estimates across the recently proposed Crouter, Sasaski and Santos-Lozano 
algorithms in a sample of reproductive- aged women. We anticipated that PA estimates 
from the Crouter algorithm would have the greatest deviation from the other algorithms 
given the unique assumptions used to develop the regression model.  Unlike Sasaki and 
Santos-Lozano, the Crouter algorithm used vertical rather than VM cpm, which has been 
proposed to reduce the accuracy of predicted measures of PA.5,9,13 Further, Crouter et 
al. varied in their approach to algorithm development by using indirect calorimetry 
under unstructured simulated free-living activities in bouts rather than structured 
activities in laboratory conditions as used Sasaki and Santos-Lozano.23 Depending on 
the type and phase of PA bouts, indirect calorimetry can under- or overestimate energy 
expenditure.24 Free-living conditions provide different types and phases of activity 
compared to structured activities conducted in laboratory conditions, which may 
contribute to significantly different results between the Crouter and other algorithms. 
Ultimately, the Crouter algorithm classified fewer PA estimates in Sedentary/Light 
intensity and more PA estimates in higher MET intensities. Differences in PA estimates 
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Table A.3. Correlation coefficients (r) between wear minutes and clinical markers of 
metabolic status (n = 24)a 
 Sedentary/Light Moderate Vigorous 
Truncal fat (kg) 
   Crouter algorithm 0.18 0.01 -0.33 
   Sasaki algorithm 0.18 -0.10 -0.13 
   Santos-Lozano algorithm 0.29 -0.53‡ -0.16 
Fasting blood glucose (mg/dL) 
   Crouter algorithm -0.12 -0.12 0.03 
   Sasaki algorithm -0.17 0.13 -0.09 
   Santos-Lozano algorithm -0.14 0.00 -0.18 
Systolic blood pressure (mmHg) 
   Crouter algorithm 0.49† 0.13 0.09 
   Sasaki algorithm 0.49† 0.01 0.23 
   Santos-Lozano algorithm 0.57‡ -0.34 0.25 
†p<0.05; ‡p≤0.01.  
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across algorithms were similar to a prior study that reported the Crouter algorithm 
significantly underestimated Sedentary24 and overestimated Moderate and Vigorous 
wear minutes compared to other MET intensity classification approaches (i.e. indirect 
calorimetry, accelerometer cutpoints).7 The overestimation of PA estimates likely 
resulted from the misclassification of walking versus lifestyle activities. Kuffel et al. 25 
showed that the 2006 Crouter two-regression model misclassified more wear minutes 
as lifestyle activity, resulting in higher calculated MET. In response, Crouter et al. 
established a coefficient of variation (CV) threshold of 10% across different 
combinations of six 10-second intervals to improve classification between walk/run and 
lifestyle activities with the modified version of the Crouter algorithm.6 However, despite 
this adjustment, we found that the current Crouter algorithm continued to classify more 
wear minutes as Moderate and Vigorous lifestyle activities even though participants 
recorded bouts of walking during those intervals in their accelerometer logs. 
We also noted significant differences in PA estimates between the Sasaki and 
Santos-Lozano algorithms. Differences in PA estimates between these two algorithms 
were indirectly observed by Santos-Lozano et al., who reported different MET estimates 
for each algorithm compared to indirect calorimetry results.9 Variations in algorithm 
development may have contributed to the wear minute differences between the Sasaki 
and Santos-Lozano algorithms. Unlike the Sasaki algorithm, the Santos-Lozano 
algorithm uses ANN models, which may provide greater precision in estimating METs 
because they rely on biological pattern recognition.9,26 Further, Santos-Lozano et al. 
developed their algorithm with a sample of adolescents aged 12 to 16 years and adults 
over 40 years. This was in direct contrast to Sasaki et al. who developed their algorithm 
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in participants of reproductive age (mean age: 28.0 ± 9.0 years). Given that age may 
influence PA levels and that participants in this study were of reproductive age, the 
heterogeneous conditions under which Santos-Lozano et al. validated their algorithm 
may have contributed to differences in wear minutes.27  
We observed interactions between weight and age with cpm derived from 
algorithms, particularly between the Crouter and Santos-Lozano algorithms. The 
interactions noted in this study are supported by previous findings on the biological 
interactions between weight and age with energy expenditure. Wilms et al. reported that 
participants in overweight and obese BMI categories had a resting metabolic equivalent 
below 1 MET, suggesting that the current standard for the resting MET estimate may 
be an overestimation for this population.28 Age was also shown to alter daily resting 
metabolic rate, consequently altering resting MET estimates.29 Thus, significant 
differences in PA estimates among algorithms, particularly between the Crouter and 
Santos-Lozano algorithms, may also be attributed to the incorporation of weight and 
age into the Santos-Lozano algorithm.9 Examination in a larger sample size with indirect 
calorimetry may help elucidate the statistical and biological interactions between 
algorithm selection with weight and age observed in this study.  
Others have also reported differences in the percentage of participants meeting 
PA guidelines depending upon the data reduction algorithm selected.7,30 Similar to our 
findings, the Crouter algorithm universally classified more participants as meeting PA 
guidelines compared to other accelerometer MET intensity classification approaches.7 
Weaver et al.30 reported that the Sasaki algorithm classified four additional participants 
as meeting guidelines compared to the Santos-Lozano algorithm; however, it was 
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unclear whether there was agreement in how individual participants were classified by 
the two algorithms. Our results also revealed discrepancies in associations between PA 
estimates and clinical markers of metabolic status across algorithms. We noted that the 
algorithms reported different correlations between Moderate PA estimates with truncal 
fat. This lack of consensus may result in mixed interpretations on the health benefits of 
PA and slow progress in formulating effective health recommendations.1  
Strengths of this study included the use of the AutoCalcMET Model, which we 
developed as a transparent platform on which to process accelerometer data. In contrast 
to manufacturer computer software, the model documents decisions taken during the 
processing stages for each cpm and provides multiple options on how PA estimates can 
be reported (e.g., day of the week, units, walk-run for the Crouter algorithm). The model 
also provided the ability to filter accelerometer data, resulting in greater expediency 
when comparing against accelerometer logs. These functions allowed us to classify PA 
estimates into different intensity by epoch, in contrast to entering the data into a program 
without understanding how the MET were categorized. The AutoCalcMET Model also 
provides greater confidence in the results since it uses Excel formulas to double check 
the generated data. Further, our use of a targeted sample of reproductive-aged women 
limited the potential confounding effect of gender since exercise habits may differ 
between males and females.15,16 However, the study was designed to address inter-
algorithm reliability of PA estimates, and therefore, the validity of data reduction 
algorithms was not examined against an independent criterion (such as indirect 
calorimetry data). Another limitation of the study was the small sample size, which may 
underestimate the effects that weight and age have on algorithm agreement. Last, this 
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study used a convenient sample and included a subset of women with reproductive 
dysfunction; thus, the results may not be applicable to all populations. Despite the study 
limitations, these results highlight potential factors that may explain the differences in 
PA estimates across algorithms.  
CONCLUSIONS 
Despite the increasing use of accelerometers in population-based studies, there 
are currently no standardized data reduction algorithm recommendations. This study 
investigated agreement across three recently developed algorithms in women of 
reproductive age in order to further understanding on how algorithm selection may 
impact data interpretation. The Crouter algorithm reported higher MET intensity PA 
estimates compared to the Sasaki and Santos-Lozano algorithms. Our findings also 
suggest that weight and age merit further consideration when selecting algorithms. 
Algorithm selection impacted the interpretation of PA results, leading to different 
conclusions about the proportion of adults meeting PA guidelines and the associations 
between PA and clinical markers of metabolic status. As such, interpretations on the 
impact of PA on health outcomes should be viewed in light of any effects of algorithm 
selection across studies. Expert consensus is needed to inform algorithm selection for 
specific populations in order to improve health-related population based studies. 
PRACTICAL IMPLICATIONS 
 Recently proposed data reduction algorithms yield different estimates of PA. As 
such, direct comparisons of PA estimates across studies may be inappropriate.  
 When selecting a data reduction algorithm for use, researchers should consider 
the approach used to develop the algorithm.  
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 Weight and age emerged as important factors to consider when selecting a data 
reduction algorithm.  
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APPENDIX B 
Development and Distributed Instrument for PCOS: Knowledge, Health-Related 
Beliefs, and Self-Efficacy (I-PCOSK) 
* Submitted as Supplementary Material to Human Reproduction.  
I-PCOSK: DEVELOPMENT 
The preliminary draft comprised of 91 items designed using SCT and HBM 
constructs to assess 1) reproduction-, nutrition-, and PCOS-related knowledge, 2) 
beliefs about health outcomes and confidence in lifestyle behaviors, and 3) self-
evaluation of current lifestyle (Supplemental Table S4.1). Items were developed using 
semi-structured interviews conducted by our research group, existing literature about 
women’s experiences with PCOS (Weiss and Bulmer, n.d.; Humphreys and Costarelli, 
2008; Moran et al., 2010) and published instruments about health-related beliefs 
(Bandura, 1990; Wang et al., 2009; Centers for Disease Control and Prevention (CDC), 
2011). The draft instrument underwent three rounds of peer review before testing with 
participants. Peers with expertise in instrument design reviewed a draft instrument to 
determine clarity and organization (N=2). In a second review, professors with expertise 
in reproductive physiology and nutrition sociology provided input on the relevance to 
the domains of interest (N = 2). In a third review, colleagues with expertise on survey 
development, physiology and nutrition provided additional feedback about the domains 
of interest and clarity of the items (N = 10). 
I-PCOSK: VALIDATION 
Methods 
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An equal number of women with and without PCOS enrolled in one of three 
rounds of semi-structured interviews where they completed a preliminary I-PCOSK 
draft (n=36; n=12 per round). Interviews were conducted using an iterative process to 
assess content validity and potential misinterpretation of items in the I-PCOSK. Each 
participant was asked to repeat the item prompt in her own words to assess her 
understanding of the item and then to evaluate its importance. Participants were also 
asked to determine the appropriateness of response options and the perceived difficulty 
level for items in the knowledge construct. Only women with PCOS were asked 
knowledge items specific to PCOS. Test-retest reliability and internal consistency were 
examined during the final interview round (PCOS n=6, comparison n=6). During this 
round, the preliminary I-PCOSK was administered twice to each participant, two weeks 
apart. The total score of each construct was calculated at each time and compared in the 
test-retest reliability analyses. An evaluation of internal consistency was performed with 
data from the second administration of the I-PCOSK in this participant sample. After 
applying the I-PCOSK in the nationwide sample, preliminary analysis was performed 
with data from the PCOS group to confirm internal consistency results from the 
interviews and to identify the valid I-PCOSK items. 
Test-retest reliability of the I-PCOSK constructs were determined using 
intraclass correlation coefficient (ICC) analyses, with an ICC ≥0.5 considered as 
acceptable (Cicchetti, 1994). Internal consistency of the I-PCOSK was evaluated for 
each construct covered by the instrument and a coefficient of 0.70 was considered as 
acceptable (Bland and Altman, 1997). Exploratory factor analysis with varimax rotation 
was used to examine the construct validity of I-PCOSK items for women with PCOS 
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(N=255). Factors with eigenvalues >1 were retained (Kaiser, 1960). If the item loadings 
for the retained factors were <0.50, items were removed in a stepwise fashion until all 
loadings were ≥0.50. 
Results 
Test-retest reliability was acceptable for all health-related knowledge, beliefs, 
and self-efficacy constructs (ICC 0.56-0.97). When examining internal consistency of 
the preliminary I-PCOSK draft, perceived inevitability, susceptibility of adverse health 
outcomes, evaluation of lifestyle behaviors, and self-efficacy constructs had high 
internal consistency (α=0.71-0.93). Estimates of worry about adverse health outcomes 
approached, but did not meet, the acceptable internal consistency threshold (α=0. 66). 
Low internal consistency was observed for perceived severity of adverse health 
outcomes, suggesting that select items were not closely related to others in the construct 
(α=0.25). Cronbach’s alpha was not performed for items within the knowledge 
constructs since knowledge was considered a non-latent variable. When examining 
construct validity in the health-related beliefs and self-efficacy constructs, factor 
analysis in the nationwide sample of women with PCOS confirmed results from the 
Cronbach’s α tests in the interview round. Seven items were identified as being 
unrelated to latent factors in each psychosocial construct. Consequently, 14 items were 
eliminated and the 77 retained items with high commonality were observed to have high 
construct validity. 
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DISTRIBUTED I-PCOSK  
[Author comments are in italicized blue. Logic statements were built into the 
instrument in order to streamline the response process. Unless otherwise stated, items 
were asked for both comparison and PCOS groups.] 
 
Q1 Thank you for taking the time to complete this survey by Cornell University. Your 
responses are very important in helping us examine current health-related knowledge 
and beliefs of adult women. 
 
Your answers will be confidential and participation is voluntary. You can stop the 
survey at any time. 
 
Completion time: 10 - 20 minutes 
Honorarium: Raffle for one of eight $50 Amazon gift cards upon completion.   
 
**Please do not look up the answers to these questions.** 
 
We anticipate that your participation in this survey presents no greater risk than 
everyday use of the Internet. If you have any questions about the survey, please 
contact us at womensimaging@gmail.com.Participants may also report their concerns 
or complaints anonymously through Ethicspoint by calling toll free at (866)293-3077 
or emailing www.hotline.cornell.edu. 
 
By selecting the “I agree” button, you are indicating that you are willing to participate 
in this survey. 
 I agree 
 I do not agree 
 
Q2 How old are you (years)? 
 
Q3 Which race(s) do you identify with most? 
 American Indian or Alaskan Native 
 Asian 
 Black or African American 
 White 
 Other ____________________ 
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Q4 What is your highest completed education? 
 1st to 5th grade 
 6th to 8th grade 
 9th to 12th grade 
 High school graduate or GED 
 Associate's degree 
 College graduate 
 Advanced degree 
 
Q5 What is your yearly household income (e.g., yourself or with significant other)? 
 ≤ $19,999 
 $20,000 to $39,999 
 $40,000 to $59,999 
 $60,000 to $79,999 
 $80,000 to $99,999 
 ≥ $100,000 
 
Q6 What is your current height (in inches)? 
 
Q7 What is your current weight (in pounds)? 
 
Q8 When did you last weigh yourself (number of days from today)? 
 
Q9 Are you currently on birth control pills or intrauterine devices (IUD)? 
 No 
 Yes 
 Unsure 
 
Q10 How would you classify your fertility status (ability to become pregnant within a 
year)? 
 Fertile 
 Infertile 
 Unsure 
 
Q11 How familiar are you with the term "polycystic ovary syndrome" (PCOS)? 
 Not at all 
 Somewhat familiar 
 Familiar 
 Very familiar 
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Q12 Have you been diagnosed with PCOS by a medical professional? 
 No 
 Yes 
 Unsure 
 
Q13 Can you usually predict when your period would start at least half of the time? 
 No 
 Yes 
 Unsure 
 
Q14 On average, what is the smallest number of days between the beginning of one 
period to the beginning of the next one? [If answered “No” to Q13] 
 Less than 20 days 
 20 to 25 days 
 26 to 35 days 
 Greater than 35 days 
 Unsure 
 
Q15 On average, what is the greatest number of days between the beginning of one 
period to the beginning of the next one? [If answered “No” to Q13] 
 Less than 20 days 
 20 to 25 days 
 26 to 35 days 
 Greater than 35 days 
 Unsure 
 
Q16 On average, what is the smallest number of days between the beginning of one 
period to the beginning of the next one? [If answered “Yes” to Q13] 
 Less than 20 days 
 20 to 25 days 
 26 to 35 days 
 Greater than 35 days 
 Unsure 
 
Q17 On average, what is the greatest number of days between the beginning of one 
period to the beginning of the next one? [If answered “Yes” to Q13] 
 Less than 20 days 
 20 to 25 days 
 26 to 35 days 
 Greater than 35 days 
 Unsure 
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Q18 On average, what is the smallest number of days between the beginning of one 
period to the beginning of the next one? [If answered “Unsure” to Q13] 
 Less than 20 days 
 20 to 25 days 
 26 to 35 days 
 Greater than 35 days 
 Unsure 
 
Q19 On average, what is the greatest number of days between the beginning of one 
period to the beginning of the next one? [If answered “Unsure” to Q13] 
 Less than 20 days 
 20 to 25 days 
 26 to 35 days 
 Greater than 35 days 
 Unsure 
 
Q20 How old were you when diagnosed with PCOS? [For PCOS Group] 
 Between 9 to 15 years old 
 Between 16 to 17 years old 
 Between 18 to 29 years old 
 Between 30 to 38 years old 
 
Q21 What PCOS symptoms did you have that led to a diagnosis? Put "DK" if unsure. 
[For PCOS Group] 
 
Q22 Were you ever diagnosed with the following? Mark all that apply. 
 Heart disease (e.g., coronary artery disease, stroke) 
 Diabetes (high blood sugar) 
 Thyroid disease (e.g., hypothyroidism) 
 Cancer 
 Kidney disease 
 None 
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Q23 Are you a New York State resident? If yes, please list the city. If no, please list 
the state where you live. 
 Yes ____________________ 
 No ____________________ 
 
Q24 We will now ask about the reproductive system and nutrition. Please indicate 
whether the following statements are True or False. 
 
Q25 Ovaries are female reproductive organs. 
 True 
 False 
 Unsure 
 
Q26 An egg is released during ovulation. 
 True 
 False 
 Unsure 
 
Q27 Ovaries do not produce hormones. 
 True 
 False 
 Unsure 
 
Q28 Women do not usually produce testosterone. 
 True 
 False 
 Unsure 
 
Q29 Ovarian cysts are unusual growths on the ovaries. 
 True 
 False 
 Unsure 
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Q30 Please click on the 2 areas where the right and left ovaries are located.  
[For Comparison Group] 
 
 
Q31 Please click on the 2 areas where the right and left ovaries are located.  
[For PCOS Group] 
 
 
Q32 How confident are you about your knowledge on the reproductive system? 
 1 (Not confident) 
 2 (Somewhat confident) 
 3 (Confident) 
 4 (Very confident) 
 
  
 195 
 
Q33 Have you heard of the Dietary Guidelines for Americans? 
 No 
 Yes 
 Unsure 
 
Q34 It is said that for a healthy diet, at least a __________ of your total grains should 
be whole grains. 
 Quarter (25%) 
 Half (50%) 
 Three-fourths (75%) 
 Unsure 
 
Q35 It is said that for a healthy diet, you should fill your plate with at least how much 
fruits and vegetables? 
 Quarter (25%) 
 Half (50%) 
 Three- fourths (75%) 
 Unsure 
 
Q36 Please select all the nutrients to limit in the average diet. 
 Sodium 
 Saturated fat 
 All carbohydrates 
 Protein 
 Added sugars 
 Unsure 
 
Q37 Please select all the foods that contain fiber. Mark all that apply. 
 Fruits 
 Whole grains 
 Meats 
 Vegetables 
 Dairy 
 Unsure 
 
Q38 Protein has a higher number of calories per gram, compared to carbohydrate and 
fat. 
 True 
 False 
 Unsure 
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Q39 According to exercise recommendations, how much weekly exercise should 
adults do for substantial health benefits? 
 15 minutes, 5 days a week 
 30 minutes, 5 days a week 
 Unsure 
 
Q40 How confident are you about your knowledge on nutrition and exercise? 
 1 (Not confident) 
 2 (Somewhat confident) 
 3 (Confident) 
 4 (Very confident) 
 
Q41 We will now ask about PCOS. Please choose the answer you feel is most 
appropriate.  
 
Q42 Please select the symptoms used to diagnose PCOS. Mark all that apply. 
[For PCOS Group] 
 High testosterone 
 Sudden weight gain 
 Trouble losing weight 
 Above average number of ovarian follicles 
 Excessive body and facial hair 
 Insulin resistance 
 Irregular or absent menstrual periods 
 Acne, male pattern baldness 
 Unsure 
 
Q43 How confident are you about your knowledge on PCOS symptoms?  
[For PCOS Group] 
 1 (Not confident) 
 2 (Somewhat confident) 
 3 (Confident) 
 4 (Very confident) 
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Q44 What do you believe causes PCOS? [For PCOS Group] 
 
Q45 How confident are you about your knowledge on causes of PCOS?  
[For PCOS Group] 
 1 (Not confident) 
 2 (Somewhat confident) 
 3 (Confident) 
 4 (Very confident) 
 
Q46 Women with PCOS are at higher risk of __________ compared to women 
without PCOS. Mark all that apply. [For PCOS Group] 
 Heart disease 
 Urinary tract infection (UTI) 
 Diabetes 
 Infertility (not able to have children) 
 Obesity 
 Unsure 
 
Q47 How confident are you about your knowledge on health risks of women with 
PCOS? [For PCOS Group] 
 1 (Not confident) 
 2 (Somewhat confident) 
 3 (Confident) 
 4 (Very confident) 
 
Q48 We will now ask about PCOS treatments. 
 
Q49 Please select all the treatments used to treat PCOS symptoms. Mark all that 
apply.[For PCOS Group] 
 Diet and exercise 
 Birth control 
 Diabetes medication 
 Fertility medication 
 Anti-testosterone medication 
 Herbal supplements ____________________ 
 Other ____________________ 
 Unsure 
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Q50 How confident are you about your knowledge on PCOS treatments? 
[For PCOS Group] 
 1 (Not confident) 
 2 (Somewhat confident) 
 3 (Confident) 
 4 (Very confident) 
 
Q51 We will now ask about resources you have used. Please select the answers you 
feel are most appropriate. 
 
Q52 Please select the resources you have used to learn about PCOS. Mark all that 
apply. [For PCOS Group] 
 Electronic media (e.g., Facebook, TV, apps, websites) 
 Paper materials (e.g., books, handouts) 
 Health food stores 
 Support groups (in person, phone) 
 None 
 
Q53 Please select the resources you have used to learn about nutrition. Mark all that 
apply. [For PCOS Group] 
 Electronic media (e.g., Facebook, TV, apps, websites) 
 Paper materials (e.g., books, handouts) 
 Health food stores 
 Support groups (in person, phone) 
 None 
 
Q54 How satisfied or dissatisfied are you with the PCOS information from...  
[For PCOS Group] 
 Dissatisfied Somewhat dissatisfied Neutral 
Somewhat 
satisfied Satisfied 
Electronic 
media           
Paper 
materials           
Health food 
stores           
Support 
groups           
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Q55 How satisfied or dissatisfied are you with the general nutrition information 
from... [For PCOS Group] 
 Dissatisfied Somewhat dissatisfied Neutral 
Somewhat 
satisfied Satisfied 
Electronic 
media           
Paper 
materials           
Health food 
stores           
Support 
groups           
 
 
Q56 We will now ask about your beliefs on health severity, risk, worry and control. 
Please select the answer you feel is most appropriate. 
 
Q57 ____________ is a very serious problem. 
 Disagree Somewhat disagree Neutral 
Somewhat 
agree Agree 
Heart disease           
Diabetes           
Endometrial 
cancer 
(cancer in 
uterus lining) 
          
Weight gain           
Infertility 
(not able to 
have 
children) 
          
 
 
Q58 Compared to most people your age and weight in the United States, what would 
you say your CHANCES are of getting... 
[Scale ranged from 1 (much lower than average) to 5 (much higher than average)]  
______ Heart disease 
______ Diabetes 
______ Endometrial cancer (cancer in uterus lining) 
______ Weight gain 
______ Infertility (not able to have children) 
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Q59 During the past year, how often have you thought about your CHANCES of 
getting...[Scale ranged from 1 (never) to 5 (almost all the time)] 
______ Heart disease 
______ Diabetes 
______ Endometrial cancer (cancer in uterus lining) 
______ Weight gain 
______ Infertility (not able to have children) 
 
Q60 There is a lot I can do to PREVENT getting...  
[Scale ranged from 1 (disagree) to 5 (agree)] 
______ Heart disease 
______ Diabetes 
______ Endometrial cancer (cancer in uterus lining) 
______ Weight gain 
______ Infertility (not able to have children) 
 
Q61 We will now ask about health-related behaviors. Please select the answer you feel 
is most appropriate. 
 
Q62 In general, how healthy is your overall DIET? 
 Poor 
 Fair 
 Average 
 Good 
 Excellent 
 
Q63 In general, how healthy is your overall LIFESTYLE? 
 Poor 
 Fair 
 Average 
 Good 
 Excellent 
 
Q64 Have you heard of MyPlate? 
 No 
 Yes 
 
Q65 Have you looked at the MyPlate plan on the Internet? 
 No 
 Yes 
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Q66 Have you tried to follow the recommendations in the MyPlate plan? 
 No 
 Yes 
 
Q67 How often do you read nutrition labels? 
 Never 
 Rarely 
 Sometimes 
 Usually 
 Always 
 
Q68 What do you look for on the nutrition label? 
 
Q69 We will now ask about beliefs about health-related behaviors and disease. Please 
select the answer that matches how much you disagree or agree with the statement. 
 
Q70 It is important for me to meet government dietary recommendations. 
 Disagree 
 Somewhat disagree 
 Neutral 
 Somewhat agree 
 Agree 
 Do not know recommendations 
 
Q71 It is important for me to meet government physical activity recommendations. 
 Disagree 
 Somewhat disagree 
 Neutral 
 Somewhat agree 
 Agree 
 Do not know recommendations 
 
Q72 A HEALTHY DIET will reduce my risk of...  
[Scale ranged from 1 (disagree) to 5 (agree)] 
______ Heart disease 
______ Diabetes 
______ Endometrial cancer (cancer in uterus lining) 
______ Weight gain 
______ Infertility (not able to have children) 
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Q73 BEING PHYSICALLY ACTIVE will reduce my risk of...  
[Scale ranged from 1 (disagree) to 5 (agree)] 
______ Heart disease 
______ Diabetes 
______ Endometrial cancer (cancer in uterus lining) 
______ Weight gain 
______ Infertility (not able to have children) 
 
Q74 Please select how confident you are in your ability to do the following things 
FOR THE NEXT MONTH. 
 1 (Cannot do) 2 
3 
(Possibly 
can do) 
4 
5 
(Certainly 
can do) 
Incorporate low 
fat foods into my 
diet. 
          
Incorporate low 
salt foods into 
my diet. 
          
Eat 5 servings of 
fruits and 
vegetables per 
day. 
          
Decrease the 
amount of 
refined sugar in 
my diet. 
          
Eat more high 
fiber foods.           
Eat smaller 
portions at 
dinner. 
          
Exercise for 30 
minutes for 5 
days a week. 
          
Control my 
eating on 
weekends. 
          
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Q75 Please select how confident you are in your ability to do the following things 
FOR THE NEXT MONTH. 
 1 (Cannot do) 2 
3 
(Possibly 
can do) 
4 
5 
(Certainly 
can do) 
Resist eating too 
much when there 
are many 
different kinds 
of food 
available. 
          
Resist eating 
when I am at a 
party. 
          
Resist eating 
when I am 
watching TV. 
          
Resist eating 
when I am 
reading. 
          
Resist eating just 
before going to 
bed. 
          
Resist eating 
when I am 
anxious or 
nervous. 
          
Resist eating 
when I am 
depressed or feel 
down. 
          
Resist eating 
when I am angry 
or irritable. 
          
Resist eating 
when I am 
happy. 
          
Resist eating 
when I 
experience 
failure. 
          
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Q76 It is easy to eat a healthy diet. 
 Disagree 
 Somewhat disagree 
 Neutral 
 Somewhat agree 
 Agree 
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APPENDIX C 
Development and Distributed Instrument for PCOS: Medical Experiences (I-
PCOSM) 
* Will submit as Supplementary Material  
I-PCOSM: DEVELOPMENT 
Forty-eight items were modified from two published instruments to assess 
perceptions of trust in physicians and social support from healthcare professionals by 
women with PCOS.1,2 Items were modified with the goal of collecting perceptions 
related to medical experiences over a broad range of healthcare providers (primary care 
physicians (PCP), specialists, and nurse practitioners and physician assistants) and 
perceptions of care over general and PCOS-related health concerns. The draft 
instrument of the I-PCOSM (Instrument for Polycystic Ovary Syndrome: Medical 
Experiences) underwent three rounds of peer review by individuals with expertise in 
instrument design to ensure clarity and organization of the items prior to administration 
in research participants.  
I-PCOSM: VALIDATION 
Methods 
Three rounds of semi-structured interviews were conducted to assess the content 
validity and reliability of the I-PCOSM (n = 36; n = 12 per round). A single interviewer 
asked a succession of questions to gauge the interpretability, difficulty, and importance 
of all I-PCOSM items. Test-retest reliability was examined in the final round of 
interviews with 12 participants (PCOS n = 6, comparison n = 6), where the I-PCOSM 
was administered twice, two weeks apart. A preliminary analysis of internal consistency 
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was performed with data from the second administration of the I-PCOSM from the 
interview rounds. To confirm the preliminary results and identify valid I-PCOSM items 
for inclusion in the final version, internal consistency analyses were performed with 
data collected from the nationwide sample.  
Intraclass correlation coefficient (ICC) statistics were used to analyze test-retest 
reliability and an ICC ≥ 0.5 was considered acceptable.3,4 Internal consistency of each 
domain was evaluated using Cronbach α, with a coefficient ≥ 0.7 considered acceptable. 
Construct validity was evaluated using exploratory factor analysis with a varimax 
rotation and factors with eigenvalues > 1 were selected.5 Items with factor loadings 
<0.50 were removed in an iterative process until all items had loadings ≥0.50. Similarly 
worded trust items were eliminated across both types of physicians [PCPs and 
specialists] if they were invalid for at least one of the domains. For the purpose of 
evaluating the test-retest reliability of the I-PCOSM, total scores for items within each 
domain were averaged and included in the final analyses for instrument validation.  
Results 
Test-retest reliability was acceptable for all I-PCOSM domains (ICC range = 
0.51 to 0.99). Internal consistency analyses could not be performed on items inquiring 
about PCPs and PCOS health concerns because of the small sample size. Items related 
to trust in specialists regarding PCOS health concerns did not reach the acceptable 
threshold for internal consistency (α = 0.37). By contrast, similarly worded items on 
general health concerns with specialists had high internal consistency (α = 0.78), though 
this result was not observed with PCPs (α = 0.34). In the comparison group, internal 
consistency was high for items related to trust in PCPs (α = 0.71), but not with specialists 
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(α = 0.18). The low consistency was likely attributed to the small sample size used in 
the interview rounds since not every participant visited each type of physicians. When 
we examined the internal consistency of the trust domain in the nationwide sample 
(n=332), we found the internal consistency was high in the trust domain across different 
types of physicians and health concerns (α range = 0.83 to 0.94). Items related to social 
support provided by healthcare professionals met the acceptable threshold for internal 
consistency in both the interview and nationwide samples (α = 0.88 and 0.85, 
respectively). Factor analysis on the nationwide sample identified 20 items as having 
low factor loadings. The trust domains retained 16 items, while the social support 
domain retained 12 items. The final version of the I-PCOSM represented 28 items with 
high construct validity and were used in the final analyses (Supplemental Table S5.1). 
REFERENCES 
1.  Thom DH, Ribisl KM, Stewart AL, Luke DA. Further validation and reliability 
testing of the Trust in Physician Scale. Med Care. 1999;37(5):510–7.  
2.  NHIS - National Health Interview Survey Homepage [Internet]. Available from:  
https://www.cdc.gov/nchs/nhis/index.htm 
3.  Cicchetti D V. Guidelines, criteria, and rules of thumb for evaluating normed 
and standardized assessment instruments in psychology. Psychol Assess. 
American Psychological Association; 1994;6(4):284–90.  
4.  Koo TK, Li MY. A Guideline of Selecting and Reporting Intraclass Correlation  
Coefficients for Reliability Research. J Chiropr Med. 2016;15(2):155–63.  
5.  Kaiser HF. The application of electronic computers to factor analysis. Educ 
Psychol Meas. Thousand Oaks, CA; 1960;20(1):141–51.  
 208 
 
DISTRIBUTED I-PCOSM  
[Author comments are in italicized blue. Logic statements were built into the 
instrument in order to streamline the response process. Unless otherwise stated, items 
were asked for both comparison and PCOS groups.] 
 
Q1 Thank you for taking the time to complete this 2nd survey by Cornell University. 
Your responses are very important in helping us examine the medical experiences and 
social support of adult women. Please complete the survey on a computer. Your 
answers will be confidential and participation is voluntary. You can stop the survey at 
any time.  
 
Completion time: 10 - 20 minutes.  
Honorarium: Raffle for one of five $50 Amazon gift cards upon completion.We 
predict this is a 1 in 30 odds. The draw will occur at the end of the study. 
 
We anticipate that your participation in this survey presents no greater risk than 
everyday use of the Internet. If you have any questions about the survey, please 
contact us at womensimaging@gmail.com. Participants may also report their 
concerns or complaints anonymously through Ethicspoint by calling toll free at 
(866)293-3077 or emailing www.hotline.cornell.edu. 
 
By selecting the “I agree” button, you are indicating that you are willing to participate 
in this survey. 
 I agree 
 I do not agree 
 
Q2 How old are you? 
 
Q3 What race(s) do you identify with most? 
 American Indian or Alaskan Native 
 Asian 
 Black or African American 
 White 
 Other ____________________ 
 
Q4 What is your highest completed education? 
 1st to 5th grade 
 6th to 8th grade 
 9th to 12th grade 
 High school graduate or GED 
 Associate's degree 
 College graduate 
 Advanced degree 
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Q5 What is your yearly household income (e.g., yourself, with significant other)? 
 ≤ $19,999 
 $20,000 to $39,999 
 $40,000 to $59,999 
 $60,000 to $79,999 
 $80,000 to $99,999 
 ≥ $100,000 
 
Q6 What is your current height (in feet, inches)? 
 
Q7 What is your current weight (in pounds)? 
 
Q8 When did you last weigh yourself (number of days from today)? 
 
Q9 Are you currently on birth control pills or intrauterine devices (IUD)? 
 No 
 Yes 
 Unsure 
 
Q10 How would you classify your fertility status (ability to become pregnant within a 
year)? 
 Fertile 
 Infertile 
 Unsure 
 
Q11 How familiar are you with the term "polycystic ovary syndrome" (PCOS)? 
 Not at all 
 Somewhat familiar 
 Familiar 
 Very familiar 
 
Q12 Have you been diagnosed with PCOS by a medical professional? 
 No 
 Yes 
 
Q13 Can you usually predict when your period would start at least half of the time? 
 No 
 Yes 
 Unsure 
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Q14 On average, what is the smallest number of days between the beginning of one 
period to the beginning of the next one? [If answered “No” to Q13] 
 Less than 20 days 
 20 to 25 days 
 26 to 35 days 
 Greater than 35 days 
 Unsure 
 
Q15 On average, what is the greatest number of days between the beginning of one 
period to the beginning of the next one? [If answered “No” to Q13] 
 Less than 20 days 
 20 to 25 days 
 26 to 35 days 
 Greater than 35 days 
 Unsure 
 
Q16 On average, what is the smallest number of days between the beginning of one 
period to the beginning of the next one? [If answered “Yes” to Q13] 
 Less than 20 days 
 20 to 25 days 
 26 to 35 days 
 Greater than 35 days 
 Unsure 
 
Q17 On average, what is the greatest number of days between the beginning of one 
period to the beginning of the next one? [If answered “Yes” to Q13] 
 Less than 20 days 
 20 to 25 days 
 26 to 35 days 
 Greater than 35 days 
 Unsure 
 
Q18 On average, what is the smallest number of days between the beginning of one 
period to the beginning of the next one? [If answered “Unsure” to Q13] 
 Less than 20 days 
 20 to 25 days 
 26 to 35 days 
 Greater than 35 days 
 Unsure 
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Q19 On average, what is the greatest number of days between the beginning of one 
period to the beginning of the next one? [If answered “Unsure” to Q13] 
 Less than 20 days 
 20 to 25 days 
 26 to 35 days 
 Greater than 35 days 
 Unsure 
 
Q20 How old were you when diagnosed with PCOS? [For PCOS Group] 
 Between 9 to 15 years old 
 Between 16 to 17 years old 
 Between 18 to 29 years old 
 Between 30 to 38 years old 
 
Q21 What PCOS symptoms did you have that led to a diagnosis? Put "DK" if unsure. 
[For PCOS Group] 
 
Q22 Were you ever diagnosed with the following? Please mark all that apply. 
 Heart disease (e.g., coronary heart disease, stroke) 
 Diabetes (high blood sugar) 
 Thyroid disease 
 Cancer 
 Kidney disease 
 None 
 
Q23 Are you a New York State resident?  If yes, please list the city. If no, please list 
the state where you live. 
 Yes ____________________ 
 No ____________________ 
 
Q24 The next 2 sections will ask about the healthcare professionals you have visited. 
It will be divided by most recent (within the last 3 years) and past (more than 3 years).  
These questions will be asked by profession.  
 
Q25 We will now ask about your MOST RECENT healthcare professionals (who are 
familiar with your health history).**Please think of your experiences for when you 
were 18 years or older. Choose the answer you feel is most appropriate.** 
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Q26 In the PAST 3 YEARS, which types of healthcare professionals have you visited? 
Mark all that apply. [For Comparison Group] 
 Primary Doctor 
 Specialized Doctor (e.g., Gynecologist, Dermatologist) ____________________ 
 Nurse Practitioner or Physician Assistant 
 Holistic Professional (Chiropractor, Acupuncturist or Naturopath) 
 Dietitian 
 Other ____________________ 
 None 
 
Q27 In the PAST 3 YEARS, which types of healthcare professionals have you visited 
for NON-PCOS issues? Mark all that apply. [For PCOS Group] 
 Primary Doctor 
 Specialized Doctor (e.g., Gynecologist, Dermatologist) ____________________ 
 Nurse Practitioner or Physician Assistant 
 Holistic Professional (Chiropractor, Acupuncturist or Naturopath) 
 Dietitian 
 Other ____________________ 
 None 
 
Q28 In the PAST 3 YEARS, which types of healthcare professionals have you visited 
for PCOS issues (e.g., hair growth, infertility)? Mark all that apply. 
[For PCOS Group] 
 Primary Doctor 
 Specialized Doctor (e.g., Gynecologist, Dermatologist) ____________________ 
 Nurse Practitioner or Physician Assistant 
 Holistic Professional (Chiropractor, Acupuncturist or Naturopath) 
 Dietitian 
 Other ____________________ 
 None 
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[Comment: Items 29 to 40 were asked for each healthcare provider. Therefore, only 
items related to recent primary doctor were provided as examples.] 
 
Q29 About how many times do you visit that most recent Primary Doctor in a YEAR? 
[For Comparison Group] 
 
 0-1 time 
 2-5 times 
 6-10 times 
 11-15 times 
 16-20 times 
 21-25 times 
 More than 25 times 
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Q30 Please list all types of treatment that were recommended by that most recent Primary Doctor (e.g., low fat diet, birth 
control).Put "NA" in the Treatment 1 box if there was no treatment; "DK" if unsure. [For Comparison Group] 
 
 How long did you use the recommended  treatment? 
How satisfied or dissatisfied are you that the treatment 
improved your health? 
 
Did not 
begin 
treatment 
Less 
than 1 
month 
Between 
1 to 6 
months 
Between 
6 to 12 
months 
Greater 
than 12 
months 
Dissatisfied Somewhat dissatisfied Neutral 
Somewhat 
satisfied Satisfied 
Treatment 
1                     
Treatment 
2                     
Treatment 
3                     
Treatment 
4                     
Treatment 
5                     
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Q31 We will ask about your trust in that most recent Primary Doctor. Please select the 
answer you feel is most appropriate. [For Comparison Group] 
 
 Strongly disagree Disagree Neutral Agree 
Strongly 
agree 
I doubt that the 
recent Primary 
Doctor really 
cares about me 
as a person. 
          
The recent 
Primary Doctor 
is usually 
considerate of 
my needs and 
puts them first. 
          
I trust the 
recent Primary 
Doctor so 
much, I always 
try to follow 
his/her advice. 
          
If the recent 
Primary Doctor 
tells me 
something is so, 
then it is 
usually true. 
          
I sometimes 
distrust the 
recent Primary 
Doctor's 
opinions and 
would like a 
second one. 
          
I trust the 
recent Primary 
Doctor's 
judgment about 
my medical 
care. 
          
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I feel the recent 
Primary Doctor 
does not do 
everything 
he/she should 
about my 
medical care. 
          
I trust the 
recent Primary 
Doctor to put 
my medical 
needs above all 
other 
considerations 
when treating 
my medical 
problems. 
          
The recent 
Primary Doctor 
is well qualified 
to treat medical 
problems that I 
experience. 
          
 
Q32 Does seeing that most recent Primary Doctor give you a sense of control over 
your health? [For Comparison Group] 
 No 
 Yes 
 
Q33 For NON-PCOS issues, about how many times do you visit that most recent 
Primary Doctor in a YEAR? [For PCOS Group] 
 0-1 time 
 2-5 times 
 6-10 times 
 11-15 times 
 16-20 times 
 21-25 times 
 More than 25 times 
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Q34 Please list all types of NON-PCOS treatment recommended by that most recent Primary Doctor (e.g., low fat diet, birth 
control). Put "NA" in the Treatment 1 box if there was no treatment, "DK" if unsure.[For PCOS Group] 
 
 How long did you use the recommended treatment? 
How satisfied or dissatisfied are you that the treatment 
improved your health? 
 
Did not 
begin 
treatment 
Less 
than 1 
month 
Between 
1 to 6 
months 
Between 
6 to 12 
months 
Greater 
than 12 
months 
Dissatisfied Somewhat dissatisfied Neutral 
Somewhat 
satisfied Satisfied 
Treatment 
1                     
Treatment 
2                     
Treatment 
3                     
Treatment 
4                     
Treatment 
5                     
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Q35 We will ask about your trust in that most recent Primary Doctor for NON-PCOS 
issues. Please select the answer you feel is most appropriate. [For PCOS Group] 
 
 Strongly disagree Disagree Neutral Agree 
Strongly 
agree 
I doubt that the 
recent Primary 
Doctor really 
cares about me 
as a person. 
          
The recent 
Primary Doctor 
is usually 
considerate of 
my needs and 
puts them first. 
          
I trust the 
recent Primary 
Doctor so 
much, I always 
try to follow 
his/her advice. 
          
If the recent 
Primary Doctor 
tells me 
something is so, 
then it is 
usually true. 
          
I sometimes 
distrust the 
recent Primary 
Doctor's 
opinions and 
would like a 
second one. 
          
I trust the 
recent Primary 
Doctor's 
judgment about 
my non-PCOS 
medical care. 
          
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I feel the recent 
Primary Doctor 
does not do 
everything 
he/she should 
about my non-
PCOS medical 
care. 
          
I trust the recent 
Primary Doctor 
to put my 
medical needs 
above all other 
considerations 
when treating 
my non-PCOS 
medical 
problems. 
          
The recent 
Primary Doctor 
is well qualified 
to treat non-
PCOS medical 
problems that I 
experience. 
          
 
Q36 Does seeing that most recent Primary Doctor for NON-PCOS issues give you a 
sense of control over your health? [For PCOS Group] 
 No 
 Yes 
 
Q37 In a YEAR, about how many times do you visit that most recent Primary Doctor 
for PCOS issues? [For PCOS Group] 
 0-1 time 
 2-5 times 
 6-10 times 
 11-15 times 
 16-20 times 
 21-25 times 
 More than 25 times 
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Q38 Please list all types of PCOS treatment recommended by that most recent Primary Doctor (e.g., low fat diet, birth control). Put 
"NA" in the Treatment 1 box if there was no treatment; "DK" if unsure. [For PCOS Group] 
 
 How long did you use the recommended PCOS treatment? 
How satisfied or dissatisfied are you that the PCOS 
treatment improved your health? 
 
Did not 
begin 
treatment 
Less 
than 1 
month 
Between 
1 to 6 
months 
Between 
6 to 12 
months 
Greater 
than 12 
months 
Dissatisfied Somewhat dissatisfied Neutral 
Somewhat 
satisfied Satisfied 
Treatment 
1                     
Treatment 
2                     
Treatment 
3                     
Treatment 
4                     
Treatment 
5                     
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Q39 We will ask about your trust in that most recent Primary Doctor for PCOS issues. 
Please select the answer you feel is most appropriate. [For PCOS Group] 
 
 Strongly disagree Disagree Neutral Agree 
Strongly 
agree 
I doubt that the 
recent Primary 
Doctor really 
cares about me 
as a person. 
          
The recent 
Primary Doctor 
is usually 
considerate of 
my needs and 
puts them first. 
          
I trust the 
recent Primary 
Doctor so 
much, I always 
try to follow 
his/her advice. 
          
If the recent 
Primary Doctor 
tells me 
something is so, 
then it is 
usually true. 
          
I sometimes 
distrust the 
recent Primary 
Doctor's 
opinions and 
would like a 
second one. 
          
I trust the 
recent Primary 
Doctor's 
judgment about 
my PCOS 
medical care. 
          
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I feel the recent 
Primary Doctor 
does not do 
everything he/she 
should about my 
PCOS medical 
care. 
          
I trust the recent 
Primary Doctor 
to put my 
medical needs 
above all other 
considerations 
when treating my 
PCOS medical 
problems. 
          
The recent 
Primary Doctor 
is well qualified 
to treat PCOS 
medical 
problems that I 
experience. 
          
 
Q40 Does seeing that recent Primary Doctor for PCOS issues give you a sense of 
control over your health? [For PCOS Group] 
 No 
 Yes 
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[Comment: Items 96 to 110 were asked for each healthcare provider to gauge earlier 
medical experiences (before the past 3 years). Therefore, only items related to past 
primary doctor were provided as examples.] 
 
Q96 We will now ask about your PAST healthcare professionals (who are familiar 
with your health history).**Unless specified, please think of your experiences for 
when you were 18 years or older.** 
 
Q97 When you were younger than 18, which types of healthcare professionals did you 
visit for PCOS issues (e.g., hair growth, infertility)? [For PCOS Group] 
 Primary Doctors 
 Specialized Doctors (e.g., Gynecologists, Dermatologists) 
____________________ 
 Nurse Practitioners or Physician Assistants 
 Holistic Professionals (Chiropractors, Acupuncturists or Naturopaths) 
 Dietitians 
 Others ____________________ 
 None 
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Q98 For when you were younger than 18, please list all types of treatment recommended by past healthcare professionals (e.g., low 
fat diet, birth control). Put NA" in the Treatment 1 box if there was no treatment; "DK" if unsure. [For PCOS Group] 
 
 How long did you use the recommended PCOS treatment? 
How satisfied or dissatisfied are you that the PCOS 
treatment improved your health? 
 
Did not 
begin 
treatment 
Less 
than 1 
month 
Between 
1 to 6 
months 
Between 
6 to 12 
months 
Greater 
than 12 
months 
Dissatisfied Somewhat dissatisfied Neutral 
Somewhat 
satisfied Satisfied 
Treatment 
1                     
Treatment 
2                     
Treatment 
3                     
Treatment 
4                     
Treatment 
5                     
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99 When you were an adult (18 years or older), which types of healthcare 
professionals did you visit? Do not include the most recent healthcare professionals. 
[For Comparison Group] 
 
 Primary Doctors 
 Specialized Doctors (e.g., Gynecologists, Dermatologists) 
____________________ 
 Nurse Practitioners or Physician Assistants 
 Holistic Professionals (Chiropractors, Acupuncturists or Naturopaths) 
 Dietitians 
 Others ____________________ 
 None 
 
Q100 When you were an adult (18 years or older), which types of healthcare 
professionals did you visit for NON-PCOS issues? Do not include the most recent 
healthcare professionals. [For PCOS Group] 
 Primary Doctors 
 Specialized Doctors (e.g., Gynecologists, Dermatologists) 
____________________ 
 Nurse Practitioners or Physician Assistants 
 Holistic Professionals (Chiropractors, Acupuncturists or Naturopaths) 
 Dietitians 
 Others ____________________ 
 None 
 
Q101 When you were an adult (18 years or older), which types of healthcare 
professionals did you visit for PCOS issues (e.g., hair growth, infertility)? Do not 
include the most recent healthcare professionals. [For PCOS Group] 
 Primary Doctors 
 Specialized Doctors (e.g., Gynecologists, Dermatologists) 
____________________ 
 Nurse Practitioners or Physician Assistants 
 Holistic Professionals (Chiropractors, Acupuncturists or Naturopaths) 
 Dietitians 
 Others ____________________ 
 None 
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Q102 Please list all types of treatment recommended by past Primary Doctors (e.g., low fat diet, birth control) as an adult. Put 
"NA" in the Treatment 1 box if there was no treatment; "DK" if unsure. [For Comparison Group] 
 
 How long did you use the recommended  treatment? 
How satisfied or dissatisfied are you that the treatment 
improved your health? 
 
Did not 
begin 
treatment 
Less 
than 1 
month 
Between 
1 to 6 
months 
Between 
6 to 12 
months 
Greater 
than 12 
months 
Dissatisfied Somewhat dissatisfied Neutral 
Somewhat 
satisfied Satisfied 
Treatment 
1                     
Treatment 
2                     
Treatment 
3                     
Treatment 
4                     
Treatment 
5                     
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Q103 We will ask about your trust in your past Primary Doctors (NOT your recent). 
Please select the answer you feel is most appropriate. [For Comparison Group] 
 
 Strongly disagree Disagree Neutral Agree 
Strongly 
agree 
I doubted that 
my past 
Primary 
Doctors really 
cared about me 
as a person. 
          
My past 
Primary 
Doctors were 
usually 
considerate of 
my needs and 
put them first. 
          
I trusted my 
past Primary 
Doctors so 
much, I always 
tried to follow 
their advice. 
          
If my past 
Primary 
Doctors told me 
something is so, 
then it is 
usually true. 
          
I sometimes 
distrusted my 
past Primary 
Doctors' 
opinions and 
would have 
liked another 
one. 
          
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I trusted my 
past Primary 
Doctors' 
judgments 
about my 
medical care. 
          
I felt my past 
Primary 
Doctors did 
not do 
everything 
they should 
about my 
medical care. 
          
I trusted my 
past Primary 
Doctors to put 
my medical 
needs above 
all other 
considerations 
when treating 
my medical 
problems. 
          
My past 
Primary 
Doctors were 
well qualified 
to treat 
medical 
problems that 
I experienced. 
          
 
 
Q104 Did seeing your past Primary Doctors give you a sense of control over your 
health? [For Comparison Group] 
 No 
 Yes 
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Q105 Please list all types of NON-PCOS treatment recommended by past Primary Doctors as an adult (e.g., low fat diet, birth 
control). Put "NA" in the Treatment 1 box if there was no treatment; "DK" if unsure. [For PCOS Group] 
 
 How long did you use the recommended  treatment? 
How satisfied or dissatisfied are you that the treatment 
improved your health? 
 
Did not 
begin 
treatment 
Less 
than 1 
month 
Between 
1 to 6 
months 
Between 
6 to 12 
months 
Greater 
than 12 
months 
Dissatisfied Somewhat dissatisfied Neutral 
Somewhat 
satisfied Satisfied 
Treatment 
1                     
Treatment 
2                     
Treatment 
3                     
Treatment 
4                     
Treatment 
5                     
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Q106 We will ask about your trust in your past Primary Doctors for NON-PCOS 
issues (NOT your recent). Please select the answer you feel is most appropriate. [For 
PCOS Group] 
 
 Strongly disagree Disagree Neutral Agree 
Strongly 
agree 
I doubted that 
my past 
Primary 
Doctors really 
cared about 
me as a 
person. 
          
My past 
Primary 
Doctors were 
usually 
considerate of 
my needs and 
put them first. 
          
I trusted my 
past Primary 
Doctors so 
much, I 
always tried 
to follow their 
advice. 
          
If my past 
Primary 
Doctors told 
me something 
is so, then it is 
usually true. 
          
I sometimes 
distrusted my 
past Primary 
Doctors' 
opinions and 
would have 
liked another 
one. 
          
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I trusted my 
past Primary 
Doctors' 
judgment 
about my 
non-PCOS 
medical care. 
          
I felt my past 
Primary 
Doctors did 
not do 
everything 
they should 
about my 
non-PCOS 
medical care. 
          
I trusted my 
past Primary 
Doctors to put 
my medical 
needs above 
all other 
considerations 
when treating 
my non-
PCOS 
medical 
problems. 
          
My past 
Primary 
Doctors were 
well qualified 
to treat non-
PCOS 
medical 
problems that 
I experienced. 
          
 
Q107 Did seeing your past Primary Doctors for NON-PCOS issues give you a sense 
of control over your health? [For PCOS Group] 
 No 
 Yes 
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Q108 Please list all types of PCOS treatment recommended by past Primary Doctors (e.g., low fat diet, birth control). Put "NA" in 
the Treatment 1 box if there was no treatment; "DK" if unsure. [For PCOS Group] 
 
 How long did you use the recommended PCOS treatment? 
How satisfied or dissatisfied are you that the PCOS 
treatment improved your health? 
 
Did not 
begin 
treatment 
Less 
than 1 
month 
Between 
1 to 6 
months 
Between 
6 to 12 
months 
Greater 
than 12 
months 
Dissatisfied Somewhat dissatisfied Neutral 
Somewhat 
satisfied Satisfied 
Treatment 
1                     
Treatment 
2                     
Treatment 
3                     
Treatment 
4                     
Treatment 
5                     
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Q109 We will ask about your trust in your past Primary Doctors for PCOS issues 
(NOT your recent). Please select the answer you feel is most appropriate. [For PCOS 
Group] 
 
 Strongly disagree Disagree Neutral Agree 
Strongly 
agree 
I doubted that 
my past 
Primary 
Doctors really 
cared about 
me as a 
person. 
          
My past 
Primary 
Doctors were 
usually 
considerate of 
my needs and 
put them first. 
          
I trusted my 
past Primary 
Doctors so 
much, I 
always tried 
to follow their 
advice. 
          
If my past 
Primary 
Doctors told 
me something 
is so, then it is 
usually true. 
          
I sometimes 
distrusted my 
past Primary 
Doctors' 
opinions and 
would have 
liked another 
one. 
          
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I trusted my 
past Primary 
Doctors' 
judgment 
about my 
PCOS 
medical care. 
          
I felt my past 
Primary 
Doctors did 
not do 
everything 
they should 
about my 
PCOS 
medical care. 
          
I trusted my 
past Primary 
Doctors to put 
my medical 
needs above 
all other 
considerations 
when treating 
my PCOS 
medical 
problems. 
          
My past 
Primary 
Doctors were 
well qualified 
to treat PCOS 
medical 
problems that 
I experienced. 
          
 
Q110 Did seeing your past Primary Doctors for PCOS issues give you a sense of 
control over your health? [For PCOS Group] 
 No 
 Yes 
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Q151 We will now ask about your social support. Please select the answer you feel is 
most appropriate. 
 
Q152 Please select the following the people with whom you talk about all health 
problems. 
 Significant other (e.g., spouse, partner, girlfriend/boyfriend) 
 Adult women in your family (e.g., mother, sister, aunt; NOT PARTNER) 
 Close friends (NOT PARTNER or RELATION) 
 Most recent health professionals (only doctors, nurse practitioners or physician 
assistants) 
 No one 
 
[Comment: Items 159 to 160 were asked for group of different support systems 
[significant other, adult women in the family, friends, healthcare providers] to gauge 
social support. Only items related to healthcare providers were provided as 
examples.] 
 
Q159 With most recent HEALTHCARE PROFESSIONALS (only doctors, nurse 
practitioners or physician assistants)... 
 Never Rarely Sometimes Usually Always 
How often do 
they give you 
advice or 
information 
about health 
(whether you 
want it or 
not)? 
          
How often do 
they give you 
advice or 
information 
about nutrition 
(whether you 
want it or 
not)? 
          
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How often do 
they give you 
advice or 
information 
about PCOS 
(whether you 
want it or 
not)? [For 
PCOS Group] 
          
How often do 
they give you 
reassurance, 
encouragement 
and emotional 
support 
(affection) 
concerning 
your health? 
          
How often do 
they listen to 
and try to 
understand 
your worries 
about your 
health? 
          
How often can 
you relax and 
be yourself 
around them? 
          
How often can 
you open up to 
them if you 
need to talk 
about your 
worries about 
your health? 
          
How satisfied 
are you with 
the emotional 
support 
provided? 
          
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Q160 With most recent HEALTHCARE PROFESSIONALS (only doctors, nurse 
practitioners or physician assistants)... 
 
 Never Rarely Sometimes Usually Always 
How often 
do they 
argue with 
you relating 
to your 
health? 
          
How often 
do they 
criticize you 
relating to 
your health? 
          
How often 
do they let 
you down 
when you 
are counting 
on them? 
          
How often 
do they 
withdraw 
from 
discussions 
or try to 
change the 
topic away 
from your 
health? 
          
 
 
 
 
